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Abstract: 
Aim: to develop and examine the effectiveness of Information Motivational Behavioural 
Model-based Diabetes Self-Management Education intervention on three self-care 
activities: diet, physical activity and medications management self-care behaviours, and 
other outcomes such as quality of life and glycaemic control.  
Setting: Outpatient clinics at two mains teaching hospitals in Jordan. 
Participants: Sample of 151 participants who were diagnosed with Type 2 Diabetes 
Mellitus for more than six months, aged between 18 and 65 years old, HbA1c > 8% 
within the last two weeks prior to recruitment and are taking any form of hypoglycaemic 
agents.  
Research design: This trial was a randomized clinical trial and was designed in line with 
MRC framework and IMB three main procedures: assessing, implementation and 
evaluation. IMB main determinants; knowledge, motivation and behavioural skills along 
with the performance of self-care behaviours, quality of life and HbA1c were assessed 
at baseline and evaluated at three-month visit and six-month visits.  
Methods: A two parallel group trial with randomized allocation of 151 participants on 
1:1 average for both groups. Intervention group received the IMBDSME intervention as 
well as the usual treatment while control group received the usual treatment only. 
IMBDSME was developed using an Arabic translated version of PRIDE educational 
toolkit. The educational toolkit was delivered using motivational interviewing and brief 
action planning approach according to IMB model assumption through two face-to-face 
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sessions and several interventional phone calls for each participant within two weeks 
from participation and for a duration of three-month period. 
Results: For those who were in the IMBDMSE group, they reported statistically 
significant improvements in the level of knowledge, motivation, behavioural skills and 
quality of life at three-month and six-month visits. Similarly, significant improvements 
in the level of practicing diet and medications management self-care behaviours were 
found at three-month and six-month visits. HbA1a was improved significantly at three-
month for those who attended JUH and received the intervention. While non-significant 
improvements were reported in physical activity behaviour and HbA1c at both time 
points among the same group. 
Conclusion: This clinical trial conceptualised IMB behavioural change model in 
IMBDSME intervention and improved the level of performing diet and medications 
management self-care activities for those who received the intervention. IMBDSME 
provided a comprehensive understanding of how Jordanian patients’ Knowledge, 
Motivation, Behavioural skills and metabolic outcomes changed overtime, in tandem 
with performing self-management behaviours. 
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1 Background and literature review: 
1.1 Introduction: 
According to World Health Organization (WHO) (2019), diabetes is defined as a group 
of metabolic disorders that are characterized by  the presence of High glucose level 
in the absence of treatment. It may be caused by defects in insulin secretion, insulin 
action, or both, and disturbances of carbohydrate, fat and protein metabolism. The 
long-term complications of diabetes include retinopathy, nephropathy and 
neuropathy, among other complications. People with diabetes are also at increased 
risk of other diseases including heart, peripheral arterial and cerebrovascular disease, 
obesity, cataracts, erectile dysfunction, and non-alcoholic fatty liver disease. They are 
also at increased risk of some infectious diseases, such as tuberculosis. 
On long term, it considers one of the primary reasons for cardiovascular and 
cerebrovascular diseases. According to the World Health Organization in 2000, 171 
million people were estimated to be diagnosed with diabetes and this will increase 
to at least 366 million by 2030 (Wild et al., 2004). Another report published in 2015 
stated that the number of those adults diagnosed with diabetes has been quadrupled 
to 422 million in 2014 since 1980 (WHO, 2015). Without interventions to halt the 
increase in diabetes, there will be at least 629 million people living with diabetes by 
2045 (WHO) (2019). The number of deaths directly caused by diabetes was 1.5 
million in 2015, and 3.7 million deaths were related to high blood glucose in 2012 
which was about 9% of the total global deaths (WHO, 2015). Almost half of deaths 
before the age of 70 years were related to high blood glucose in 2012, and 80% of 
diabetes deaths occurred in low- and middle-income countries. WHO in (2019) 
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reported that half of people with diabetes (50%) die of cardiovascular disease 
(primarily heart disease and stroke), and 10-20% of people with diabetes die of 
kidney failure. This will eventually be the seventh leading cause of death by 2030. As 
this number is still growing, the proportion of healthcare budgets specified for Type 
2 Diabetes Mellitus (T2DM) and its related complications is always increasing. 
Diabetes prevalence is rapidly increasing in the Eastern Mediterranean Region (EMR) 
in comparison to American and European Regions (AER). Prevalence of diabetes 
amplified by more than double from 5.9% in 1980 to 13.7% in 2014 in EMR, while the 
rise was only 1.5 folds in AER (WHO, 2016). EMR has the greatest rise in diabetes 
prevalence with the highest incidence of diabetes among WHO regions now (WHO, 
2016). Diabetes in low and middle-income countries has risen faster than in high-
income countries (WHO, 2015 , 2016); hence, cost effective treatment strategies are 
crucial to reverse this inclination in these countries. 
International Diabetes Federation (IDF) published the diabetes Atlas 9th edition in 
2019 where they estimated that almost half a billion people have diabetes, and this 
number is projected to reach 578 million by 2030, and 700 million by 2045 (Saeedi et 
al., 2019). They stated that over four million people aged 20–79 years are estimated 
to die from diabetes-related causes in 2019. The majority of the data sources used in 
IDF report were population-based studies that have been published in peer-reviewed 
periodicals, national health surveys, including some of the World Health Organization 
(WHO) STEPwise approach to Surveillance (STEPS) were used where they meet 
inclusion criteria. Findings of the latest edition confirmed that diabetes is one of the 
fastest growing global health emergencies of the 21st century. 
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1.2 Diabetes-related complications: 
Uncontrolled glucose level in patients with T2DM is one of the leading causes of 
microvascular and macrovascular complications (Rosolova et al., 2008). Using anti-
hyperglycaemic medications in managing diabetes showed an improvement in 
glucose level and reduced complications on the long term (Stratton et al., 2000). 
Results drawn from Randomized Controlled Trials (RCTs) have verified that intensive 
glycaemic control of HbA1c <7 is highly correlated with a considerable decline in the 
risk of microvascular complications in patients with T2DM (Stratton et al., 2000). 
However, a glycaemic target of HbA1c<7 is often not accomplished among patients 
with DM (ADA, 2015 , Saydah et al., 2004). Although using anti-hyperglycaemic 
medications to control blood-glucose level intensively improved metabolic outcomes 
in UKPDS study, side effects such as hypoglycaemia and weight gain were more likely 
to occur among study participants (UKPDS, 1998). However, this disease requires 
more efforts and attention to improve metabolic outcomes and minimising side 
effects through appropriate tailored glycaemic management (Sansgiry et al., 2013).  
The United Kingdom Prospective Diabetes Study (UKPDS) clearly concluded that self-
care behaviours to improve glycaemic control, lipid and blood pressure have shown 
to improve long-term outcomes for patients with T2DM (Turner et al., 1996). 
Epidemiological scrutiny of The United Kingdom Prospective Diabetes Study (UKPDS) 
showed that for each 1% decrease in HbA1c, there was a consistent reduction by 21% 
in any diabetes-related endpoint, with a decrease of 14% in myocardial infarction, 
12% decrease in stroke incidence, and a 37% decrease for microvascular 
complications (Stratton et al., 2000). 
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1.3 Diabetes in Jordan: 
Jordan is one of EMR countries according to WHO (2016) and classified as lower 
middle income country by the World Bank Group (WBG) in 2017 and diabetes 
prevalence was rising rapidly and alarming. In a cross-sectional study of 1121 
Jordanians, Ajlouni et al. (2008) estimated that approximately one million people - 
17.1% of the total population- were diagnosed with T2DM. This is a 31.5% increase 
in diabetes incidence to rates established 10 years earlier (Ajlouni et al., 1998) that 
was 13.4%. Moreover, WHO (2002 , 2015) stated in non-communicable diseases 
reports in Jordan profile that deaths related to T2DM increased from 1% in 2002 to 
7% in 2010, and more than half million people have uncontrolled level of 
Glycosylated Haemoglobin A1c (HbA1c >7.5)1 due to many factors such as a 
sedentary lifestyle and poor medication management (Khattab et al., 2010). Another 
study that was conducted in Jordan by Al-Khawaldeh et al. (2012) showed that more 
than half of Jordanian patients with T2DM had uncontrolled glycaemic level (HbA1c 
>7.0%) and had poor adherence to the universally recommended diabetes self-care 
behaviours. This is important since this study showed that glycaemic control was 
significantly predicted by practicing healthy diet behaviour and their self-efficacy 
score for diet self-care behaviour in the same sample (n=223). Studies with Jordanian 
populations are scarce but demonstrated that many Jordanian patients with T2DM 
were still in the pre-action stage of change for important self-care behaviours such 
as physical exercise and consuming five servings of fruits and vegetables per day 
 
1 HbA1c normal range is (4.6%-6.2%) 
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(Bawadi et al. (2012). Findings derived from the aforementioned studies in Jordan 
demonstrated that better diabetes management was needed.  
1.4 Diabetes Self-Management Education (DSME): 
Diabetes care is a complex process and requires multifactorial risk reduction 
strategies that necessitate complex interventions to address several essential 
components in diabetes management such as psychological, educational and 
behavioural change skills (ADA, 2015). DSME is considered as an essential element in 
diabetes treatment process since 1930 (Bartlett, 1986). DSME is an ongoing process 
that provides appropriate knowledge and skills related to patient’s health condition, 
identifies needs and goals to enhance the capability of managing self-care 
behaviours, problem solving and decision-making (Marathe et al., 2017 , Beck et al., 
2017). International Diabetes Federation (IDF) report in (2011) strongly 
recommended that patients with diabetes were encouraged to take responsibility 
toward better controlling glucose level and any symptoms associated. This can only 
be supported by appropriate diabetes educational programs on self-management. 
DSME was found to improve glucose level, maximized quality of life and prolonged 
or avoided chronic complications in a cost effectiveness manner (Haas et al., 2014 , 
ADA, 2015). Moreover, performing diabetes self-management activities was found 
to explain 90-98% of variance in glycaemic control (O'Connor et al., 2008 , Tuerk et 
al., 2008). Previous DSME programmes have been shown to improve metabolic 
outcomes for patients (Dube et al., 2015). However, these effects were generally 
short-lived and were not sustained for more than six months (Norris et al., 2001). 
They rationalised the shortcomings due to the lack of emphasis on factors such as a 
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patient’s confidence in self-management or their problem-solving skills to address 
everyday barriers. However, most DSME programs in literature were not 
underpinned by a theoretical framework and specifically behavioural change models. 
Clement (1995) in a qualitative review stated that behavioural changes strategies 
were more effective than didactic programs, particularly, if it is integrated with a 
frequent reinforcement of educational messages in repeated sessions.  
1.5 Why DSME is complex? 
Although limited number of research studies described DSME as complex 
intervention (Cooper et al., 2003), management of chronic diseases such as T2DM 
always required extensive responsibility and high level of skills. The burden of 
meeting patients’ needs shifted the responsibility away from health care 
professionals to patients by the virtue of the nature of chronic conditions. The 
management entails different activities such as taking medications, controlling 
symptoms, changing lifestyle and problem solving. Patients’ involvement in the 
caring process was defined as self-management by Barlow et al. (2002) and necessary 
to reduce the disease impact on biological, psychological and social health status 
(Newman et al., 2004). They also stated that patients should be able to monitor his 
disease conditions to influence his cognition, behavioural and emotional responses 
to sustain an acceptable level of quality of life. Clark et al. (1991) stressed that self-
management should be in accordance with the financial and social conditions of 
patients involved. They suggested that patients should possess appropriate 
knowledge of the disease and its treatment and necessary skills to successfully 
perform self-management activities. Optimum self-management process is 
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multifaceted and not only a simple adherence to treatment rules, because it includes 
patients’ psychological and social aspects. Self-management practice was always 
found difficult to be achieved as reflected by poor rates of adherence to treatment 
regimens that were reported across several chronic diseases such as asthma, 
diabetes and heart failure (Cline et al., 1999 , Schmittdiel et al., 2008 , Bender, 2002). 
Diabetes care requires multifactorial risk reduction strategies and need a 
multifaceted intervention to address several essential components such as 
psychological, social and behavioural change in diabetes management (ADA, 2017). 
Therefore, these difficulties should be addressed in the development of any self-
management intervention to tackle different aspects of patients’ management of 
chronic disease. DSME reflects the characteristics of being complex intervention and 
should be developed as an intervention with an interacting component. 
1.6 MRC framework: 
The Medical Research Council (MRC), defined complex interventions as an 
intervention that consists of several interacting components and need to be 
formulated in a standardized way of design and evaluation (Craig et al., 2008). 
Therefore, developing and evaluating complex intervention entail systematic phased 
approach as have been described by Campbell et al. (2000). Developing the 
intervention starts by identifying an appropriate theoretical framework that 
correlates and link the active ingredients properly to cause a change, modelling the 
intervention (how does it work), and evaluation (Craig et al., 2008). Evaluation should 
be rigorous and comprehensive enough to understand how the intervention works 
and how its components are integrated within causal mechanism and manipulating 
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the desired effects (Greenhalgh, 2002). They stated that develop better future 
complex interventions requires to consider previous results from systematic reviews 
of DSME interventions and theoretical frameworks that were used in developing 
previous interventions to establish the best available evidence in literature.  
MRC framework are described into five phases according to Campbell et al. (2000) 
and are presented in Table 1 .A pre-clinical phase to explore relevant behavioural 
change theories to ensure the best available evidences are followed in developing 
the intervention, hypothesis and familiarise with the confounders. The first phase is 
the modelling phase. Modelling the intervention means to recognise the active 
components of an intervention and understand the embedded causal mechanism 
that may influence the related outcomes. Understanding how components are 
correlated and interconnected provides a substantial information for designing both 
the intervention and evaluation process. The second phase is the exploratory phase 
that describes the constant and variable components of the intervention and outline 
a feasible protocol for comparing the intervention with control group. During this 
phase, a large amount of information is gathered throughout previous phases to be 
used in developing the intervention, study design and evaluation as well as defining 
the comparative arm. A previously established effect size is used to calculate the 
sample size for the definitive trial. Outcome measures should be comprehensive and 
relevant to the patients with the disease conditions and if possible, to be assessed in 
trials. The third phase is to compare the developed intervention with a control group 
using a controlled, replicable and theoretically based study design with appropriate 
statistical power that allocate participants randomly to study groups to prevent 
23 
PhD Thesis September 2020 Student ID 4220143 
 
selection bias. Outcomes should be classified to primary and secondary outcomes in 
this phase and long term follow up is necessary to determine the sustainability of the 
changes on short or long term. The fourth phase is to widely implement the 
intervention on long term and in other settings. Process and outcomes evaluation 
should be reported properly with a clear description of the intervention to allow 
replication and evidence synthesis using the study-related reporting guidelines to be 
used by others. A process evaluation adds more insight into trial intervention to 
understand the causal assumptions that underpinning the DSME intervention and 
how it works in real life. It provides more understanding into the way the intervention 
is implemented, how it works, elucidate causal mechanisms. Furthermore, it can 
identify the contextual factors that may be related to the changes in the outcomes 
to facilitate the assessment of the quality of the implementation. All the previous 
phases are recommended to be followed within any RCTs that examines the 
effectiveness of a complex intervention. As such, the process of developing and 
evaluating complex interventions require several studies, research team and fund to 
indicate all of them which is not feasible within PhD. However, researcher has 
addressed the MRC framework satisfactorily in this trial.  
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To explore relevant theories to ensure the best available evidence are 
followed in developing the intervention and hypothesis.  
Phase 1 Modelling the intervention to recognise the active components of an 
intervention and understand the causal mechanism  
Phase 2 The second phase is the exploratory phase that describes the 
components of the intervention and outline a feasible protocol. 
Phase 3 The third phase is to conduct a randomised controlled trial to compare 
the developed intervention with a control group.  
Phase 4 The fourth phase is to widely implement the intervention on long term 
and in other settings.  
Table 1 MRC framework phases as was described by Campbell et al. (2000) 
In conclusion, Campbell et al. (2007) from MRC, encourage researchers to implement 
behavioural change theories or models that conceptualizing measurable 
determinants while designing a behavioural intervention, permitting for recognizing 
whether the intervention was more or less effective in promoting behaviour, thus, 
improving the underlying mechanism of behavioural performance. The need for 
developing an effective DSME is crucial, and this process needs to be in a phased 
approach, starts by defining theoretical structure. In the next section, a review of the 
literature is presented to show how the intervention theoretical framework was 
identified using the best available evidence.  
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1.7 Literature review: 
Searching and reviewing the literature occurred in an iterative approach to fulfil the 
systematic phased approach described in the above section by MRC framework. As 
per the recommendations of Craig et al. (2008) in their publication about developing 
complex interventions, published systematic reviews, stakeholders’ statements and 
meta-analysis of studies about DSME programs were chosen to be reviewed to 
explore relevant evidence-based theoretical framework in the pre-clinical phase. 
Ideally, researcher is required to carry out systematic review unless there is one 
available in literature. Then, another search strategy was carried out to identify 
studies that used the chosen theoretical model to recognise the active components 
and their casual mechanism prior developing the DSME intervention. 
1.7.1 DSME Systematic reviews (pre-clinical phase): 
At this stage, reviewing literature review aimed to identify theoretical framework 
that was successful in improving the desired outcomes effectively after delivering 
DSME (Campbell et al., 2000). Therefore, researcher widely reviewed the literature 
through several databases such as MEDLINE, PubMed, CINAHL, PsycINFO, Web of 
Knowledge, Web of science and SCOPUS. Searching strategy used the following 
keywords and subject headings: 
1- Diabetes: Diabetes Complications/ or Diabetes Mellitus, Type 2/ or Diabetes 
Mellitus/ or NIDDM/ or Non-Insulin Dependent Diabetes Mellitus.  
2- Self-management: Self-Care 
3- Education: Health Education/ or Patient Education as Topic/ or Education/ or 
Patient Education Handout/ or "Early Intervention (Education)"/ or "Physical 
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Education and Training"/ or Nursing Education Research/ or Competency-
Based Education/ or Area Health Education Centres/ or Education, Nursing. 
The outcome of the above searching strategy resulted in 642 studies where 189 
studies were identified and included different delivery models such as technology or 
other chronic diseases alongside T2DM.  Only 81 studies were about the 
effectiveness of DSME for patients with T2DM in RCTs. Those 81 studies were 
screened and found that 16 reviews had the highest quality to be included. 
Zhao et al. (2017)  published a systematic review and meta-analysis to synthesize the 
effects of theory-based self-management educational interventions on patients with 
T2DM in RCTs following Cochrane methods. They found that theory-based self-
management education of patients with T2DM is limited in literature. The chosen 
studies showed improvements in the intervention groups in HbA1c, self-efficacy, 
diabetes knowledge, and self-care behaviours. It was noticeable that self-efficacy 
was improved in groups who received the intervention due to the psychological 
component in most of the interventions as they were theory-based. Conclusion on 
the quality-of-life level could not be drawn due to the heterogeneity factor. 
Cheng et al. (2017) did a meta-analysis of RCTs to synthesis a scientific evidence on 
studies that examined the effectiveness of interactive self-management 
interventions in poorly controlled patients (HbA1c  7.5%) with T2DM. Their meta-
analysis showed that interactive self-care behaviours improved significantly HbA1c, 
self-efficacy, diabetes knowledge and reduced diabetes-related stress. Behavioural 
change techniques such as providing tailored feedback on performance, problem-
solving, and action planning, were associated with a significant reduction in HbA1c. 
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in their conclusion, they emphasized on the importance of developing complex 
interventions on theoretical frameworks due to the noticed weakness in the 
literature. 
Almutairi et al. (2020) conducted a systematic review to assess the effectiveness of 
DSME that used patient activation intervention within patient with T2DM on their 
glycaemic level and self-management behaviours. They found that seven studies out 
of the reviewed ten studies showed significant reduction in HbA1c in patients who 
were in the intervention group, particularly, those who had high level of HbA1c at 
baseline. In addition, those that showed improvement in HbA1c had at least an 
improvement in one self-care behaviour such as diet, physical activity or glucose self-
monitoring. 
 (Fredrix et al., 2018) reviewed the effectiveness of goal-setting interventions on 
diabetes outcomes and to identify the most frequent used behavioural change 
technique in those interventions. Their review found that Feedback and monitoring’ 
techniques were less frequent and was found in only two of the 12 studies despite 
the fact that it is an active component of goal-setting theory and can have significant 
impact on diabetes-related outcomes especially HbA1c. They concluded that goal-
setting technique appeared to reduce HbA1c, however, more research is needed to 
consolidate this evidence. 
A systematic review conducted by Dube et al. (2015) on DSME studies that took place 
in high and low mortality developing countries. Their main aim was to provide a state 
of the art of current practices and assesses educational programs outcomes among 
published articles between 2009 and 2013. The inclusion criteria were restricted only 
28 
PhD Thesis September 2020 Student ID 4220143 
 
for studies that provided full description of the DSME intervention among patients 
with T2DM and were assessed using a validated checklist for measuring study quality. 
Accordingly, they identified three reviews and 23 primary studies that were 
conducted in developing countries. Despite the evidence of the effectiveness of 
DSME in this review, they also identified shortcomings in those DSME programs. They 
found that very few studies reported the qualification of those who delivered DSME 
or their training. They stated that without a qualified provider the quality of DSME 
program cannot be certain. Moreover, seven interventions were found to be steered 
by behavioural change theories or supported by theoretical frameworks and those 
found to produce significant improvement in patients’ outcomes despite the 
methodological weaknesses in their study designs. However, they concluded that 
several influences were found to impact the effectiveness and sustainability of DSME 
programs outcomes; underpinning interventions by behavioural change theories, 
health care provider qualifications and the cultural sensitivity of programs. They 
added that by including these factors, it is predicted that the effectiveness of DSME 
programs in developing countries will be boosted. The ultimate goal of DSME is 
enabling patients adopting healthy lifestyle and it is all about the core component of 
changing daily behaviours, in other word, DSME programs should target patients’ 
behavioural skills alongside with metabolic outcomes (Pbert, 2013). 
Back in 2001, one of the milestones in DSME field was a systematic review that was 
done by Norris et al. (2001) to review the effectiveness of self-management training 
programs in 72 RCTs published between 1980-1999. They wanted to provide 
comprehensive guidelines to guide future diabetes self-management programs. 
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Their conclusion regarding interventions effectiveness and methodological quality 
assessment in the reviewed studies was noteworthy. They stated that didactic 
interventions that focused on providing knowledge showed a significant 
improvement on patients’ information outcome within less than six months, mixed 
results on glycaemic level and blood pressure but not on weight. Despite the 
statistically significant relationship between the knowledge and glycaemic control in 
some studies, the effectiveness of knowledge on glucose level was mediated by other 
factors. These factors need to be addressed in future DSME interventions to improve 
the sustainability of glycaemic control. Although metabolic outcomes could be 
improved by intensive treatment, incorporating patient’s attitudes and motivational 
strategies within educational programs proved to achieve better metabolic control 
than providing knowledge alone. The relationship between Self-Monitoring Blood 
Glucose (SMBG) and glycaemic control was not statistically significant in most 
studies. 
Norris et al. (2001) and the team clarified that results were consistent with previous 
DSME reviews. Clement (1995) in a qualitative review stated that behavioural 
changes strategies were more effective than didactic programs, particularly, if they 
were integrated with medications titration and frequent reinforcement of 
educational messages in more than single session. Other reviews noted that effective 
DSME should be individualized to patients’ lifestyle and routine habits, goal setting 
and planning; a variety of self-management training and support, considering 
patients’ readiness to change and self-efficacy (Anderson, 1990 , Von Korff et al., 
1997 , Wagner et al., 1996 , Mullen et al., 1985). According to the methodological 
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quality assessment, Norris et al. (2001) stressed the noticeable lack of blinding 
outcomes assessors, deficits in the reliability and validity of the tools used to evaluate 
knowledge and self-care activities. Moreover, DSME interventions were 
inadequately described in literature, and few studies based their intervention on 
behavioural change theories and data were insufficient to choose the most effective 
behavioural theory. They concluded that behavioural change theories had vital role 
and should be employed in future DSME to improve the understanding of behaviour 
change in self-management. They added that the impact of DSME on patient’s quality 
of life should be a major concern in future research. All these recommendations can 
guide future DSME intervention, but they did not emphasise or recommended 
specific behavioural change theory. Another meta-analysis conducted by Norris et al. 
(2002) on the effect of DSME on glycaemic control disclosed that contact time 
between health care provider/diabetes educator and patient was the only significant 
predictor to show improvement on glycaemic level. To explain, total duration of 23.6 
hours of contact time found to predict an absolute decrease of 1% in HbA1c and this 
was found to be significant to avoid or prolong diabetes complications as have been 
shown by the epidemiological scrutiny of UKPDS results earlier in this chapter. 
Gary et al. (2003) conducted a meta-analysis of randomized educational and 
behavioural interventions to assess their effect on body weight and glycaemic control 
among patients with T2DM. They identified 18 studies that were published between 
1966 and 1999 and were used in the main quantitative analysis. Briefly, they found 
that educational and behavioural interventions were responsible for 0.45% decline 
in HbA1c and this improvement was statistically significant.  
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Furthermore, Knight et al. (2006) reviewed behavioural educational interventions 
that were examined in RCTs to summarize the empirical evidence-base of DSME. 
They identified 37 studies that were published between 1990 and 2003. The review 
showed that only 50% of studies incorporated a behavioural component, only one-
third used psychosocial elements in those interventions and around 20% were 
theoretically based. They stated that interventions based on behavioural change 
theories were explicitly absent. They concluded that transferring knowledge can 
improve glucose level only by making people behave differently, and knowledge was 
an essential component of DSME process but not sufficient to enhance patient’s 
abilities for behavioural change. In addition, they suggested that producing the most 
effective and positive outcomes needs to develop a multifactorial intervention that 
should include teaching, counselling and behavioural modification strategies. These 
factors can influence patient’s knowledge and skills to make informed choices for 
autonomic self-care behaviours change, empowering them to engage self-
management into daily lives, and ultimately, improve glycaemic level and reduce 
diabetes complications. Moreover, they emphasized on the Scottish Intercollegiate 
Guidelines Network statement that was published in 2001 and stated that patients 
with diabetes should receive lifestyle interventions based on valid theoretical 
framework such as empowerment or motivational interviewing, follow up behaviour 
modification and support by telephone (2001).  Their conclusion recommended that 
DSME interventions should integrate behavioural change theories and psychosocial 
concepts that potentially strengthen the link between education process and the 
performance of self-management activities. This can occur by motivating patients to 
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maintain autonomy and independence, hence, improve the effectiveness of DSME 
program. 
In order to clarify the effectiveness of DSME, Clark (2008) reviewed the published 
evidence in several systematic reviews in the literature. His review concluded that 
there is no one superior DSME program. However, programs incorporating 
psychological and behavioural change strategies, culturally and age appropriate 
additionally with ongoing support through phone calls and behavioural goal setting 
techniques would ultimately improve metabolic as well as quality of life outcomes. 
Similarly, Borgermans et al. (2008) published a review of 21 systematic reviews that 
aimed to explore views on high quality diabetes care and related quality indicators. 
They stressed that despite the wide variety and heterogeneity in DMSE programs, no 
single conceptual framework was comprehensive to provide an overview of 
attributes of high-quality diabetes care to self-care structure, process and outcome 
level, and eventually, metabolic outcomes. They addressed the need for a rigorous 
action to develop a standardized framework on high-quality diabetes care 
complemented by a practical tool to provide guidance to the design, implementation 
and evaluation of DSME programs.  
While searching for either a conceptual model or theoretical framework, Greaves et 
al. (2011) conducted a systematic review of 30 reviews to summarise the evidence 
related to the content of interventions for promoting dietary and physical activity 
change to their effectiveness in behavioural change enactment. In their review, they 
found that interventions that used self-regulatory techniques such as goal-setting 
theory, self-monitoring practice, providing feedback on performance and goal review 
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had an association with an increased effectiveness in weight loss, change in dietary 
and physical activity behaviours. 
The Cochrane Metabolic and Endocrine Disorders Group (CMEDG) published a 
systematic review that was done by Duke et al. (2009) to evaluate the effectiveness 
of individualized DSME interventions on metabolic control, diabetes knowledge and 
psychosocial outcomes. Their findings showed significant advantages of those 
individualized DSME on glycaemic control in a subgroup analysis among patients with 
a higher mean baseline HbA1c > 8%. This result proposed that one of the challenges 
in validating DSME benefits on diabetes patients’ clinical parameters are related to 
the patients’ characteristics who participated in previous DSME studies. This can 
inform future DSME programs to target the appropriate patients by detecting those 
who have uncontrolled glycaemic level HbA1c > 8.0% and refer them to diabetes 
educator. Furthermore, DSME that consisted of personally tailored and patient-
centred messages proved to be more effective than the generic DSME “one-size-fits-
all”, which is commonly delivered in the form of targeted group-level curriculum 
(Kreuter and Skinner, 2000). 
Another systematic review of RCTs that was conducted by Baker et al. (2011) aimed 
to understand and translate the evidence of effective behavioural change strategies 
for lifestyle T2DM prevention programs that was published between 1966 and 2009. 
This review showed that behavioural strategies used in these interventions, included 
a multiplicity of theoretical methodologies including Social Cognitive Theory, the 
Trans-theoretical Model, and the Theory of Planned Behaviour. Their implication for 
future research emphasized on the integration of vigorous behavioural change 
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strategies in DSME programs and the noticeable absence of thorough individualized 
educational delivery.  
As a conclusion for the above reviews, there is a continuous need for further 
individualized diabetes education studies based on behavioural change theory and 
self-regulatory techniques that need to include knowledge provision, teaching self-
care behavioural skills and focus on psychological aspects such as motivations and 
beliefs. This may help to secure optimal effectiveness on metabolic outcomes. 
1.7.2 The Theoretical Model: 
A systematic review of the psychometric properties and theoretical grounding of 
instruments evaluating self-management activities among patients with T2DM for 
the published studies between 1990 and 2012 was conducted by Caro-Bautista et al. 
(2014). This review aimed to provide valuable information for researchers on 
selecting the most appropriate instrument to evaluate patients’ self-care 
requirements in diabetes care research. They indicated that diabetes care is 
multidimensional and barriers in diabetes self-care behaviours are consisted with the 
Information-Motivation-Behavioural skills model (IMB). This model focuses on the 
set of Informational (diabetes knowledge), Motivational (both personal and social) 
and Behavioural skills (targeted behaviour-related skills) factors that are conceptually 
and empirically associated with changing health-related behaviour See Error! 
Reference source not found.. Indeed, this model has been used previously to address 
behaviours in other contexts. For example, It has been shown to be effective in the 
construction of educational programmes and prevention interventions for clients 
living with HIV risk (Fisher and Fisher, 1992). 
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Figure 1 Information-Motivation-Behavioural model 
IMB model included diabetes information and motivational constructs and both were 
considered the key determinants of changing patient behaviour, consequently, 
improving the glycaemic level. Therefore, instruments that were grounded by the 
IMB Model were extensive enough to assess the required personal and social 
motivations to promote behavioural change (Osborn and Egede, 2010). 
After exploring the IMB behavioural change model, an extensive search for studies 
that used this model with diabetes patients took place in databases such as MEDLINE, 
PubMed, CINAHL, PsycINFO, Web of Knowledge, Web of science and SCOPUS for 
those published until 2017. Searching strategy used the following keywords and 
subject headings: 
1- Diabetes: Diabetes Complications/ or Diabetes Mellitus, Type 2/ or Diabetes 
Mellitus/ or NIDDM/ or Non-Insulin Dependent Diabetes Mellitus.  
2- Self-management: Self-Care 
3- Education: Health Education/ or Patient Education as Topic/ or Education/ or 
Patient Education Handout/ or "Early Intervention (Education)"/ or "Physical 
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Education and Training"/ or Nursing Education Research/ or Competency-
Based Education/ or Area Health Education Centres/ or Education, Nursing. 
4- IMB model: Health Behaviour/ or Motivation/ or Models, Psychological/ or 
Adult/ or Health Education/  
5- Motivation: Motivation/ 
6- Behavioural skills: Health Education/ or Health Knowledge, Attitudes, 
Practice/ or Adult/ or Behaviour Therapy/  
Results of searching strategy found 393 studies where 383 studies were excluded for 
either being reviews, duplications or about other diseases. Ten publications were 
identified, and seven studies were relevant to IMB model with diabetes. In the next 
sections, an exploration of IMB model fundamental assumption is addressed 
additionally with an overview on the limited number of studies that used IMB model 
in the literature. 
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1.7.3 Diabetes self-care and IMB model:  
Osborn and Egede (2010) hypothesized that the theoretical assumption of IMB 
model could be significantly associated with performing diabetes self-care 
behaviours, and this would be significantly associated with glycaemic status. 
Therefore, she conducted a cross sectional study to evaluate IMB model with 
consideration to diabetes self-management behaviour through structural equation 
model tests. The Information-Motivation-Behavioural skills model (IMB) was used to 
functionalize the main determinants of diabetes self-care behaviours and glycaemic 
control. They proposed that patients who had more diabetes knowledge, more 
personally motivated (positive attitudes toward healthy behaviour) and more socially 
supported for that behaviour are expected to impact the level of practicing self-care 
behaviours positively, thus, enhancing glycaemic control. Study findings showed that 
more diabetes knowledge, less fatalistic attitudes and more social motivations were 
not significantly correlated in the model by measuring the covariance. In contrast, 
they were significantly independent and direct interpreters of diabetes self-care 
behaviours that ended up explaining 17% of variance in SDSCA score (Osborn and 
Egede, 2010). Using IMB model, diabetes knowledge, diabetes fatalism and social 
support were not significantly associated with HbA1c, but diabetes self-care 
behaviours such as healthy diet, blood glucose testing and foot care were directly 
associated with lower HbA1c, which is consistent with IMB model assumption. These 
findings recommended that IMB model was appropriate to conceptualize the main 
determinants of diabetes self-care behaviours where information and motivation 
were essential elements. They concluded that more research is necessary to identify 
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the role of self-care behavioural skills, which were prerequisites for any behavioural 
change performance. 
After IMB model Validation study, Osborn et al. (2010) conducted a randomized 
controlled trial to evaluate a brief intervention that was developed to address 
predefined barriers and facilitators of Diabetes Self-Care Behaviours (DSCBs). The 
intervention was delivered based on motivational interviewing strategies to provide 
Puerto Ricans patients with T2DM the knowledge and behavioural skills. The model 
drove the intervention’s design, content, delivery, and evaluation. However, they 
hypothesized that patients in the intervention group are expected to have better 
outcomes than control group in glycaemic control and diet adherence and physical 
activities. They did not follow up study participants and delivered the educational 
message in one session. 
The intervention was based on three elements of IMB model and interwoven into 
one session lasted approximately 1.5 hours. As far as the intervention was evaluated 
after three months endpoint, patients in the intervention group were reading food 
labels and adhering to the diet recommendation significantly more than patients in 
the control group from baseline. On the other hand, there was no significant effect 
on exercise behaviour between groups from baselines despite the higher score of 
physical activity among patients in the intervention group from baseline compared 
to control group. As for glycaemic control, patients in both groups showed an 
improvement in HbA1c and decreased from baseline, but improvement was only 
significant among patients in the intervention group. However, adjusted HbA1c 
values didn’t change between the intervention and control groups at endpoint. 
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At the end, they concluded that intervention was effective enough to decrease 
HbA1c by 0.48% in the intervention group through an hour and a half contact time. 
Regarding contact time, Norris et al. (2002) proposed earlier that patient contact 
time was the only clinical significant predictor of improvement in HbA1c and 
concluded that 1% decrease in HbA1c required 23.6 hours of contact time. Osborn et 
al. (2011) stated that their IMB model-based intervention improved HbA1c by what 
it equals 11.8 hours to achieve according to the results published by Norris et al. 
(2002). Moreover, the they stated that the impact of their intervention was greatest 
among those with higher levels of HbA1c >7%, a secondary analysis showed a 
reduction of 0.80% in HbA1c in the intervention group from baseline in another 
publication for the same study (Osborn et al., 2011). This study was the first to design 
a culturally tailored diabetes self-management intervention based on IMB model. It 
showed the potential usefulness to be used for designing future individualized 
diabetes self-management interventions. They recommended that IMB model has 
shown its usefulness to be used for designing future individualized DSME 
interventions and suggested that providing several follow up sessions by phone calls 
or home visits over an extended period of time would enhance the intervention 
effectiveness by giving more time to practice the educational content to implement 
multiple behavioural changes. In addition, follow up period would be crucial in future 
studies to uncover the sustainability of the intervention impact on diabetes self-
management behaviours and glycaemic control. Furthermore, Osborn et al. (2010) 
published an analysis of MB model on diet and exercise self-care behaviours for the 
same conducted RCT among Puerto Ricans to discuss the efficacy of using IMB model 
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in designing and evaluating DSME that are focused on promoting healthy eating and 
physical activity behaviours. 
Data was analysed by structural equation modelling to identify the relationship 
among the constructs for each of the diet and exercise self-care behaviours. Osborn 
et al. (2010) showed that the model accounted for 46% of the variability in diet 
behaviour and was significantly related with lower HbA1c level. In contrast, exercise 
self-care behaviour has been explained by the IMB model and accounted for 23% of 
the variability but the behaviour was not significantly associated with lower HbA1c. 
However, she referred the non-significant association with HbA1c for the lack of 
sufficient sensitivity of the used measures to detect true relationships and the 
possibility of being a cross sectional study that measuring all constructs at a single 
point of time. She concluded that the results supported using IMB model to 
conceptualize diet and exercise behaviours determinants and to develop IMB model-
based intervention targeting diet and exercise self-care behaviours. 
In Iran, Gavgani et al. (2010) conducted a study to assess the effectiveness of IMB 
model on self-care behaviours and HbA1c among 30 patients with T2DM who had 
HbA1c>7% and attending an endocrine specialization clinic. Patients were assessed 
for their diabetes self-care activities by SDSCA, weight and HbA1c were measured at 
the day of clinic visit and after two months. They concluded that providing knowledge 
and motivation to improve behavioural skills in diet adherence and physical exercise 
were beneficial in improving behavioural change and HbA1c level among patients 
with T2DM. In Gavgani et al. (2010) study, there were limitations such as small 
sample size that would threat the generalizability of the results and limited statistical 
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power. In addition, there were not any details mentioned in study manuscript about 
study design, participants’ allocation sequence or the description of intervention. 
1.7.4 Diabetes self-care in Jordan: 
The only study in Jordan was a RCT conducted by Jarab et al. (2012) to evaluate the 
effectiveness of a pharmacist-led intervention program on metabolic outcomes and 
self-management behaviours among uncontrolled T2DM patients (HbA1c>7.5%). 
Patients were recruited and allocated to either intervention group or control group 
within a period of four months. However, patients in the intervention group were 
given a home copy of an educational booklet on meal planning, physical activity and 
medications management and were prepared to assist them in educational sessions. 
Each patient received 8 weekly phone calls to provide feedback for their concerns. 
Each call lasted approximately 20 minutes to emphasize the importance of 
adherence to the prepared plan. On the other hand, patients in the control group 
received only the usual care that included a treating physician visit each three or six 
months. In their study, a sample size of 250 patients attended the primary clinic and 
were assessed for eligibility where only 180 patients were eligible. Clearly, due to 
many causes such as refused to complete follow up period or absence of outcome 
measurements, 77 patients completed the study in the intervention group and 79 
patients in control group. Patients in both groups were assessed at baseline and at 
the end of 6 months for medications adherence and diabetes self-care behaviours. 
After data analysis, patients in the intervention group showed a significant reduction 
in both systolic and diastolic blood pressure, lipid Profile except HDL and a significant 
reduction of 0.8% in HbA1c over six months compared to patients in the control 
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group. Whereas for BMI, patients in the intervention group experienced reduction in 
weight compared to control group, but this reduction was not statistically significant. 
They concluded with the recommendations of providing individualized self-
management education by determining types and proportions of healthy eating, 
physical exercise, regular telephone follow up support as well as optimizing 
pharmacotherapy. All these factors helped in significant improvements in study 
outcomes. But there were some methodological limitations in their study; for 
example, the educational intervention was not established on theoretical framework 
and was not explicitly described and lacked in assessing the outcomes blindly by an 
independent assessor.  
1.7.5 Why using IMB model? 
In particular, IMB model provides a simple theoretical framework for complex 
behaviours that makes it easier to be translated empirically as well as specify 
relationships between constructs. In Osborn et al. (2010) study, the effectiveness of 
DSME using IMB model in 1.5 hours session was significant enough to decrease 
HbA1c compared to 11.8 hours needed to accomplish the same decrement. 
Although, this considerable improvement was as a result of one session, using 
ongoing educational support that addresses multiple self-care behaviours can 
enhance the sustainability of patients’ self-management behaviours, which was 
recommended by Norris et al. (2001); thus, extend the improvement of glycaemic 
control. In addition, Chang et al. (2014) systematically reviewed the IMB model-
based behavioural interventions to investigate specific intervention strategies and to 
evaluate their effectiveness for people with different chronic diseases. They detected 
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12 studies, of which nine studies investigated patients with HIV. They concluded that 
IMB model is a robust theoretical framework for developing behavioural 
interventions among patients suffering from chronic diseases. In their review, they 
found that the effects of IMB model-based interventions on behavioural changes can 
persisted up to 12 months and this was clear in those studies that followed up 
patients for 12 months. Moreover, a report by Fisher et al. (2014) stated that IMB 
model was widely used in cross sectional studies and need to be further tested in 
experimental research. They stated that those studies that used IMB model and 
tracked the induced changes in IMB main determinants are very few in literature and 
remain a challenge. 
1.7.6 Current Research Gap: 
The literature is still limited in studies examined individualized DSME programs 
underpinned by theoretical framework, particularly, behavioural change theories. 
Several limitations in literature should be addressed in future studies such as: 
frequent reinforcement of educational messages more than single session, 
integrates psychological factors and being individually tailored, patient centred as 
well as suites busy clinic.  
Rigour methodological techniques in developing intervention and study designs such 
as employing blinding outcomes assessor additionally with using reliable and valid 
tools to evaluate the intervention are prerequisites in forthcoming studies. In 
addition, implementing IMB model would consider a unique step in diabetes care 
providing a high-quality standardized framework to guide the design, 
implementation and evaluation of DSME program. 
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DSME interventions were widely examined through RCTs in literature and very few 
studies used qualitative method or used combined methods to evaluate the 
effectiveness. therefore, the original plan was to study the effectiveness of IMB 
model-based intervention using a a mixed-methods approach but due to the timeline 
of the PhD program, it was agreed to examined the effectiveness through 
randomised controlled design due to the high level of control in this design in 
comparison to other study designs. 
1.7.7 Research hypothesis: 
The primary hypothesis in this trial entailed that participants who received the IMB 
model based DSME in the intervention group were predicted to experience greater 
improvement in three self-care behaviours; diet, physical activity and medications 
management, than participants who received the Treatment As Usual (TAU) in 
control group at three-month and six-month points. A secondary hypothesis 
proposed that those who received the IMB model based DSME were also predicted 
to report greater level in diabetes knowledge, motivation, behavioural skills, quality 
of life and glycaemic control compared to those in control group at three-month and 
six-month points. 
1.7.8 Research question: 
The research question in this trial was formulated as follow: what is the effectiveness 
of the IMB model based DSME intervention on the three self-care behaviours, diet, 
physical activity, medications management self-care behaviours and on other 
secondary measures such as HbA1c and quality of life at three-month and six-month 
visits among patients with T2DM compared to the usual care in Jordan? 
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2 Developing and designing the IMBDSME intervention: 
As mentioned above in section (1.4), DSME interventions are important in diabetes 
management to change unhealthy lifestyle behaviours to improve glucose level and 
avoid microvascular or macrovascular complications. DSME needs to be multifaceted 
and includes several interactive components to be effective as was described by the 
MRC as complex interventions. Therefore, DSME interventions should be 
underpinned by behavioural change theories and effective strategies to alter 
patients’ behaviours and achieve constructive behavioural outcomes. 
According to MRC framework in section (1.6), the process of developing complex 
intervention such as DSME is a phasic process and starts with collecting the best 
evidence and choosing a theoretical framework from the literature before 
progressing to modelling. In the previous chapter, it was explained why the IMB 
model was chosen as the theoretical framework where it was used to link the 
essential determinants of the IMB model with the required behavioural change 
techniques in this DSME intervention. 
2.1 Theoretical framework (IMB model): 
The Information-Motivation-Behavioural skills (IMB) model focuses on set of factors 
of informational, motivational and behavioural skills that are conceptually and 
empirically associated with changing health-related behaviours. It determines a set 
of causal relationships among the constructs as well as a set of techniques to be 
employed in translating the model into behavioural change interventions (Fisher and 
Fisher, 2000). This section introduces the origins of the IMB model and its 
fundamental assumptions. 
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2.1.1 IMB model development: 
William Fisher and Jeffery Fisher, both used the concepts of previous models and 
theories such as the theory of reasoned action (Fishbein and Ajzen, 1975), theory of 
planned behaviour (Ajzen, 1991) and social-cognitive theory (Bandura, 1977) to 
construct the Information-Motivation-Behavioural skills (IMB) Model. The IMB model 
was critically constructed based on analysing previous prevention programs and 
health promotion interventions as well as addressing limitations of the 
aforementioned theories that have been used in other areas of health behaviour in 
the literature such as HIV risk and prevention interventions (Fisher and Fisher, 1992). 
Limitations such as the absence of a clear definition of the specifications of the 
relationships between active ingredients, weakness of predictive validity between 
the constructs, lack of constructs that might be essential to the changing of health-
related behaviours and finally the difficulties in empirically translating the theoretical 
constructs were inherited in those theories. As a result, those theories became 
intuitively translated and the benefits were diminished to generate substantial 
literature (Fisher et al., 2003). They developed the IMB model to involve and 
implement social psychological factors of HIV risk in future preventive behaviours 
(Fisher and Fisher, 1992 , Fisher and Fisher, 1993).  
2.1.2 IMB fundamental assumption: 
The IMB model fundamental assumption proposed that health-related behaviour 
information, motivation and behavioural skills were primary determinants of 
promoting health behaviour. As a fact, the model assumes that a well-informed 
client, well-motivated and possess the required behavioural skills of a specific 
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behaviour is more likely to initiate and adjust a health promotion behaviour 
positively. Figure 2 presents the IMB model constructs. 
 
Figure 2 IMB model constructs adapted from Fisher and Fisher (1992) 
According to the IMB model, health behaviour information is directly associated with 
the health behaviour skills and can be indorsed easily in client’s social environment, 
which is essential in behavioural performance, and can indicate simple facts or 
relevant heuristics that tolerate rational decisions automatically to interfere and 
guide effective health promotion behaviour (DiClemente et al., 2002).  
Motivations to involve in health promotion behaviour is another primary 
determinant of health behavioural change that well-informed individual is persuaded 
to perform what they know about health behavioural skills. According to IMB model, 
motivation has a critical influence on performance of health promotion behaviour in 
two ways, personal motivation and social motivation. Clearly, personal motivation is 
demonstrated in the personal attitudes toward performing specific health–related 
behaviour, and social motivation is implied as the perception of social support for 
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Behavioural skills determinant is the third and last critical part of the IMB model of 
whether well-informed and well-motivated individual is more likely to practice the 
health promotion behaviour effectively. The behavioural skills determinant is 
composed of client’s actual objective abilities and his perceived self-efficacy 
regarding the practice of specific health behaviour (Fisher et al., 2003).  
The IMB model determines that both information and motivation of a health-related 
behaviour are expressed through the deployment of behavioural skills, which directly 
influence and initiate the performance of that behaviour (Fisher and Fisher, 2000). 
Furthermore, the model also asserts that information and motivation have direct 
effect on initiate and practice the behaviour, in a fashion that behaviour does not 
requisite to possess such behavioural skills as critical element (Fisher and Fisher, 
2000). From IMB model perspectives, well informed client should not be necessarily 
well motivated to perform health promotion behaviour, and highly motivated client 
should not be necessarily well informed to practice health promotion behaviour, 
which potentially implies that those two constructs are independently associated 
(Fisher and Fisher, 2000). 
2.1.3 IMB model procedures: 
The IMB approach to promote and understand specific health-related behaviour 
specifies number of procedures in order to design, implement and evaluate particular 
population’s health promotion behaviour of interest. The first procedure is to assess 
weaknesses and properties related to the information, motivation and behavioural 
skills of specific health behaviour for particular population of interest (Fisher et al., 
2003). 
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The second procedure involved designing and implementing conceptually based and 
empirically targeted intervention. The identified weaknesses and properties in the 
assessment procedure and are related to the information, motivation and 
behavioural skills determinants should be addressed and treated in the empirically 
targeted intervention (Fisher et al., 2003). 
The third and final procedure involved the conduct of methodologically rigorous 
intervention evaluation to conclude whether the intervention can produce significant 
effects on the level of information, motivation and behavioural skills determinants 
that are directly related with performing and maintaining particular health 
promotion behaviour (Fisher et al., 2003). The IMB model set of procedures are well 
explained in Figure 3. 
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2.2 Developing the trial Intervention: 
The process of developing and designing complex interventions has always been 
considered as challenging. In literature review in (1.7), it can be seen that theories of 
behavioural change offer little information about how to select and identify the 
appropriate methods or techniques and translating them into practice. Equally, there 
is a lack of a detailed guidance on how to progress through the initial phases of the 
MRC framework for developing complex intervention, in particular, the referral to 
develop a theory-based intervention. Subsequently, these theories were used more 
commonly to inspire the development of interventions or to develop measures 
rather than developing theory-based interventions. As a result, a framework was 
required to provide researcher with a manual to decide at each step during 
intervention development, and in this trial, researcher followed the Intervention 
Mapping (IM) approach. 
2.2.1 Intervention Mapping (IM) concept: 
The process of mapping behavioural change techniques on the behavioural 
determinants of a chosen theory is called Intervention Mapping (IM). It is a problem-
driven process and explains how to integrate theories and behavioural outcomes 
stage by stage during the intervention development. IM is essential to advance the 
benefits of developing theory-based intervention and achieve behavioural outcomes 
(Eldredge et al., 2016 , Bartholomew and Mullen, 2011). It was used to develop self-
management programs for several chronic diseases such as stroke, asthma, diet and 
physical activity (Schmid et al., 2010 , Dima et al., 2016 , Brug et al., 2005). The IM 
approach can be applied to target multiple levels such as individual, community or 
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organisation. However, in this trial, the aim was to develop and examine an 
individualised DSME intervention to change the behaviours of patients with T2DM as 
mentioned in section (1.7.7), thus, IM was utilised to design an individualised DSME 
intervention based on the IMB model. Although IM approach can be applied through 
several steps and each one forms the base for the other, IMB model also proposed 
its own set of procedures and behavioural determinants which were presented 
earlier in this chapter in (2.1.3). Therefore, researcher integrated both to develop the 
intervention and to inform the design of this trial and the intervention delivery. The 
DSME intervention in this trial is called IMBDSME throughout this document. 
2.2.2 Intervention Mapping (IM) steps: 
First, according to the first procedure of IMB model, an assessment for behavioural 
determinants of a health behaviour was required before implementing the 
intervention. It was required first to choose health behaviours that need to be 
changed or improved. However, by following the first step of IM approach, the needs 
of patients with T2DM in Jordan were identified within the literature. Those self-care 
behaviours were diet, physical activity and medications management as was 
explained clearly in (1.7.4). Therefore, their behavioural determinants according to 
the IMB model (Information, Motivation, Behavioural skills) were assessed along with 
clinical measurements during the trial as is presented in trial design in section (3.11). 
Second step by IM approach was defining goals and behavioural outcomes. 
Fundamentally, trial outcomes were required to be linked with the targeted health 
behaviours. After detecting the behaviours of interest during the need’s assessment, 
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trial outcomes were defined, and they are presented in (3.7) and (3.8) and were 
linked to the IMBDSME intervention. 
The following step by IM was to identify a theory that provides a theoretical base of 
determinants of behaviour change. Correspondingly, this step was the core of the 
second procedure of IMB where it discussed the need to develop and design a 
theory-based intervention. This step was crucial because it required the linkage of 
IMB determinants (knowledge, motivation, behavioural skills) with behavioural 
techniques by creating a matrix guided by the IMB theory determinants. By creating 
the matrix, it was simpler to stem proximal change objectives. Those change 
objectives were considered as the mediating factors for changing specific behaviours 
and were demanding IMBDSME intervention to influence the targeted behaviours, 
and thus, achieve the desired performance and improve quality of life and glycaemic 
control. In this case, the change in IMB determinants (knowledge, motivation, 
behavioural skills) were demanding the IMBDSME intervention to influence diet, 
physical activity and medications management self-care behaviours.  
At that point, it was required to select the methods and strategies to develop the 
IMB determinants to achieve each change outcome. Not all determinants required 
the same strategies or methods. So, due to practicality reasons as well as the timeline 
of the development of DSME intervention, researcher selected different strategies 
or methods to fulfil the requirement of every determinant as shown in sections (0), 
(0) and (2.2.2.3) below. 
After selecting methods and strategies, researcher proceeded to construct IMB 
determinants together along with their methods and planned for the 
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implementation and delivery as explained in detail in sections2.2.2.4) and (2.2.2.5). 
Then, following IM approach and IMB procedures, last step was to perform an 
evaluation of the effectiveness of delivering IMBDSME intervention on the main 
determinants, clinical outcomes and on the performance of self-care behaviours. 
Therefore, evaluation was conducted by an independent assessor after the delivering 
the intervention and after following up period as explained later in chapter (3). 
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2.2.2.1 Knowledge determinant: 
To start with the knowledge determinant, literature was searched for an educational 
material to be utilised as a source of diabetes-related information. Evidences in 
literature stressed that patients with low literacy and numeracy levels were 
independently associated with poor health-related outcomes such as glycaemic 
control (HbA1c) and self-care behaviours (Schillinger et al., 2002 , Cavanaugh et al., 
2008 , Tang et al., 2008). Moreover, Cavanaugh (2011) stated that low level of health 
literacy is prevalent among patients with T2DM and might range from 15%-40% 
depending on the targeted population. For Jordanian population, Ajlouni et al. (2008) 
found that patients with T2DM in Jordan were older and less educated compared to 
those who had a normal glucose level in their prevalence study. Out of those who 
were diagnosed with T2DM, they had a mean age of 55.5±10.6 years, and mean level 
of education of 6.3±5.6 years of education. Based on their results, patients with 
T2DM in Jordan were more likely to be older age and having an elementary level of 
education. It was clear that any efforts to develop IMBDSME programs should 
consider the low level of literacy for Jordanian patients with T2DM to produce an 
effective and comprehensible DSME intervention. An educational toolkit called PRIDE 
that fir the above requirement was selected and adopted to provide the knowledge 
regarding the targeted diabetes self-care behaviours.  
PRIDE toolkit builds on the previously validated Diabetes Literacy and Numeracy 
Education Toolkit (DLNET), which was developed by Wolff et al. (2009), the American 
College of Physicians Foundation’s Living with Diabetes Guide (CPFLDG) and the 
American Association of Diabetes Educators (AADE). DLNET was modified to produce 
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PRIDE based on the recommendations of American Diabetes Association (ADA) and 
AADE national standards for DSME as they stated that DSME materials should allow 
for cultural adaptation, interactive, include action oriented behavioural goals, be 
sensitive to patients with low literacy and numeracy skills and capabilities to afford 
treatment. The PRIDE toolkit text, layout and format were developed by literacy and 
numeracy experts, behavioural psychologist and diabetes specialists allowing for 
patients with low-literacy and numeracy skills to be educated through behavioural-
oriented images and pictograms, colour coding and plain simple language to avoid 
information complexity. PRIDE toolkit included a comprehensive set of 30 education 
modules in English to support different self-care health behaviours of T1DM and 
T2DM. All modules were designed to be used interactively between health care 
providers and patients. They were grouped into 12 categories: general information 
about diabetes, blood glucose monitoring, nutrition information, oral diabetes 
medication, insulin and exenatide, lifestyle management and behaviour change, foot 
care, cardiovascular risk factors, coping with stress and depression, oral health, 
women's health, and men's health. PRIDE modules are shown in Appendix 1. 
Wolff et al. (2016) used the Suitability Assessment of Materials (SAM) instrument to 
evaluate the PRIDE modules. SAM instrument was used to determine the weaknesses 
of each module that may decrease their suitability for low-literacy patients. The 
mean score of SAM instrument received for the modules was 91.2% (SD ± 5.4), which 
is a superior score according to SAM scoring criteria that was evaluated by two 
independents assessors. The mean reading grade level of the 30 modules was 5.3 
±1.0 ranging from the lowest of 3.7 when it was calculated by the Automated 
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Readability Index (ARI), and to a maximum of 7.7 when it was calculated by Simple 
Measure of Gobbledygook (SMOG). ARI and SMOG are online instruments; ARI is a 
readability test to assess the understandability of a text, while SMOG formula is 
method to evaluate the reading level of a written material. As for the content of the 
PRIDE, they concluded that all 30 modules scored at or below 8th grade level using 
SAM. Wolff et al. (2016) concluded that PRIDE modules were found to be literacy 
sensitive to patients with T2DM who have literacy and numeracy skills deficiencies. 
In this trial, the selected PRIDE modules were related to the targeted self-care 
behaviours diet, physical activity and medications management and included in 
IMBDSME intervention. As an introduction to diabetes, general information about 
diabetes low blood glucose and were included in the first chapter for those who 
received the intervention. However, insulin and glucose monitoring modules were 
not included and handed unless they were being treated by insulin. Hence, insulin 
and glucose monitoring modules were prepared separately to be delivered for those 
who required them. For diet self-care behaviour, modules such as “Introduction to 
Eating with Diabetes”, “using your plate to control your carbs”, “Eating Out”, “How 
Losing Weight Can Help Me”, “What Can I Eat for a Snack” and “Cholesterol” were 
used to inform about healthy diet lifestyle as was recommended by guidelines of ADA 
(2019) and AADE. For example, the three main food groups (carbs, protein and fat), 
how food affects the blood glucose level, tips on healthy cooking and how to reduce 
fat or control the cholesterol level, what consider as a snack, difference between high 
and low carbs food as well as lists of culturally appropriate (Jordanian) food for each 
food group that can be consumed on breakfast, lunch and dinner. For physical 
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activity, “Be Active” module was used to inform patients how to be more active 
during the day. For example, exercising healthy walking, using stairs instead of lifts 
and creating fun ways such as dancing. For medications management, “Diabetes 
Pills” and “Taking your Medicines” modules were used to inform patients about the 
importance of adhering and managing their medicines. While for patients on insulin 
treatment, modules such as “Drawing and Self-Injecting Insulin”, “Where to Give 
Insulin Shots” and “How to Use Insulin Pen” were explained through linear steps 
pictograms to show patients the correct way of using and injecting different types of 
Insulin such as pre-mixed, long or short acting insulin whether they use pen or 
syringe. To achieve the maximum benefit from insulin and reduce hypoglycaemic 
episodes, copies of blood glucose log sheets enough for the trial period were given 
to follow their blood glucose readings and the amount of administered insulin prior 
each meal. The log sheet aimed to correct their insulin doses according to their 
glucose readings during the interventional phone calls to stabilise HbA1c level. 
2.2.2.1.1 Translating and adapting PRIDE: 
To start with the adaptation and translation process, corresponding authors of PRIDE 
toolkit were contacted in Vanderbilt university by email, and they sent all the PRIDE 
modules with the permission to translate it to Arabic language and to use it as an 
educational toolkit in this trial. However, the required PRIDE modules were 
translated literally to Arabic language except the original food lists for breakfast, 
lunch and dinner as they need to be set by a dietician. In that meantime, two 
independent bilingual Jordanian dieticians offered to contribute to the food lists 
chapter of the PRIDE Arabic-version. They replaced all western food lists with an 
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Arabic-translated local food lists that match the Jordanian culture regarding all daily 
meals. It was stressed out that any food lists replacement must be coherent with the 
contents of the English-version PRIDE. All translated materials were sent to an 
independent professional translator to back translate them into English language 
except for Jordanian food lists. Then, the translated and back translated PRIDE 
versions were thoroughly scrutinised by researcher, two dieticians and a Jordanian 
bilingual endocrinologist to produce the final version of PRIDE Arabic-version. The 
final Arabic-version was handed to three senior patients with T2DM who were 
randomly chosen to comment on and express their opinions upon the modules and 
food lists. As a result, although they were pleased with the graphical content and the 
simplicity of the design and guidance style, they suggested to add some local food 
that are being eaten in rural areas of Jordan. However, their suggestions were 
introduced to the dieticians who were aligned with the new input and the final 
Arabic-version of PRIDE modules was produced and printed without any changes to 
the original design and format. The PRIDE Arabic-version was used to support the 
knowledge determinant in the IMBDSME intervention and piloting the final version 
prior starting the trial was not feasible due to the timeline of the PhD program. 
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2.2.2.2 Motivation determinant: 
It is very clear that motivating disinclined patients is considerable a significant 
challenge among Health Care Professionals (HCPs) (Hardcastle et al., 2015). As for 
the motivation determinant, Motivational Interviewing (MI) approach was utilised 
and was first described by Miller and Rollnick (1991). To be trained for using MI style, 
researcher received an advanced training in MI by Stephen Rollnick the co-founder 
of MI in Cardiff medical school before conducting the trial. MI is a focused, patient-
centred counselling approach for provoking behaviour change. MI is used to engage 
with patients’ health problems and discuss their strengths and weaknesses. The core 
purpose of MI was to prompt their inner motivation and solve their ambivalence, 
hence, promoting patient’s autonomy of decision making. During the course of MI, 
the HCP maintains the direction of the consultation when providing any necessary 
information related to a specific behaviour, and at the same time, ensures that the 
patient preserves the responsibility over the change. MI was commonly applied in 
various healthcare settings with people who required assistance in behavioural 
change. It showed a great efficacy with patients who had an uncontrolled diabetes, 
alcohol and drug addiction problems (Rollnick et al., 2010 , West et al., 2007) . Indeed, 
a systematic review conducted by Ekong and Kavookjian (2016) showed a promising 
results of MI to improve dietary behaviours and clinical outcomes. Therefore, it is 
believed that MI approach can be effective with patients with T2DM who are 
ambivalent to change their unhealthy DSCB behaviours.  
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2.2.2.2.1 Spirit of Motivational Interviewing (MI): 
MI is not a technique and it is important to differentiate between the spirit of MI and 
the techniques that are used to show its spirit. MI spirits can be described in few 
points and they are; motivation to change should not be enforced rather to be 
provoked, solving the patients’ ambivalence is not the HCP mission, direct 
confrontation needs to be avoided with them, MI counselling style is quite and 
passive approach, the HCP intention is to help them to resolve fluctuation to change, 
this fluctuation in readiness to change or resistance is a reflection of therapist 
behaviour and not an inherited attribute of patients, and lastly, the therapist-patient 
relationship is partnership or comradeship rather than sender-receiver relationship.  
HCPs who used Motivational Interviewing (MI) style practised specific skills and most 
importantly focused on active listening during the communication process with 
patients. According to MI, it is recommended to use open-ended questions to 
understand the situation and their surroundings through active listening, showing 
acceptance and affirmation, reinforcing their concerns and intention to change 
through reflective listening, monitoring their responses and willingness to change 
known as “change talk” without generating resistance, the more change talk and less 
resistance talk the highly likely of subsequent behavioural change (Hettema et al., 
2005). Lastly, summarising by respecting their choices and self-determination. 
Amrhein (2004) stressed the importance of the content and strength of change talk, 
thus, those who plan to utilise MI should be trained how to exercise MI during the 
change talk and this could be seen as burden. When patients’ speak about a specific 
behaviour, the HCP needs to focus on problem recognition and tries to bring to light 
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or read up on the clients’ ambivalence, and then, providing the opportunity to assess 
for themselves what they need next and how they think they can achieve it. This way 
gives the responsibility of self-management daily work to be done by them where 
the HCP can offer some help and practical advice to overcome real life obstacles 
during the performance of a specific self-management behaviour. To support clients 
toward their responsibility, it was stressed by (Burt et al., 2014) on the importance 
of documenting patient-centred plans and goals. For that reason, a technique called 
Brief Action Planning (BAP) was used in this trial used to support clients to make 
behavioural changes that can be implemented in their practical life. 
2.2.2.2.2 Brief Action Planning (BAP): 
BAP is a structured self-management technique that comprises of three main 
questions and five skills. BAP integrated principles and practice of MI to facilitate 
patient-centred goal settings and action planning to enhance self-efficacy in 
managing their chronic condition. This technique was developed into this current 
version by Gutnick et al. (2014). and was consistent with MI style that was described 
as the spirit of MI in the previous section. BAP technique allowed those who received 
the IMBDSME intervention the opportunity to express what self-care behaviours they 
need help with and what they can do about them once engagement was established. 
This was the first question of BAP to provoke patients’ interest in self-care or 
behaviour change. Once they were ready to change, they generally were used to 
respond by either they had an idea and knew what they needed, or they did not know 
what to do afterwards. For those who were not sure what they wanted to do, three 
main skills were used after answering the first question of BAP. In the first skill, they 
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were asked for their permission to discuss and share some ideas on three Diabetes 
Self-Care Behaviours (DSCBs); diet, physical activity and medications management. 
Those behaviours were offered on table to provide participants with the opportunity 
to choose which one they wished to start and work on. At that point, they were 
required to choose one self-care behaviour which was frequently a behaviour that 
they were more familiar with or in other words easy task for them to enhance their 
self-efficacy toward diabetes self-management daily task as was recommended by 
Lenz and Shortridge-Baggett (2002). They stated that patients were more likely to 
succeed with easy task than complicated task until eventually practicing the 
complete management of T2DM. Experiences of success can provide patients the 
proof that they can succeed while negative experiences can disrupt the feeling of 
self-efficacy. Previous experiences whether successes or failures can greatly attribute 
to persons’ self-efficacy (Bandura et al., 1999). Then, it was proceeded to the second 
skill where they were offered to create an action plan that had Specific, Measurable, 
Achievable, Relevant and Time-lined (SMART) goals. To help creating those SMART 
goals, researcher used to probe patients with questions that were related to the plan 
such as what, when, where, how frequent and how long, and utilized the answers to 
inform SMART elements. Consequently, the discussion used to end up with eliciting 
a commitment statement, and this was the third skill. After that, it was important to 
ask the patient to repeat back the action plan and commitment statement to prop 
up an inner self-reflection about the feasibility of its implementation. Repeating 
backs skill smoothed the way to ask the second question of BAP where researcher 
asked patients to express how confident/ sure they felt to achieve the SMART goal 
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they had committed to perform. They were asked to choose a number on a scale 
from zero to ten where ten was “totally confident” and zero was “not confident at 
all”. Those who scored less than seven had a problem-solving discussion to come up 
with any ideas that could assist to overcome the low confidence level (skill four), 
otherwise, researcher would have referred back to the behavioural menu again, 
while those who scored with a confidence level of seven and over were asked to 
allow the researcher to revise action plan and goals with them on a later date, which 
was the last question of BAP. At that instant, patients knew their SMART goals and 
they were highly likely sure to practice them afterwards, they were informed that 
their progress about following the proposed action plan and their SMART goals is 
going to be revised during the next intervention phone call. Klinkner et al. (2017) 
showed that exercising goal-setting documentation was statistically highly likely 
associated with an increase in the amount of support received from nurses in their 
study. Therefore, and to support reporting their progress and goal achievements, 
patients were provided with twelve copies of weekly logs to document their progress 
over the intervention period as it is presented (3.11.2). The fifth skill of BAP was 
following up the patients’ self-care behaviours plan either by modifying their BAP or 
making new BAP, and this was originated as part of the clinical trial design as 
presented in (3.11). 
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2.2.2.3 Behavioural skills determinant: 
Although most of the required knowledge and information for diet, physical activity 
and medications management self-care behaviours were documented in the Arabic-
translated PRIDE version as mentioned in (2.2.2.1), behavioural skills were portrayed 
alongside as well. Behavioural skills were necessary to enhance patients’ self-efficacy 
to support the implementation of each self-care behaviours. Those skills were 
explained and discussed with patients during the interventional phone calls and were 
not necessarily required to be discussed face to face.  
Multiple behavioural skills for diet were portrayed in the educational toolkit. Skills 
such as “Dividing the Plate” helped patients to learn how to control their carbs intake 
during lunch and dinner. A pictogram of 9-10 inches plate was used to show the user 
how to divide the plate into three parts to put together the three main types of food 
as well as a pictogram to show the palm of hand to teach them what counts as one 
serving as illustrated in Figure 4. 
 
Figure 4 A 9-10 inches Divided Plate and Palm of Hand to teach Diet Behavioural Skills (Source: PRIDE toolkit). 
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For physical activity self-care behaviours, the introduced skills helped patients to 
prevail over the difficulties of practicing the recommended healthy walking. 
Examples of those skills that were suggested, chair exercises for those who 
complained about knee or joint pain, stairs instead of lifts for those who had place 
and time restrictions due to their job nature and practicing with a company such as 
family member or friend if they felt lonely or bored during physical activity.  
For medications management behavioural skills, appendix for insulin dose 
adjustment was discussed with patients who experienced a fluctuation in their daily 
blood glucose level if they were prescribed insulin. Those appendixes helped patients 
to manage their daily doses to receive the right amount of insulin according to their 
health condition and base on their blood glucose reading as they usually receive a 
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2.2.2.4 Constructing the IMBDSME intervention: 
Although it can be seen that researcher defined all determinants of IMB model for 
the trial self-care behaviours, this did not mean that IMBDSME intervention was 
ready to be delivered. As part of Intervention Mapping (IM), it was required to 
construct the three determinants together to form the intervention and plan for the 
implementation. While delivering those determinants could have been done using 
different approaches, the aim was to use the best evidence available and implement 
the IMBDSME intervention using evidence-base techniques. Therefore, and to build 
up the intervention, various effective techniques were utilised from the literature 
above in section (1.7) as well as from key DSME systematic reviews that were 
conducted by (Dube et al., 2015 , Norris et al., 2001 , Clement, 1995). Those DSME 
techniques were recommended by different scholars who stressed the importance 
of including them in future DSME interventions. Out of all, sensible and culturly 
acceptable techniques were discussed with the research team concerning the 
feasibility aspect as well as the barriers of implementation of those techniques within 
the treatment regimen of T2DM in outpatient clinics in Jordan, which is explained 
later in (3.9.4). 
The delivery of IMBDSME using MI style and BAP was lengthy process because MI 
approach requires active listening and this required considerable time to interact 
with those receiving DSME intervention. Adding to this, delivering the intervention 
all at once targetting three self-care behaviours could cause information 
misintrepretation as a result of overloading patients with information about self-care 
behaviours that could act as barrier to the adherence to DSME (Rushforth et al., 
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2016). Other barriers that could have jeopardized attending DSME sessions on 
several occasions such as work commitments, forgotfulness, weather conditions as 
well as the burden of travelling from different and distanced parts of the governerate 
as were published by (Lawal et al., 2018). These barriers need to be addressed to 
increase the uptake of DSME interventions. Therefore, other remote ways of 
delivering DSME interventions were at the sight. In literature, DSME was delivered 
over telephone and in some cases they applied MI style, and their results were 
promising and supportive to the fact that MI style has the potential to improve the 
adherence to therapeutic regimen, patients’ self-efficacy and clinical outcomes (Dale 
et al., 2007 , Welch et al., 2006 , Krishna and Boren, 2008). Therefore, it was agreed 
by the team that delivering IMBDSME intervention need to be distributed on several 
occasions using an acceptable way of communication that do not necessarily 
requisite their physical presence at the clinic such as phone calls. However, due to 
the difficulties of sending chapters of PRIDE to patients separately on several 
occasions, the idea of handing a complete PRIDE toolkit at the beginning was more 
realistic. To simplify, the main idea was to discuss knowledge and skills related to a 
specific self-care behaviour from the PRIDE educational toolkit using MI style and BAP 
over phone calls, which are called as Interventional Phone Calls (IPCs) in this trial. 
2.2.2.5 Interventional Phone Calls (IPCs): 
IPCs were the place where the interaction between the patients and researcher 
occurred for intervention delivering purposes, which was defined by Norris et al. 
(2002) as the patients’ contact time in their meta-analysis. The length and frequency 
of IPCs can be defined by the patients’ contact time that was required to deliver 
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IMBDSME intervention to produce a behavioural change. They pointed out that an 
average of 23.6 hours of interaction of DSME between patient and therapist was the 
only clinically significant predictor to lower HbA1c by 1%. Although their calculations 
targeted HbA1c as a clinical outcome, it was a strong indication to estimate the 
amount of time required to produce a behavioural change that might eventually 
decrease their HbA1c. Having mentioned that estimation, on the other hand, Osborn 
et al. (2010) claimed that their 1.5 hours of IMB model-based DSME intervention 
lowered participants’ HbA1c by 0.48% and proceeded to presume that their dose was 
equal to 11.8 hours of patients’ contact time in comparison to Norris et al. (2002) 
calculations. Based on these calculations, it was proposed that an interaction of three 
hour-time (180 minutes) using IMB model-based DSME could be adequate to lower 
participants’ HbA1c by roughly 1% to match the clinically significant prediction of 
Norris et al. (2002). Therefore, 180 minutes were estimated to be adequate and was 
planned to deliver IMBDSME over at least six phone calls, 30 minutes each. IPCs were 
proposed to range from at least six to eight IPCs and were distributed over three-
month intervention period as described in (3.11.2). Over IPCs, patients were 
encouraged to complete the weekly logs along with delivering the IMBDSME and 
were able to start with a self-care behaviour of their interest over the first IPC. 
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2.2.3 Logic model of IMBDSME development: 
Logic modelling was used to visually present the steps of developments and 
relationships between needs, IMB behavioural determinants, behavioural outcomes 
and methods or strategies (resources) in a chronological systematic order (Hayes et 
al., 2011 , Savaya and Waysman, 2005). The logic model is presented below in Figure 
5.  
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2.3 Conclusion: 
In this chapter, it was explained the theoretical framework of IMB model and its 
fundamental assumption. It was explained that IMB model determined that 
information and motivation of a health-related behaviour are expressed through the 
deployment of behavioural skills, in which they were found to directly influence and 
initiate the performance of that behaviour (Fisher and Fisher, 2000). By utilising IMB 
model procedures as well as intervention mapping approach, essential determinants 
of IMB model were defined considering the targeted self-care behaviours in this trial; 
healthy diet, physical activity and medications management. Furthermore, relevant 
evidence-based methods and strategies were selected to construct an individualised 
IMBDSME intervention and planned for the implementation and delivery. To 
conclude, all IMB determinants were placed together where the related knowldege 
and skills for the trial self-care behaviours were mainly demonstarted in the Arabic-
translated PRIDE, and Motivational Intervieiwing (MI) and Brief Action Planning (BAP) 
were the medium in which those determinants were carried to patients over the 
Interventional Phone Calls (IPCs). 
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3 Evaluating the IMBDSME intervention (RCT): 
3.1 Overview: 
At chapter one, the evidence for the effectiveness of DSME interventions and the 
need for a tailored, individualized and multicomponent programs was presented. 
Indeed, those programs need to be underpinned by appropriate behavioural change 
theories. Systematic reviews and other studies in the literature revealed how the IMB 
model was effective among clients with high HIV risk. They have emphasized that 
IMB model can be utilized across health promoting programs and was consistent with 
the required determinants to promote diabetes management. Very few studies have 
used IMB model among patients with diabetes and there were no studies in which 
patients have been followed up after delivering the DSME intervention. Developing 
educational programs and modelling them with outcomes using the IMB model have 
been discussed in chapter two. In this chapter, methodological factors and other 
design matters that were well-thought-out were called to develop an appropriate 
research design. The narrative shows how an approach to design an experimental 
trial was constructed to evaluate the effectiveness of IMB model based DSME 
intervention for patients with T2DM. 
3.2 Pre-trial and Design considerations: 
Designing a research trial depends on the type of the research question. Our research 
question was looking to know the answer of whether IMBDSME intervention can 
make an effect on self-care behaviours among patients with T2DM. The answer for 
that question can provide a causal explanation and description of the relationship  
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between the intervention as an independent variable and the self-care behaviours as 
dependent variables. It is generally classified as relational research question that 
investigate cause-and-effect relationship (Privitera, 2017). The experimental, quasi -
experimental and non-experimental research designs can all be used to answer our 
relational research question. They are distinguished by the level of control instituted 
in the design. The level of control in a design describes the manipulation of a variable 
while holding the other variables constant. A crucial asset of the experimental design 
that it is competent to explain cause and effect relationship, enabling researcher 
proficiently to control the conditions of the participants adequately. This means, to 
demonstrate how the intervention causes a change in the trial outcomes variables, 
researcher should be able to adequately control the conditions of the participants by 
choosing the experimental design (Polit, 2008). 
3.2.1 Choosing the Experimental Trial design: 
The notion of applying control was illustrated in a hierarchy of evidence pyramid that 
indicates which research design gives the highest weight and classifies the evidence 
during evaluating an intervention, see the pyramid of hierarchy of evidence in Figure 
6. Rigorous scientific methodologies increase as long we are moving from the bottom 
of the pyramid upwards. On the other hand, the risks of bias inherited in trial design 
increase as long we are moving downwards within the pyramid (Akobeng, 2005). The 
pyramid was adopted from Golden and Bass (2013) article and they acknowledged 
that it is permitted to use any part of their work as long as it is cited properly for 
educational purposes. 
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Figure 6 Pyramid of Hierarchy of Evidence 
Overall, Randomized Controlled Trial (RCT) was recognized to be the gold standard 
and known to provide the most reliable evidence when evaluating the effectiveness 
of the interventions. The included controlling measures during the conduct of an RCT 
minimize the risk of affecting the results by the confounding factors. The level of 
control in trials refers to the validity or in other words it is the extent of the trial 
design to allow the researcher to draw a true cause and effect relationship 
(Bondemark and Ruf, 2015). 
3.2.2 Why Randomized Controlled Trial? 
During RCT, participants are randomly allocated to the trial groups to distribute 
participants’ characteristics such as disease duration and severity, socioeconomic 
status and sex between trial groups. Accordingly, it creates a status of balance of 
baseline systematic differences that might affect the outcome, so that any difference 
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in the outcome can be rationalized by the trial intervention (Sibbald and Roland, 
1998). A true experiment or RCT characterized by applying control using three 
essential elements: Randomization , Manipulation and Comparison (Control) that 
allow researcher to draw cause-and-effect conclusion (Polit and Beck, 2008 , 
Privitera, 2017). In this trial, researcher will be referred to those elements in sections 
(3.3), (3.3) and (3.4) respectively. 
3.2.3 Validity of the RCT results: 
Validity refers to the accuracy of the results and considered whether the 
effectiveness of the intervention reported in the trial stands for the actual magnitude 
or directions of the intervention effect. It can be demonstrated in answering the 
following question “Do these results represents an unbiased evaluation of the 
effectiveness of the intervention? Or have they been affected in a methodical fashion 
leading to a false inference?” Many factors may act as a source of threats to validity 
whether internal or external validity. Therefore, a criteria of a previously developed 
critical appraisal tool such as CASP tool was considered during the process of 
designing this experiment to increase the level of control in the trial design to 
safeguard the validity of the trial results, as well as, following CONSORT statement 
that entails a transparent reporting of randomised clinical trial (CASP, 2017 , Schulz 
et al., 2010). Entail  
3.2.3.1 Threats to internal validity: 
The greater control in a trial design, the higher is the internal validity and RCT design 
has the greatest control, and therefore, has the highest interval validity. However, 
76 
PhD Thesis September 2020 Student ID 4220143 
 
threats to internal validity such as bias, significance level and power are potential 
confounders that need to be practically controlled in this trial. 
3.2.3.1.1 Bias: 
Bias can be defined to be any trend in sampling process, collection, analysis, 
interpretation of data that may generate a deviated conclusion from the truth. 
Generally, bias is any influence that produces a misrepresentation in the trial results 
randomly or systematically. The result of bias in a trial might underestimate or 
overestimate the effectiveness of the intervention when it really does not. Several 
types of bias can influence trial results such as selection bias, performance bias, 
detection bias and attrition bias (Juni et al., 2001). Those types are addressed 
throughout this trial design and within the randomisation section below. 
3.2.3.1.2 Significance level, power and sample size calculation: 
Significance level α should be defined at the planning stage to be able to reject or 
accept the null hypothesis after completing the trial analysis. Usually, α is known as 
0.05 or 5%. If p-value larger than 0.05 then we fail to reject the null hypothesis and 
conclude that the difference between trial groups is not statistically significant. On 
the other hand, if p-value is smaller than 0.05, we can reject the null hypothesis and 
conclude that there is a statistically significant difference between trial groups. A p-
value of 0.02 means that the likelihood of obtaining a positive trial results when the 
null hypothesis is in fact true is 2 in 100. However, there is still risk of rejecting the 
null hypothesis when it is in fact true. In this case, it will lead to type I error or alpha 
error where there is no real difference between trial groups. 
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The power of a significance test is the probability that a test yields a statistically 
significant results when the null hypothesis is truly not true, enabling researcher to 
detect a small difference between trial groups when there is a real difference existed. 
Several factors may determine the power of the trial including the frequency of the 
outcome being studied, the size of the effect, sample size and trial design. However, 
the feasibility of recruiting enough participants to detect the smallest statistically 
significant difference that considers clinically important is a crucial aspect. In other 
words, power should be high enough to calculate a sample size that is large and 
represent the population adequately to detect a small difference between the trial 
groups. On the other hand, an under-power trial means that calculation of sample 
size will yield a small sample that might not allow the researcher to detect a 
statistically significant difference between trial groups where it really exists. In this 
situation, we fail to reject the null hypothesis when it is in fact not true and make a 
type II error (or false-negative) and the probability of this is presented by the symbol 
β. The probability of type II error is related to the power of the trial; which is (1-
power). Both, type I error and type II error, are due to a term called random sampling 
error and illustrated in Table 2 below. 
State of nature Experimental conclusion 
Accept null hypothesis Reject null hypothesis 
Null hypothesis true Correct conclusion Type I or α error 
Null hypothesis false Type II or β error Correct conclusion 
Table 2 Types of Random Sampling Error (Type I or α error and Type II or β error)  
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In the light of the above discussion, and to calculate sample size for this trial, 
researcher referred to an earlier RCT conducted to examine the effectiveness of 
diabetes education program in one of the royal medical services hospitals in Jordan 
(Jarab et al., 2012). In their trial, the mean difference in the primary outcome which 
was the Summary of Diabetes Self-Care Activity (SDSCA) scale score was 0.7 higher in 
the intervention group than control group at six-month endpoint with a Standard 
Deviation (SD) of 2.0 and alpha (α) level was 0.05. Moreover, they had a dropout’s 
rate of 13.5 % of eligible participants during trials’ follow up. As a result, it was 
assumed that 15% of participants will be lost to follow up during the trial to address 
the attrition bias. All in all, in coordination with the school’s statistician, a statistical 
software for professional STATA version 13 was used to calculate the trial sample size 
and was based on a level of power of (0.8) to compute a feasible sample size and 
avoid falling in type II error (Jones et al., 2003). Consequently, calculation resulted in 
recruiting 100 participants per group to detect 0.7 mean difference between two trial 
groups at six-month endpoint. Therefore, a sample size of 230 participants for both 
trial groups was decided to be the trial sample size adding the proposed attrition 
rate. 
3.2.3.2 Threats to External validity: 
External validity refers to the degree of which the relationship observed in a trial can 
be generalized beyond the specific constrains or manipulation in the trial. The lower 
constrains in a trial design, the higher external validity. External validity is a matter of 
judgements and depends on several factors such as the characteristics of the 
participants and different treatment regimens across trial settings. These factors 
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make trial results sometimes difficult to interpret and elucidate a precise component 
of the intervention that can be generalised to the wider setting. RCT may be more 
rigorous in the recruitment process and may not reflect the real clinical practice. To 
address this point, pragmatic eligibility criteria was utilized to choose patients with 
T2DM as participants to reflect the real clinical practice. For example, participants 
have been choosing from a wide age range regardless of any comorbidities, 
psychological problems or diabetes-related medications. Moreover, exclusion criteria 
were minimized to take account of any condition that may impact participants’ 
compliances with trial protocol or trial intervention as well as recruiting two trial sites 
to increase the external validity while maintaining the internal validity of the trial 
results. Thus, criteria to follow for choosing participants was developed and is 
described below. 
3.2.4 Eligibility criteria 
Patients with T2DM were eligible if: 
1- They were aged between 18 and 65 years old. According to Selvin et al. (2006), 
patients who are older than 65 years old considered as elderlies and distinct from 
middle aged patients with diabetes who are 18-65 years old. The distinction is 
clear regarding the burden of diabetes and other comorbidities such as 
hypertension, thus, possibly the need for different treatment goals. 
2- They have been diagnosed with type 2 diabetes for at least six months. This term 
was to ensure that hyperglycaemia is primarily related to type 2 diabetes. 
Hyperglycaemia as a sign may occur by multiple disorders such as auto-immune 
diseases or hypothyroidism etc. Clinically, we cannot judge that initial sign of 
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hyperglycaemia is related to T2DM unless patient undertake several lab tests to 
confirm that insulin resistance is the cause behind hyperglycaemia. Therefore, 
leaving six months after being diagnosed with T2DM increase the chance of being 
diagnosed accurately. 
3- They have been experienced an uncontrolled glycaemic level (HbA1c >8%) within 
two weeks prior the day of visiting the clinic. According to Duke et al. (2009), 
patients with high glycaemic level (HbA1c >8%) were responded and benefitted 
from DSME significantly more than patients who had HbA1c < 8%. 
4- They are attending the outpatient clinic regularly once each 3-month for the last 
two appointments. It was decided to recruit patients who attended their previous 
appointments on time and according to their treatment plan. This point aimed to 
increase the chance of attending their prospects appointments which were used 
to follow them up according to trial requirements. In fact, any patient with 
diabetes is free to attend any of the trial sites for a consultation. However, using 
this criterion meant to recruit patients who are being treated for their diabetes 
condition and have a medical record at that trial site. 
5- Taking any form of diabetes medications (pills or injections such as insulin). One 
of this trial outcomes was to improve the management of diabetes medications. 
Some patients usually are not prescribed any form of diabetes-related 
medications and were given a chance to reverse their hyperglycaemic symptom 
by following a tight diet plan or physical activity regimen. This was in accordance 
with the diabetes treatment universal regimen to control diabetes and they were 
out of the scope of this trial. 
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By referring to a previously collected data in Jordan for patients with T2DM who 
attended the National centre for Diabetes, Endocrinology and Genetics (NCDEG) 
during researchers’ master’s degree in 2012, it was estimated to recruit 68.4% of all 
patients with T2DM when applying the criteria. This proportion of almost two third 
of patients was justified because the other third had a relatively controlled glycaemic 
level (HbA1c < 8). Neither data nor the research study were published. 
3.2.4.1 Inclusion criteria: 
Once patients with T2DM meet the eligibility criteria, they were checked if they were 
compatible with the trial inclusion criteria by asking them during the recruitment 
interview whether: 
1- They have had access to a telephone whether mobile or landline in order to be 
contactable. 
2- They were capable to give informed consent for themselves as well as being able 
to communicate, read, write and understand Arabic language to complete self-
report outcomes questionnaires and interpret the trial booklet. 
More details on the recruitment interview are presented in (3.12.2). 
3.2.4.2 Exclusion criteria: 
Patients with T2DM who were eligible to participate were excluded if: 
1- They were suffering from any cognitive impairment or taking medication that 
affects their memory (self-reported by patient and/or companion). 
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In this trial, researcher depends heavily on participants’ involvement and compliance 
with the trial protocol. Trial parameters were assessed and evaluated using self-
report measurements, and this require mentally healthy volunteers. 
2- Patients with terminal illnesses such as cancer, pregnant women and patients 
who were scheduled for a major surgical operation  
Those patients have different treatment goals and different targets in terms of 
glucose levels pre and post prandial. Indeed, terminal illnesses affect the way that 
patients should control their diabetes condition. Therefore, they were excluded as 
they need different treatment approach. 
3- They were attending or had attended a diabetes education program within 
six months prior enrolment.  
Patients who attended a different diabetes education program in that period may 
affect the trial outcomes as researcher solely intended to examine the effectiveness 
of IMBDSME. 
3.3 Manipulation (the trial intervention): 
Researcher should develop the trial intervention (the independent variable) that will 
be administered to one of the trial group to observe a change in the trial outcomes 
(or dependent variable). The manipulation of the intervention occurs to some 
participants and withholding it from the others by the researcher using random 
assignment as researcher will describe shortly. As a result, researcher is deliberately 
producing multiple groups in the trial to observe the variation in the dependent 
variable between the groups occurred by the independent variable. For this reason 
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and to examine the intervention in an experimental design, the design of the 
intervention should be appropriate to the problem, theoretically rationalized and 
sufficiently intense to expect a sensible effect. Furthermore, to allow replicability in 
future trials, the intervention design should be clearly described. This trial 
intervention was mapped to the IMB theoretical framework and trial outcomes to 
cause a change. Mapping process was described in detail in section2.0). 
3.4 The Control Condition: 
Manipulation is not always enough to obtain an evidence about cause-and-effect 
relationship. Because manipulation alone cannot explain the relationship between 
the independent and dependent variables. A control group was important to make 
at least one comparison. A control group was defined to be those participants who 
did not receive the trial intervention or their act on the dependent variable was used 
to evaluate the act of the intervention group on the same dependent variable. 
Without control group, it is impossible to isolate the effectiveness of the intervention 
from those who are in the intervention group. In this trial, participants in the control 
group received the Treatment As Usual (TAU) during data collection period. However, 
since it is unethical that control group receive nothing at all during an experiment 
(Nardini, 2014), participants in the control group were given the educational booklet 
after completing the trial. 
3.5 Sampling procedure (Randomization): 
One of the distinguished features of RCTs is the randomization sampling procedure. 
Randomization refers to the method of randomly selecting a sample (random 
sampling) from a population of patients to be recruited in a trial and assigning them 
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randomly to trial groups (random assignment or random allocation). Random 
sampling is being conducted in RCTs to avoid sampling bias that is considered as a 
type of selection bias and a weakness in other research designs such as case-control 
and cohort studies (Mann, 2003). So, each participant has an equal chance of being 
selected to participate in the trial and an equal chance to be assigned to one of the 
trial groups. This will help to eliminate bias of selecting participants based on certain 
characteristics to create a difference in specific trial group. (Kim and Shin, 2014). It 
improves the sense of balance by distributing participants’ characteristics equally 
and sufficiently among trial groups as well as to create a control group that is highly 
capable to be utilized as a comparator to the intervention group (Roberts and 
Torgerson, 1999). In this trial, several measures that are explained below in the trial’s 
procedure section have been employed to form a randomization list. The list was 
uploaded to an online randomization platform to warrant a random assigning of 
participants to two trial groups within each trial sites (Kim and Shin, 2014). 
3.5.1 Online randomization: 
The process of assigning participants was conducted through an online 
randomisation platform via internet during the recruitment interview. Nowadays, 
randomizations software and internet services have facilitated the maintenance of 
the process of randomization and allocation. Researchers are able to allocate 
participants to different trial groups within multiple trial centres. They allow 
researcher to exercise control over the different aspects of randomization including 
blocks design, sizes and its sequences, trial strata, providing of codes or unique 
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identifiers and control over the way of delivering the randomization outcome 
(Saghaei, 2004). 
3.5.1.1 Trial’s Procedure: 
An independent colleague who neither was involved in data collection nor in the 
delivery of intervention used a randomization website to create a sequentially 
numbered list that consisted of simple randomized blocks prior conducting the trial. 
The list was established using two strata according to trial sites, each was comprised 
of different blocks sizes of four, six and eight to allocate participants to two trial 
groups on 1:1 basis. Each participant on the list had a number for their turn, and each 
number had a code. Once baseline data has been collected, the researcher manually 
used the software to enter the participant number according to their turn and 
received a message via internet service indicating which group the participant should 
be allocated to. Indeed, due to the nature of the intervention that required 
researcher interaction with participants in the intervention group, participant 
allocation concealment was not possible. 
3.5.1.2 What is Simple Randomization? 
Simple randomization is a basic procedure that allows researcher to assign each 
participant in one of trial groups completely by a chance. If researcher is interested 
to examine the effectiveness of an intervention between two groups, a method of 
coin flipping for each participant can be used. If the coin turns to give “head”, 
participant will be assigned to control group; but if the coin turns to give “tail”, 
participant will be assigned to intervention group. This procedure preserves group 
balance in terms of the number of participants and their characteristics to be 
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assigned to each group if the trial sample is large. However, if the trial has a small 
sample size, other strategies such as block randomization and stratification are 
preferred to be utilised to ensure a balance between groups in numbers and patient 
characteristics. 
3.5.1.3 What is Block Randomization? 
Block randomization means that participants are considered in blocks. It can be used 
to try to equalize the number of participants among trial groups. For example, using 
a block size of six for two trial groups (Intervention and Control) will lead to 6 possible 
arrangements of 2Is and 2Cs blocks, each participant will be assigned into trial groups 
according to their predetermined allocation in the blocks by using a sequential 
numbered list respectively. To illustrate this, the table below show the random 
allocation of 20 participants to two trial groups using five blocks with a size of four 
participants for each. See (Table 3). 
Block number 1 2 3 4 5 
Participant’s sequence  1-2-3-4 5-6-7-8 9-10-11-12 13-14-15-16 17-18-19-20 
Allocation I-I-C-C C-C-I-I I-C-I-C C-I-C-I I-C-C-I 
Table 3 Random Allocation Using Blocks 
As such, participant number 1 will be assigned to Intervention group, participant 
number 2 will be assigned to Intervention group and participant number 3 will be 
assigned to control group and so forth. In this example where the block size is small, 
it allows researcher to predict the allocation of the 4th participant in the first block, 
which is the control group. In this case, researcher is recommended to use the 
random permuted block sequence or (Hadamard randomization). 
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3.5.1.4 What is Stratified Randomization? 
Stratification or stratified block sampling is used to ensure that groups are as much 
as possible identical to produce separate block randomization list for specific or 
multiple prognostic variables. This strategy is used when important predefined 
prognostic factors are aware of before the trial. For example, a block randomization 
list can be generated stratified by gender or disease duration or trial site to ensure 
that variations in those factors are sufficiently distributed within the randomization 
blocks. 
3.6 Trial Hypothesis and purpose: 
The purpose of this trial was to examine the effectiveness of IMBDSME among 
Jordanian patients with T2DM on diabetes self-management behaviours: diet, 
physical activity and medications management. In this trial, researcher hypothesised 
that participants who received the IMBDSME intervention should have experienced 
a greater improvement in performing the self-management behaviours than patients 
who received usual care at three-month and six-month visits. 
3.7 Primary outcomes: 
Primary outcomes were to evaluate the performance of diabetes-self-management 
behaviours after delivering IMBDSME intervention to examine its effectiveness 
among patients with T2DM. Those behaviours were diet modification, physical 
activity and medications management at three-month and six-month endpoints. 
Those outcomes were measured by the Summary of Diabetes Self-Care Activities 
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Scale (SDSCA) and the Medication Adherence Rating Scale (MARS). Both are 
explained in detail later in section (3.13.2). 
3.8 Secondary outcomes: 
Secondary outcomes were designed to examine the effectiveness of delivering 
IMBDSME intervention on the main three elements of IMB model (Information-
Motivation-Behaviour skills), glycaemic level and quality of life among patients with 
T2DM. Those outcomes were measured at three-month and six-month endpoints 
using Spoken Knowledge in Low Literacy in Diabetes scale (SKILLD), Diabetes 
Empowerment Scale (DES), Medical Outcomes Study (MOS), Perceived Diabetes Self-
Management Scale (PDSMS), glycated haemoglobin blood test (HbA1c) and Audit of 
Diabetes Dependent Quality of Life (ADDQOL). Details on those scales are described 
in section (3.13.3). 
3.9 Recruitment of Trial-settings: 
Before choosing the trial settings, the health care system in Jordan was screened to 
identify the appropriate health care centres that were high likely feasible to recruit 
the required sample size in a limited recruitment and follow up periods in accordance 
with PhD program. 
3.9.1 The public health care system in Jordan: 
The Jordanian health care system is formed of six sectors according to the Ministry 
of Health (MoH) and they are: 
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1- Ministry of Health that consist of some hospitals and health centres 
distributed over the country and serve all Jordanian citizens whether covered 
by national health insurance or not. 
2- Royal Medical Services is principally developed to treat the military staff and 
their family members additionally to be used by civilians who have been 
granted referrals by the Royal Hashemite Council (RHC). 
3- Government university medical institutions such as Jordan University Hospital 
in Amman city and King Abdullah University Hospital in Irbid city. These 
hospitals serve mainly government university staff and their dependents, 
civilians covered with national health insurance (special categories) or have 
been granted referrals by the RHC. 
4- The National Centre for Diabetes, Endocrinology and Genetics (NCDEG) 
serves mainly civilian sectors’ employees and their family members and 
civilians who have been granted referrals by the RHC to be treated there. The 
centre is affiliated by the Higher Council for Science and Technology and 
developed initially for research purposes and manage patients’ conditions 
who suffer from any disorders related to endocrinology especially diabetes. 
5- United Nations Relief and Works Agency (UNRWA) runs and administers 
health care centres that serves the registered Palestinian refugees who are 
living in Jordan. 
6- Various private hospitals. 
The High Health Council (HHC) coordinates all these sectors. Any patient who doesn’t 
fall under the national health insurance or any of the above categories can apply for 
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the RHC to be exempted from treatment costs at any of those sectors (Alhadidi and 
Alkurdi, 2013). 
3.9.2 Managing Diabetes in Jordan: 
Patients with diabetes in Jordan are treated by attending outpatient clinics whether 
they are in primary care centres or available at MoH hospitals. A considerable 
proportion of patients who are covered by private health insurance attend private 
diabetes consultants for treatment. Few patients who can afford the treatment fees 
choose to attend private diabetes consultants by their own. Generally, patients with 
T2DM are treated by family physicians as long as they can manage their condition 
within governmental sectors. Once their condition is difficult to manage, and their 
HbA1c is uncontrolled, they are referred to diabetes consultant who are available 
only in MoH hospitals. While this is not the case at the NCDEG, patients are seen by 
a family physician and a treatment plan agreed upon with an endocrinology 
consultant who reside in the centre. 
The National Centre for Diabetes, Endocrinology and Genetics is the largest centre to 
treat and manage diabetes in Jordan and located at the capital Amman. It has the 
highest attendance rate. Many patients with diabetes tend to try to apply for full 
health coverage to be treated at the centre through RHC to be exempted from 
treatment fees. Whilst it might have been the most obvious context for the research, 
it has been contacted to seek approval of conducting the trial, but this was not 
available due to the high number of trials that were conducted at that period. 
Therefore, other centres were investigated which included diabetes outpatients’ 
clinic, have high attendance rate of patients with T2DM, covered with MoH health 
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insurance and preferably managing T2DM in parallel with the treatment regimen of 
the NCDEG such as Jordan University Hospital (JUH) and Prince Hamzah Hospital 
(PHH). 
3.9.2.1 Jordan University Hospital (JUH): 
JUH is the most specialized and advanced teaching medical centre in the public 
sector. It contains of 534 beds and includes several outpatient clinics; one of them is 
the outpatients’ endocrinology clinic (see Figure 7). Around 60-150 patients are 
attending the endocrinology clinic to treat and manage their endocrine disorders 
such as diabetes, thyroid diseases and conditions each Sunday, Monday and 
Wednesday of the week. The treatment regimen in the endocrine clinic for patients’ 
with T2DM is parallel to the one in NCDEG. Patients who start insulin therapy are 
usually referred to the diabetes educator to be educated on administering insulin 
injections or pens. Not every patient is referred to dietitian or diabetes educator who 
are available within the department, only obese patients or those who expresses 
his/her willingness to make counselling visit. Generally, patients with T2DM should 
attend the clinic to manage and follow up their diabetes condition once each three 
months regularly and should attend the pharmacy each month to receive their 
medications that cover one-month period. 
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Figure 7 Jordan University Hospital 
3.9.2.2 Prince Hamza Hospital (PHH): 
Prince Hamza Hospital is one of the largest Ministry of Health (MOH) hospitals in 
Amman and holds 434 beds distributed on nine floors (see Figure 8). The hospital has 
several outpatient clinics to treat and manage chronic conditions such as 
cardiovascular diseases, neurological and endocrinology disorders. Around 30-70 
patients with chronic diseases attend the internist clinic to manage and treat their 
health condition on each Sunday, Tuesday and Thursday of the week and receive 
their medications once a month. In PHH, around 10-25 patients with T2DM attend 
the internist clinic to follow up their diabetes condition and its complications. The 
clinic doesn’t have nutritional or diabetes educational services for patients with 
diabetes. 
 
Figure 8 Prince Hamza Hospital 
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3.9.3 Rational for choosing trial settings  
The Jordan University Hospital (JUH) and Prince Hamza Hospital (PHH) have been 
chosen to be the trial sites. JUH is affiliated by the University of Jordan and PHH is 
one of the largest governmental hospital in Amman. Each one of them serves 
different populations as have been described earlier in this section, and a 20 minute 
distance trip by car separates them (Figure 9). Patients do not routinely receive 
behavioural change strategies and theoretically informed educational interventions 
at both sites. The utilization of two hospitals as trial sites served to enhance the 
credibility and the reliability of trial results, improve the external validity and increase 
the heterogeneity of patients’ characteristic. Multicentre trial improves the basis for 
subsequent generalization of trial findings, since the effectiveness of the DSME 
intervention is not dependant on a specific centre; thus, allow to be reproducible at 
other centres (Friedman, 2010). 
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Figure 9 Location of Trial Sites in Amman 
3.9.4 Treatment regimen in outpatient clinics in trial sites: 
On each clinic day, patients who are supposed to attend the clinic are recorded and 
listed on computerized medical records. All patients should attend the clinic either in 
the morning session for the morning clinic, which starts at 8:00 am, or afternoon for 
the afternoon clinic which starts at 12:00 pm. Therefore, most of the patients who 
used to attend those clinics usually arrive at those two sessions every day. Once they 
arrive, they go to the receptionist to confirm their attendance to generate a 
confirmed list of patients that appears on the computer screen inside the physician 
room. Each one of the trial sites differs in terms of patients’ health investigations and 
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examinations prior the consultation. To describe the routine treatment regimen, 
usual clinical visit procedure at both JUH and PHH is outlined in below. 
Trial Sites 
JUH PHH 
Patients who confirm their attendance are 
invited as part of their routine care to measure 
blood glucose level and HbA1c if they did not 
measure them in advance of two-week period. A 
small laboratory located at the same department 
is dedicated to obtaining HbA1c result. It needs 
approximately 20-30 minutes waiting period to 
provide blood sample and analyse it. Once they 
finish laboratory routine, they return to waiting 
area and wait 15-20 minutes to attend the 
physical examination room. 
Patients who confirm their 
attendance should wait for 
their physician consultation 
turn. This waiting period may 
take 60-120 minutes prior their 
consultation according to the 
number of patients who are 
attending that day and the 
available physicians who are 
providing consultations. 
As soon they are called for physical examination, 
a qualified and trained nurse examines patients 
physically and measures their anthropometric 
parameters (weight, height and blood pressure) 
that takes approximately 5-10 minutes. 
As soon it is their turn for 
consultation, a qualified and 
trained nurse invite them for 
the consultation and measure 
patients’ blood pressure as a 
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Following physical examination, patients return 
to the waiting room and wait for their physician 
consultation turn. This waiting period may need 
45-75 minutes prior their visit according to the 
number of patients attending at that day or the 
available physicians who are providing 
consultations. 
part of the routine care. If the 
physician needs a weight 
reading, patients are asked to 
measure the weight in another 
clinic room with an 
accompanied nurse  
Table 4 Usual care description in both trial sites 
After finishing the consultation that varies in time between patients from 15 to 25 
minutes according to their condition, they visit the pharmacy to collect a sufficient 
quantity of diabetes-related medication that is enough medication to last for one 
month. The pharmacy visit might also need 30-40 minutes waiting period for them 
to receive their diabetes-related medications and pay for the expenses if applied. The 
whole treatment visit in the outpatient clinics might entails 2.5-3.5 hours for the 
participant if all procedures happened according to planned time schedules, which is 
not common, and patients usually spend longer time in waiting rooms. It was 
therefore feasible to recruit patients and collect research data during their waiting 
period within scheduled visit day, which is approximately 110 – 165 minutes. 
Appointments are usually every three months.  
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3.10 Trial Management: 
This trial was managed by the researcher at the trial sites under the supervision of 
the PhD supervisors. The researcher put together a printed copy of PRIDE educational 
toolkit, which was presented in section (2.2.2.1), three copies of the outcome 
measurements as well as 12 copies of weekly logs. See Appendix 13 Weekly Logs. 
Prior the day of visiting clinic, the educational toolkit and the Case Report Forms 
(CRFs) was prepared for the recruitment interview. The detail statistics of patients 
who were assessed, eligible, recruited, excluded, declined and could not be 
approached were recorded on the recruitment follow up sheet to be used in data 
analysis see Appendix 7 Recruitment follow up sheet. 
During the recruitment interview, randomisation procedure was generated online via 
the internet using www.sealedenvelope.com . Each participant was assigned a trial 
unique identifier at the time of randomisation and was used on their Case Report 
Forms (CRFs), on trial documents and on the electronic database. Information that 
could identify participants such as participants’ real personal data (name and 
telephone number), date of birth, medical file number and randomization code were 
recorded on a separate register see Appendix 4 Participants Personal Information 
Sheet. The register was developed to permit identification of all participants enrolled 
in the trial for follow-up and reference purposes. In addition, another sheet was 
developed to record the dates of participant’s second and third visits and the 
conducted laboratory examinations such as HbA1c and lipid profile see Appendix 5 
Follow up Information Sheet. Independent assessors were trained and supervised by 
the researcher with overall guidance from the research supervisors. They used to 
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hand in the completed outcome measures personally to the researcher and then to 
be attached to their CRFs.  
Data collection occurred mainly throughout the working hours of the clinics, while 
interventional phone calls took place on every working day afternoon. On several 
occasions, researcher received phone calls from participants in the control group and 
were managed briefly and instructed to follow the medical advice given during the 
consultation. In case they asked for more information and could not attend the clinic 
due to travel distance, researcher used to refer them to the nearest pharmacist. 
A diary was used to record dates and timings of all conducted phone calls whether 
they were for delivering the intervention or collecting the outcomes. The delivered 
intervention over the phone calls was concisely transcribed on a purposely 
developed chart to follow the participant progress with the educational toolkit 
content and to document the phone calls’ length and frequencies see Appendix 6 
Interventional phone calls contents. Any unexpected events occurred during the trial 
were recorded on the researcher diary. Similarly, any adverse events were managed 
according to the adopted policy at trial sites and by informing the trial chief 
investigator and the available supervisor at the department. 
3.10.1 Research governance and ethical considerations 
The trial was conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, 1996; the principles of Good Clinical Practice, 
and the Department of Health Research Governance Framework for Health and 
Social care, 2005. Each trial needs a sponsor and this trial was sponsored by the 
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University of Nottingham who cover their researchers, research participants and 
research protocols with both public liability insurance and clinical trials insurance. 
Ethical approval was pursued from the Faculty of Medicine and Health Sciences 
Research Ethics Committee (REC) and from the Institutional Review Board (IRB) at 
the original trial site the National Centre for Diabetes, Endocrinology and Genetics 
(NCDEG) in Jordan. The trial received approvals from trial sites and favourable 
opinion from REC on respecting and following all ethical and regulatory permissions 
in accordance with all Jordanian laws and those required by the host institution; 
ethics reference no: OVS18012016 SoHS. Ethical approvals letters are presented at 
appendices (see Appendix 8 and Appendix 9). 
As a result of changing the original trial site which was described earlier in section 
(3.9), a notice of amendment was submitted to REC to include the new trial sites. The 
amendment received approval and is attached in appendices. See Appendix 10. 
Ethical approvals were sought from JUH and PHH and were granted on April 2016. 
Approval letters from both JUH and PHH are presented in appendices. See Appendix 
11 and Appendix 12. 
3.10.2 Informed Consent, Confidentiality and Data Protection: 
The process for obtaining participant informed consent was in accordance with the 
REC guidance, Good Clinical Practice (GCP). The researcher and the participant both 
signed and dated the Informed Consent Form (ICF) before the person can participate 
in the Trial. 
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Patients who agreed to participate were given a copy of ICF, one was kept by the 
researcher, and a third was retained in the patient’s records to notify each 
participants’ treating physician of their patients’ willingness to participate in the trial. 
It has been explained that in the event of their withdrawal, their data collected could 
not be erased because their data were entered onto the University of Nottingham 
secure network and it was not possible to be traced and erased. All completed 
documents and CRFs have been kept and treated with confidentiality in a folder that 
was placed in a locked filing cabinet, and was stored and will be kept for seven years 
in accordance with the regulations (Data Protection Act, 1998, and local hospital 
regulations); as there is no data protection law in Jordan (Privacy, 2018).The locked 
filling cabinet was secured by a lock and the trial database were protected by a 
password. 
3.10.3 Registering the trial in Clinicaltrial.gov: 
Web-based databases of clinical trials are acting as clinical trials registries that serve 
ethical and scientific purposes. Publicly, they serve as a source of information about 
ongoing and previously conducted trials to ensure the ethical considerations. While 
they also provide scholars and journal editors by a complete list of trials regardless 
of the results status. They are distinct by the sponsor, scope and type of information 
about trials. International Committee of Medical Journal Editors (ICMJE) 
recommends that clinical trials registries should be administered by a non-profit 
organization and provide a free of charge service for users and registrants (Krleza-
Jeric et al., 2005). Presently, one of the largest international clinical trials registries 
that meet the former criteria is the ClinicalTrials.gov web-based register. It is 
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managed by the U.S. National Library of Medicine of the National Institutes of Health 
(NIH) and contains approximately over a quarter million of registered research trials 
nowadays (Zarin and Keselman, 2007). Only two conditions needed to be existed at 
the time before registering our research trial. Firstly, it had to be approved by the 
University of Nottingham faculty Research Ethical Committee (REC) or Institutional 
Review Board (IRB), and secondly, it should follow the regulations of the related 
health authority which is the Jordanian MoH (Zarin et al., 2005). Once this trial 
received ethical approval, researcher registered the trial before starting data 
collection process to avoid any possibility of retrospective data analysis or fishing 
expeditions that look for significant outcomes. The unique identifier for this trial on 




PhD Thesis September 2020 Student ID 4220143 
 
3.11 Trial design: 
In the third phase of the MRC framework, authors recommended that randomised 
controlled trial is the most rigorous way to evaluate complex interventions. Two main 
designs of RCT can be chosen to evaluate the effectiveness of the IMBDSME 
intervention and compare outcomes with a group who received the TAU; 
individualised design or clustered design. So, due to the nature of the developed 
IMBDSME intervention, the approach of delivering the intervention cannot be in a 
group setting and need to be individualised, as a result, individualised design was 
sought to be more appropriate.  
The trial was designed to be consistent with the Consolidated Standards of Reporting 
Trials CONSORT statement (Moher et al., 2012) as well as the general treatment 
regimin of busy diabetes outpatient clinics in Jordan. The majority of patients with 
T2DM attend outpatients’ clinics for follow up once each three-month to manage 
their disease condition and to renew or change the prescription of diabetes-related 
medications. Participants in this trial were assessed at baseline, three-month (second 
visit) and six-month (third visit) in both groups through self-reported questionnaires, 
medical records and interviews. Overall, and in order to collect the primary trial 
outcome which was the frequency of performing the participants’ self-care activities, 
phone calls were initiated by two qualified independent assessors, once at the end of 
each month during the intervention and follow up periods to complete the outcomes 
measurements and to remind them about their next appointment. 
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3.11.1 First visit (baseline): 
At first visit, patients with T2DM who attended the outpatients clinics were screened 
and eligible patients were invited to a recruitement interview, which is explained in 
more details in section (3.12). During the interview, those who agreed and consented 
to particpate were invited to complete the baseline assessment where possible. 
Following this, the randomisation took place and participants have been allocated to 
either the intervention group or control group. Intervention group participants 
received the TAU plus the intervention booklet additionally with the explanation on 
how the intervention will be delivered on phone calls using the educational toolkit 
during the following three months (Intervention period). Subsequently, if they were 
free and available, they have had the choice to immediately receive the first 20-30 
minutes individualised face-to-face orientation session. It included some facts about 
T2DM and statistics on the prevalence of T2DM in Jordan and world-wide. Those facts 
were cited from Jordanian scholars’ publications as well as WHO facts sheets about 
Jordan and worldwide. Indeed, the schedule of the interventional phone calls was 
agreed with the participant and was documented in the researcher trial’s diary. On 
the other hand, control group participants received the TAU and have been asked to 
adhere with their usual assigned treating physician’s instructions and did not receive 
any intervention from the researcher. 
Participants in both groups were provided with all necessary information related to 
follow-up through PIS, then, were free to leave the room. Participants who did not 
have sufficient time either to complete the baseline assessment or to receive the 
intervetion were followed up using phone calls during the intervention period and 
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within 48 hours from the first visit. Baseline measurements are mentioned in (3.13.2) 
and (3.13.3). 
3.11.2 Intervention period (Month one to three) 
Durng this period, participants in the intervention group have been receiving the 
interventional phone calls from the researcher, while those who are in the control 
group did not receive any intervention. Both have been contacted by the 
independednt assessors to complete the main trial outcome on phone calls and to 
be reminded about their next appointment. Those who had to leave the clinic due to 
time constraints have been called to deliver the first orientation session within two 
weeks period of the first visit.  
After finishing the delivery of the interventional phone calls, participants were 
reminded about their next appointment to bring the completed weekly logs. If the 
participant was not available when it was the time to be contacted by telephone for 
the first time, they were further contacted by phone call two times at different times 
and days of the week. When they failed to answer, they were considered as being 
lost to follow up unless they had actively indicated their preference to withdraw from 
the trial by contacting the researcher. 
3.11.3 Second visit (post-intervention): 
At second visit, participants in both groups who attended their regular appointments 
in the outpatients’ clinics and were expected to show up were invited by trained 
independent assessors for a follow up interview and to complete the measurements 
of the trial outcomes and they are mentioned in (3.13.2) and (3.13.3). 
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. Those who did not attend their predefined appointments were contacted by the 
researcher to determine whether they were able to complete the outcomes 
measurements on phone calls with the independent assessors. Based on the 
researcher availability at the trial site, the earlier delivered intervention was 
summarized in a 20-30 minutes face-to-face meeting, otherwise, they received a 
phone call for the same purpose. All participants were asked to complete the three 
months assessment. Then, only control group participants were free to leave. While 
intervention group participants were asked to hand in the completed weekly logs and 
were invited to complete other tasks regarding process evaluation.  
3.11.4 Follow up period (Month four to six): 
Durng this period, participants in both groups did not receive any intervention from 
the researcher. They have been only contacted by the independent assessors to 
complete the main trial outcomes and to be reminded about their next appointment. 
3.11.5 Third visit (post-follow up): 
At the third visit (post follow up), participants in both groups who attended their 
regular appointments in the outpatients’ clinics and were expected to show up were 
invited by a trained independent assessor for post-follow up interview to complete 
the assessment of the six months. Those who did not attend their predefined 
appointments were contacted by the researcher to know if they were able to 
complete the primary and secondary outcomes measurements on phone calls with 
an independent assessor. The measurements are mentioned in (3.13.2) and (3.13.3). 
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The diagram below describes each period in the trial. See Diagram 1 Trial Flow and 
table below briefly demonstrates the trial design in points see Table 5. 
 




1- Patients screening for eligibility early at the morning (20 
minutes). 
2- Eligible patients were invited to participate (10 minutes 
maximum). 
3- Participants’ baseline assessment (30-35 minutes). 
4- Participants were allocated randomly to one of trial groups 
(2 minutes).  
5- Participants in the intervention group received first face-to-
face session with the intervention booklet (20-30 minutes). 
While participant in the control group received TAU. 
Intervention 
period 
(month one to 
three) 
1- Participants in the intervention group received the rest of 
the intervention through phone calls at preferred frequency 
and followed up for weekly logs (approx. 30 minutes per 
call). 
2- Participants in the control group did not receive any 
intervention from the researcher. 
3- Participants in both groups were called to collect the trial 
outcome using phone calls by two qualified independent 
assessors, once at the end of each month and to be 
reminded about their next appointment. 
Second visit  
(post 
intervention) 
1- Participants in both groups were invited by trained 
independent assessors for a follow up interview to 
complete the assessment of the three months. 
2- A 20-30 minutes face-to-face meeting was conducted with 
participants in the intervention group to summarize the 
delivered intervention. 
3- They were asked to hand in the completed weekly logs and 
were invited to complete other tasks related to process 
evaluation. 
Follow up 
(month four to 
six) 
1- All participants have been contacted by the independednt 
assessors to complete the main trial outcome and to be 
reminded about their next appointment. 
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Third visit  
(Post-follow up) 
1- Participants in both groups were invited by the trained 
independent assessors for a post-follow up interview to 
complete the assessment of the six months. 
Table 5 Brief Trial Procedure 
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3.12 Recruitment of individuals-participants: 
Participants were recruited from the outpatient clinics in both participating hospitals 
through consecutive sampling within a three-month recruitment period that started 
on the 1st April 2016 and ended on 30th June 2016. Recruiting participants in PHH 
started two weeks earlier than JUH and was attended on Sunday, Tuesday and 
Thursday, while attending JUH on Monday, Tuesday and Wednesday to recruit 
participants. On each clinic day, all patients who were supposed to attend and 
registered on the medical record list were screened for eligibility, initially through 
accessing the electronic medical records and then verified in a face-to-face 
recruitment interview. Patients who met the eligibility criteria were recorded on the 
researchers’ list of potential participants and have been invited verbally to a 
recruitment interview at one of the empty clinic rooms.  
3.12.1 Approaching participants: 
Approaching eligible participants formed a challenge to the researcher in this trial. 
Advertisements about the trial were posted at the department waiting area and 
clinics’ corridors. See Error! Reference source not found.. Patients were screened, 
checked for eligibility, generated a list of potential participants and invited them for 
a short interview prior recruitment on the same day. That day was considered as first 
visit once they were recruited. The efforts spent to recruit potential participants 
would not be constructive without the assistance of the physicians and nurses at both 
trial sites. They were provided with the Personal Information Sheet (PIS) before 
commencing the trial and were acknowledged through informal meetings about the 
trial purpose and the characteristics of the eligible participants see Appendix 3. They 
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have informed and encouraged eligible participants to take part in the trial and 
referred them to the researcher. Once they have been referred by any Healthcare 
professionals, they were asked to return to the waiting area until researcher finishes 
with the engaged participant if possible. On few occasions at JUH, researcher have 
had the chance to use a spacious meetings room located at the same department to 
meet and recruit a number of patients concurrently. 
3.12.2 Recruitment interviews: 
Eligible patients were called from the waiting area and invited for a recruitment 
interview in a clinic room to check if they meet the inclusion criteria through a face 
to face conversation. Patients who met inclusion criteria were invited to participate 
in the trial verbally and were provided with PIS. Those who did not meet the inclusion 
criteria were free to leave. Patients who agreed to participate have been asked to 
sign an informed consent prior to completing baseline assessment. It was explained 
to the potential participant that entry into the trial is entirely voluntary, and they 
were free to withdraw at any time. On the other hand, patients who wanted to leave 
either to discuss participation with other family members or have not had sufficient 
time to consent have been given a period of 48 hours to consider their participation. 
They could have opted to take part by calling the researcher, or the researcher should 
have followed them up by phone call after 48 hours. If patient has verbally consented 
to participate by phone call, the researcher should have elaborated on all aspects 
and procedures pertaining to their participation in trial. Upon the final verbal 
agreement, the researcher should have organized a face-to-face meeting at the 
outpatient clinic at a time convenient to the patient. This had to be within 48 hours, 
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and the patient should have required to sign the ICF and complete baseline 
questionnaires assessment prior randomization. Researcher has proposed that all 
participants who will be attending the outpatients’ clinics again for any research-
related purposes will be reimbursed for travel costs. 
3.13 Data collection and Outcomes Measurements 
As presented in recruitment interviews as was described in section (3.12.2), 
participants were asked to complete the baseline assessment questionnaires 
following randomisation procedure. CRFs contents was briefly described and they 
were asked to respond to all questions if possible. Any clarification was provided 
when they had any questionnaires-related inquiries during the recruitment 
interviews. Those who had eyesight complications have been assisted by the 
researcher who had to read the questionnaires and write their responses. However, 
participants who consented during the recruitment interview and have not had 
sufficient time to complete the baseline assessment questionnaires were offered to 
choose either to complete them on phone or to attend the clinic to complete the 
baseline assessment questionnaires. 
3.13.1 Participant’s demographics and clinical characteristics: 
Participant’s demographics and clinical characteristics were collected at the 
recruitment interviews. Demographics were gender, age, marital status, level of 
education, income and occupation status. Other clinical characteristics such as latest 
readings of lipid profile, weight, blood pressure, fasting glucose level, HbA1c, being 
diagnosed with other chronic diseases or diabetes complications such as retinopathy, 
duration of diabetes and diabetes-related medications were collected by the 
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researcher from the electronic medical records. If any information was missed in the 
record, it was gathered by asking patients to self-report the missing details, and this 
was noted as self-reported information. These measures were collected again at the 
second visit and at the third visit without asking again for their demographics again. 
3.13.2 Primary outcomes: 
As mentioned in section (3.7), the trial primary outcomes were evaluated using two 
scales; the Summary of Diabetes Self-Care Activities Scale (SDSCA) to measure the 
diet and physical activity performance, and Medications Adherence Rating Scale 
(MARS) to assess T2DM Medications adherence. Total score of performing Diabetes 
Self-Care Behaviours (DSCB) was computed by summing all three scales after 
weighting adjustments (Bethlehem, 2019). Both scales are described in detail as 
follow: 
3.13.2.1 Summary of Diabetes Self-Care Activities Scale (SDSCA): 
This is a multidimensional, well validated, self-reporting instrument measuring the 
occurrence of diabetes behaviours and asking participants to recall their self-care 
activities in the last seven days at six areas: diet, physical activity, Self-Monitoring 
Blood Glucose (SMBG), foot care, medications and smoking (Toobert et al., 2000). 
Only diet and physical activity subscales were used to collect the performed self-care 
activities. SDSCA was used in previous intervention studies among patients with 
T2DM (Glasgow et al., 1996 , Glasgow and Toobert, 2000 , Glasgow et al., 1992 , 
Wagner et al., 2001). These studies showed that means and SDs for each subscale in 
these studies showed a significant consistency among patients who reported higher 
levels of dietary healthy habit than physical activity. Toobert et al. (2000) calculated 
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means across the studies for each subscale to calculate the average inter-item 
correlations within scales and they were high (mean r = 0.47); test-retest correlations 
over 3-4 months were moderate (mean r = 0.40). In addition, correlations with other 
measures of diet and physical activity behaviour supported the validity of subscales 
within SDSCA (mean r = 0.23). 
3.13.2.2 Medication Adherence Rating Scale (MARS): 
Thompson et al. (2000) developed a medication compliance questionnaire to be used 
among psychiatric patients and used Item Response Theory (IRT) as a tool for 
developing the scale. The development of Medication Adherence Rating Scale 
(MARS) was based on two existing self-report measures of compliance; the Drug 
Attitude Inventory (DAI) scale and Medication Adherence Questionnaire (MAQ) 
(Hogan et al., 1983 , Morisky et al., 1986). The new emerged scale consisted of 10 
questions with a response of Yes/ No answer. An answer with “No” rated as one and 
an answer with “Yes” rated as zero except for questions seven and eight which have 
been reversely rated as one for “Yes” and zero for “No”. MARS score was calculated 
to be the total of ten responses. Thus, the total score will then reflect a greater 
degree of compliance if it is high, and non-compliance if it is low. The reliability 
analysis of the MARS using Cronbach’s alpha was 0.75 compared to 0.76 and 0.77 for 
the MAQ and the DAI respectively. 
Two independent assessors have contacted all participants in both groups to 
complete 2 copies of (SDSCA) and (MAS) questionnaires on phone call 2 times, once 
at the end of each month during the delivery of intervention period.  
114 
PhD Thesis September 2020 Student ID 4220143 
 
3.13.3 Secondary outcomes: 
As mentioned in section (3.8), trial secondary outcomes were evaluated by several 
measurements to examine the effectiveness of IMBDSME intervention on the main 
three elements of IMB model (Information-Motivation-Behavioural skills). 
Information; to measure the level of diabetes self-management knowledge, 
Motivation; to measure the level of motivation toward diabetes self-management 
behaviours, Behavioural skills was measured by evaluating the perceived self-efficacy 
to perform those behaviours, glycaemic level (HbA1c) and quality of life among 
patients with T2DM at three-month and six-month endpoints. Those outcomes were 
evaluated using several measurements as follows: 
3.13.3.1 Knowledge of diabetes self-management behaviours:  
Patients’ knowledge level about diabetes self-management was measured using an 
adjusted version of the Spoken Knowledge in Low Literacy in Diabetes scale (SKILLD) 
(Rothman et al., 2005). The original SKILLD scale consisted of ten items assessing 
patients’ knowledge about diabetes self-care, including glucose management, 
lifestyle modifications, treatment of acute complications, and appropriate activities 
to prevent long-term complications of uncontrolled diabetes. The coefficient of 
internal reliability was 0.72, proposing adequate reliability. 
The original version was adjusted by merging some items and extra questions were 
added to assess aspects that were related to trial purposes and outcomes such as 
diet and medications management. Participants were required to self-report the 
answers for the ten open-ended questions by handwriting. If they answered an item 
correctly, a score of one was accounted. While if they answer part of the question 
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correctly, a score of 0.5 was accounted. The adjusted scale was ten items and was 
weighted equally to calculate as total of ten if all answers were correct and zero if all 
answers were not correct.  
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3.13.3.2 Motivation toward Diabetes self-management behaviours:  
Motivational level of patients with diabetes was measured using two scales, one for 
personal motivation and the other for social support. Firstly, Diabetes Empowerment 
Scale (DES) was used to measure the personal psychosocial self-efficacy. It was 
developed by Anderson et al. (2000) and comprised of 28 items representing and 
distributed into three domains: managing psychosocial aspects of diabetes (9 items), 
dissatisfaction and readiness to change (9 items) and setting and achieving goals (10 
items). DES scores were significantly correlated with both subscales of Diabetes Care 
Profile (DCF); the validated Positive Attitude scale (coefficient ranged from 0.32 to 
0.59) and with the validated Negative Attitude scale (coefficient ranged from 0.38 to 
0.59). All participants were required to respond to each item of DES by stating how 
much do they agree or disagree with the statement in each item apply to their 
condition. An item checked “strongly agree” received five points; “agree” received 
four points; “neutral” received three points; “disagree” received two points; and 
“strongly disagree” received one point. Total score for DES was calculated by 
summing all of the items scores and dividing by 28 and ranged from one to five. 
Secondly, social support was measured by a brief, self-report multidimensional 
questionnaire developed by Sherbourne and Stewart (1991) and used with patients 
in the Medical Outcomes Study (MOS). It consisted of 19 items demonstrating four 
main dimensions (emotional/informational, tangible, affectionate, and positive 
social interaction), alpha reliability was more than 0.91 in MOS. All participants were 
required to respond to each of the 19 items by stating how much time they were 
offered social support for each statement in all items. Each item had five options; 
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each option received a score. An item checked “all of the time” received five points; 
“most of the time” received four points; “some of the time” received three points; 
“a little of the time” received two points; and “none of the time” received one point. 
To generate an overall score, researcher used both scales (DES) and (MOS) to create 
a dummy variable, which was generated to represent the total score of personal and 
social motivation for patients with T2DM. Therefore, and as long as both were scored 
from one to five, both scales were summed and divided by two to approach a range 
score from one to five similar to the original scoring system. 
3.13.3.3 Diabetes self-management self-efficacy: 
Diabetes patients’ self-efficacy in managing their health status was measured by the 
Perceived Diabetes Self-Management Scale (PDSMS) developed by Wallston et al. 
(2007). It derived from the Perceived Health Competence Scale (PHCS) where the 
word “condition” in the original instrument was replaced with “diabetes”. The 
derived version was used in several investigations and found to be a reliable and valid 
measure (Smith et al., 1995). PDSMS is an 8-item scale that assesses the degree to 
which patients with T2DM feel competent or self-efficacious in managing their 
disease condition. All participants were asked to respond to each item, and they 
ranged from one “‘Strongly Disagree’’ to five “Strongly Agree”. Four of the items 
were phrased such that high agreement indicates low self-efficacy or perceived skill. 
Consequently, these four items were reverse scored prior to being added to the other 
four items. Then, the total PDSMS score was divided by 8 and ranged from 1 to 8, 
with higher scores indicating more confidence in self-managing one’s diabetes. 
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The scale indicated internal consistency with a Cronbach’s alpha of 0.83. PDSMS 
scores were significantly correlated with SDSCA subscales in the psychometric 
validation trial (Wallston et al., 2007).  
3.13.3.4 Glycaemic level (HbA1c) 
Glycaemic level for trial participants was measured using the widespread glycated 
haemoglobin blood test that called (HbA1c). It is a specific form of glycated 
haemoglobin formed through the irreversible binding of glucose particle to the N-
terminus of the haemoglobin β-chain (Marshall and Barth, 2000). HbA1c reflects 
average glycaemia over approximately three months period. The test is the main tool 
for assessing glycaemic control and has strong predictive value for prospects diabetes 
complications (ADA, 2019). 
Although different approaches were available to measure patients’ glycaemic level, 
HbA1c was chosen for several reasons. First, it was considered and used in clinical 
research by the representatives of several medical bodies such as the Association of 
Clinical Biochemists, Association of British Clinical Diabetologists, British Diabetic 
Association and Royal College of Physicians. Second, the decision of using HbA1c 
helped in limiting the lack of standardisation and heterogeneity in the implemented 
approaches to measure patients’ glycaemic level within this area of clinical research 
in literature. Consequently, it improved the interpretation of trial results and the 
comparison with other trials. Third, using HbA1c made it possible to estimate the risk 
of developing diabetes complications for an individual through the harmonization of 
HbA1c results in this trial with UK Prospective Diabetes Study (UKPDS) and Diabetes 
Control and Complications Trial (DCCT) results. Those trials demonstrated an 
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association between the development of different diabetes complications and HbA1c 
values. Finally, it is the only measure for which a considerable amount of data is 
available on the risk of subsequent diabetic complications.  
In both trial settings, several blood tests including HbA1c were ordered by their 
treating physician for health check purposes every three months. On some cases, 
treating physicians were ordering HbA1c blood test each six-month if they had a 
controlled level of HbA1c, which might be less than 7% or 7.5%. The results and 
readings of HbA1c were made available by the laboratory technician and was 
accessible on the electronic record of each patients who attended PHH and JUH.  
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3.13.3.5 Audit of Diabetes Dependent Quality of Life (ADDQOL): 
Diabetes patients’ quality of life was measured using an Audit of Diabetes-Dependent 
Quality of Life (ADDQOL) scale. ADDQOL is an instrument designed to measure 
patients’ perceptions of the impact of diabetes on their quality of life. Bradley et al. 
(1999) reported that factor analysis and Cronbach’s alpha coefficient of internal 
consistency during the development stage was 0.85 for all items, which supported 
that all of them need to be combined in one scale.  
It consisted of two items regarding their quality of life in general at the beginning, 
and an additional 18 items asking about certain aspects related to their DM. The two 
overview questions were developed to inquire about the generic present status of 
their quality of life and the second was asking about how their quality of life would 
be without diabetes. Participants were required to respond to the first item by 
choosing a number on a seven-point scale and they ranged from “excellent” received 
score of +3 to “extremely bad” received score of -3. The second required participants 
to choose a number on a five-point scale and they ranged from “very much better” 
received score of -3 to “worse” received score of +1. The additional 18 items were 
designed to ask participants to express the impact of diabetes on certain aspects of 
life such as enjoyment of food, holidays or leisure activities and ease of travel by 
choosing a number on a five-point scale and they ranged from “very much more or 
better” received score of -3 to “less or worse” received score of +1. Then, participants 
were asked to respond on each item by stating how important that item was in their 
life by choosing a number on a four-point scale that ranged from “very important” 
received a score of +3 to “not at all important” received a score of zero. Each item’s 
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score was calculated by multiplying their score of response with the score of 
importance for each specific item to produce scores ranging from -9 to 3. Total score 
of the 18 items was calculated by summing their scores and divide the total by 18. 
All of the measurements were administered in Arabic language. SKILLD, DES MOS, 
and PDSMS questionnaires were translated to Arabic language using translation and 
back translation method (Sperber, 2004). All translated measurements were not 
tested as they have sort of credibility in their original languages. All questionnaires 
were made available in Arabic language as have been provided by the original 
authors. The following Table 6 is briefly describing the timing of administering each 
instrument in this trial. The questionnaire in is presented in the Appendix  14 . 












Demographics X       
Contact Details  X       
Anthropometric 
Measurements 
X   X   X 
Disease Duration X       
Next Clinic Appointment X   X    
Group Allocation X       
Diabetes Self-
Management Knowledge  
X   X   X 
PDSMS X   X   X 
DES and MOS-SSS X   X   X 
SDSCA and MARS X X X X X X X 
HbA1c (Medical Records)  X   X   X 
ADDQOL  X   X   X 
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Weekly Logs*¥2  X X X X X  
Table 6 Brief description about the timing of administering trial instruments and tools  
 
2 *For intervention group participants only, ¥ Developed for Trial purposes 
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3.14 Data handling: 
Once data collection ended, the completeness of the clinical and demographical data 
was checked by the researcher. Any detected missing data were collected again by 
researcher from the electronic medical records at trial sites where possible. Indeed, 
any empty or blank responses on CRFs were considered as missing raw data. Data 
collected throughout the trial such as participants’ responses on the CRFs and trial 
sheets were numerically coded and entered onto a Software Package for Social 
Sciences (SPSS) database version 24.0. For analysis purposes, SPSS datasets were 
transferred and exported to Stata format due to the robusteness of STATA over SPSS 
as was advised by the school statistician. All electronic databases were protected by 
a password and original CRFs and trial sheets were stored in a locked filling cabinet, 
while the real participants’ information sheet was stored separately. 
3.14.1 Data cleaning: 
Two types of errors can happen during data entry, random and systematic. Random 
errors can occur as a result of typing wrong value or coding the variable’s value with 
an erroneous value, while systematic errors can occur due to a misunderstanding on 
how data should be recorded, and they are more easily to be detected. Theoretically, 
random errors are evenly distributed among trial groups and are more difficult to be 
discovered. However, an increase rate of random errors may reduce the power of 
the trial (Polit, 1999). After entering the coded data onto a computer by the 
researcher, data on the electronic database were verified visually with the original 
documentation to detect any systematic errors that were inevitable made. Until that 
point, data were not ready for analysis because they are not cleaned. Therefore, data 
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cleaning was initiated by checking data for outliers or wild codes and internal 
consistency. To find the outliers within database, and depending on the level of 
measurements of variable, frequency distributions, central tendency and range 
checks of trial variables were carried out to inspect variables for implausible errors. 
The detected errors were compared with the original documentation to determine 
whether errors were an entry errors or coding errors. Missing data were not coded 
and left blank to reduce the chance of using missing codes in statistical calculation 
(Roberts et al., 1997). 
Data internal consistency was checked by testing whether a relation between two 
variables is compatible. For example, a response for the Body Mass Index (BMI) 
should be consistence with weight and height responses.  
3.14.2 Handling missing data  
As is the case with many clinical epidemiological research, missing data are inevitable 
during data collection process and are often constitute a considerable challenge 
during analysis and interpretation of the results and can negatively affect and may 
compromise the validity of the conclusions. Missing values are presented across most 
trials’ datasets and can reduce trial sample size and the trial power (Jakobsen et al., 
2017). If attrition rate was higher in one of the trial arms due to participants drop 
out, it may generate group imbalance and bias (Vickers and Altman, 2013).  
They are due to number of reasons such as being in short supply of trial equipment 
or participant failing to provide data for trial measures. It is commonly happening 
because they may have died, hospitalized, declined the participation, lost to follow 
up and cannot be approached again because it is impossible to trace them. In order 
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to reduce missing values in this trial, several actions were proposed by researcher 
during designing the trial: 
• At recruitment interviews, researcher was available to answer participants 
inquires on the CRFs. In addition, they were assisted if they had eyesight 
complications. CRFs then was reviewed to be certain that they have answered 
all questions. 
• Consented participants had the choice to return to the clinic to continue the 
recruitment interview or to complete CRFs on phone call if they have not had 
sufficient time to do so. 
• Participants who were not able to attend the second or third visit were 
contacted to complete the outcome measures on phone calls by independent 
assessors. 
• On every occasion where participants have been contacted by researcher or 
independent assessors, they were reminded about their next appointment 
and were followed up if they have changed it. Moreover, intervention group 
participants were reminded to complete the weekly logs whenever it is 
possible, and it was short and formatted to be on one paper and wording was 
kept to the minimum for easiness. 
These actions were adopted in an attempt to be vigilance and decrease the number 
of missing values, but some loss of data could not be avoided. Missing values can be 
handled by several accepted methods such as “Complete Case Analysis”, “Last 
Observation Carried Forward” or “Multiple Imputation”. The selection of such a 
method depends on the patterning and distribution of the missing data across the 
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dataset variables. As Stata handles missing data by a “listwise deletion” which is 
usually called “Complete Case Analysis” approach, it was inappropriate to use it for 
some statistical tests such as regression due to the risk of introducing bias within 
outcomes (Pedersen et al., 2017). Therefore, data were analysed using complete case 
analysis approach after imputing missing data. However, type of missingness across 
RCTs is commonly Missing Completely At Random (MCAR) where the estimate of the 
mean remains unbiased and can best be treated using the mean imputation, but it 
biases the standard error. Therefore, and in order to solve the problem of having 
either large or small standard errors, multiple imputation was used to provide 
unbiased and valid estimates of associations based on the available data (Pedersen 
et al., 2017). 
3.14.3 Multiple Imputation: 
Multiple imputation (MI) is a general approach to handle incomplete dataset and is 
existed in many statistical packages. This approach allows for the uncertainty about 
missing data by predicting multiple different plausible imputed datasets and then 
combined together to produce an overall estimated association. Rubin’s rules that 
consider the variability in results between the imputed datasets, are reflecting the 
implausibility associated with the missing values to calculate the standard errors and 
confidence intervals (Rubin, 1987 , Sterne et al., 2009). In contrast to the statistically 
invalid general approaches, such as mean substitution or last value carried forward, 
the technique of MI requires the researcher to model the distribution of each 
variable with missing values based on the observed responses. It includes a random 
element as a reflection that imputed values are estimated rather than known with 
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certainty. As a result, MI has the potential to enhance the validity and generate more 
likely accurate measures of standard errors and variances of the means than other 
approaches of imputations (McKibben et al., 2012). 
3.15 Data analysis: 
3.15.1 General consideration: 
Data were analysed using STATA software package version 15.0. A statistical 
significance level was two sided tested at 0.05. Descriptive statistical tests were used 
to summarize clinical and sociodemographic data. In order to calculate the mean, 
median and standard deviation for continuous variables, and frequency distributions 
to describe categorical variables. 
3.15.2 Assessing data distribution: 
Data were assessed for normality by visual inspection of the shape of the variables’ 
distribution using histograms or plots. Categorical variables were described using 
frequencies of distribution. While continuous variables were assessed for normality 
using visual inspection of histogram, skewness and kurtosis statistical tests, and 
Shapiro-Wilk test (Ghasemi and Zahediasl, 2012). By using skewness and kurtosis 
tests, a probability of (>0.05) for any measure indicates that data distribution is not 
violating the assumptions of normal distribution. If the probability was less than 0.05 
in one of them, a joint probability was used to decide on normality. If the joint 
probability was significant, Shapiro-Wilk statistical test was used for the same 
purpose due to its high power for testing the correlation between the data and the 
corresponding normal values in comparison to Kolmogorov-Smirnov (K-S) test for 
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normality. As a result, Shapiro-Wilk was used to test all continuous variables and they 
were defined as normally distributed if the probability of z was statistically non- 
significant, otherwise, they were considered as non-normally distributed (Brzezinski, 
2012). In addition, summary statistics of skewness and kurtosis were calculated to 
examine whether the distribution indicated any significant skewness or kurtosis 
(Rose et al., 2014).  
Another way was used is check that sample data are drawn from a normally 
distributed population through Kolmogorov-Smirnov and the Shapiro-Wilk statistical 
tests. Those tests compare trial responses against those that should be expected 
from a normally distributed population. Both were check in conjunction with the 
former measure above (Ghasemi and Zahediasl, 2012). If the distribution has had any 
abnormality such as skewed or leptokurtic, then assumptions of normality were not 
valid. In that case, researcher used to transform data by using logarithmic 
transformation where possible. This procedure was used to normalise the data by 
manipulating the magnitude of the variance of the non-normally distributed 
variables. Several types of transformations were used to change the shape of a 
distribution or relationship. Stata offer the gladder statistical command that uses a 
graphical approach and produces an array of nine possible histograms, one for each 
ladder-of-power transforms (Kirkwood and Sterne, 2010 , Becketti, 1994). 
3.15.3 Intention to treat analysis (ITT): 
Primarily, data were analysed using intention to treat analysis and included all 
participants who were randomly allocated to trial groups. Intention to treat (ITT) 
approach is a strategy that is commonly used to analyse RCTs that compares 
129 
PhD Thesis September 2020 Student ID 4220143 
 
participants according to the treatment groups they were originally allocated at 
Randomisation procedure. It includes all participants who were enrolled in the trial 
regardless of the treatment they actually received, lost to follow up, complied with 
the trial intervention or any deviation from the protocol. If trial results were obtained 
without an intention to treat analysis, clinical effectiveness of the studied 
intervention maybe overestimated (Craig et al., 2008). 
To begin with, ITT approach sustains trial groups that are alike irrespective from 
random disparity, which is the main rationale behind randomisation. For example, 
patients with uncontrolled glucose level are more likely to die from advanced 
complications such as Myocardial Infarction or renal failure. If those patients were 
assigned to an intervention and died during the implementation period, intervention 
seems to be attributed to death events. If these deaths are included using an ITT 
analysis, intervention might have a falsely high mortality. Secondly, it allows for 
exceptional aberration from the policy by practitioners because it may occur only 
within the trial setting. To clarify this point, in a trial comparing a phone calls 
educational intervention with the TAU service, intervention provider might 
incorrectly educate a control group participant on one of the intervention contents 
through a phone call before identifying the condition of that participants’ 
assignment, but this will not happen in a real-life situation and, therefore, it needs 
not to be considered for a potential effectiveness. Thus, Intention to treat approach 
is the most appropriate way for trials of effectiveness, and emphasizes a considerable 
accountability for all recruited patients in the trials (Hollis and Campbell, 1999)  
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Nevertheless, many arguments put forward in favour of the invalidity of ITT. To 
explain, if a participant was allocated to intervention group and did not actually 
receive the intervention, it may underestimate the effectiveness of the intervention. 
Intervention impact is generally conventional due to heterogeneity of participant 
where compliant, non-compliant and lost to follow are included in the analysis. 
However, although ITT minimize type I error, it has been criticized for being very 
vigilant and more vulnerable to type II error (Gupta, 2011). 
3.15.4 Data transformation 
A process of data transformation was initiated if a variable was non-normally 
distributed. Data transformation is a mathematical function to convert data from one 
format to another. It can help to improve the homogeneity of variable’s variance, so 
that robust parametric statistical tests can be applied (Manikandan, 2010). Several 
methods of transformation were utilized to improve the assumption of normality 
such as log, square root and reciprocal transformations. Therefore, if data 
transformation changed the variable variance to be normally distributed, mean and 
standard deviation was used to describe the data, otherwise, median and 
interquartile range was applied.  
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3.15.5 Measuring IMBDSME effectiveness: 
Comparing trial groups can be done in different ways. Trial groups can be compared 
at the end of the trial to show which group has improved more, or a change score 
can be calculated by deducting the follow up score from the baseline score to show 
which group has the higher/ lower change score. However, using the change scores 
in analysis takes account of the chance of imbalances at baseline but does not control 
it (Vickers and Altman, 2001). In RCTs, randomisation is used to reduce the 
probability of generating an imbalance in baseline measurements between trial 
groups. Although this is the case in most trials with high number of participants, it 
may happen within small trials. In fact, there is no recommendation within CONSORT 
statement about which analysis should be used in RCTs and whether or not an 
adjustment for baseline measurements is preferred.  
Baseline imbalances can occur as a result of chance when choosing participants 
randomly (Nash et al., 2014). This imbalance may have an impact on the outcomes 
of the trial during analysis because baseline measurements are negatively correlated 
with the difference in the scores before and after the treatment. For example, 
participants with low score at baseline may improve greater than participants with 
higher score whether they were allocated to control or IMBDSME group. This can 
lead to creating an artificial underestimation or overestimation in the treatment 
effect due to the regression to the mean, which has a confounding role since both 
trial groups are from the same population. Therefore, it is strongly recommended to 
adjust for the baseline values of the outcome variable regardless having a statistically 
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significant differences between trial groups or not at baseline (J et al., 2018 , de Boer 
et al., 2015). 
Different methods are existed in the literature that are being used to estimate 
treatment effect within RCTs. J et al. (2018) used four common methods in their 
educational article to estimate the effectiveness of a treatment intervention in 
reducing systolic blood pressure. They concluded that using longitudinal analysis of 
covariance is strongly advised to estimate treatment effect between trial groups 
rather than using regular repeated measures analysis and the regular analysis of 
changes which both are unable to secure proper adjustment for baseline value of the 
outcome variable during performance. While longitudinal analysis of covariance 
takes into account the fact that the repeated observations of the outcome variable 
for each participant are adjusted for the baseline value. However, analysis of 
covariance can be applied under the assumption of the independency between the 
independent variable and covariates within subjects where there is no interaction 
between them. This is a common problem for analysis of covariance because in 
longitudinal data, observations are collected repeatedly across subjects and a 
structure of correlation could have been be generated. This assumption, in addition 
that analysis of covariance support only well-balanced data without any missing 
values, are big disadvantages to this method (Locascio and Atri, 2011). Therefore, a 
more flexible advanced approach was chosen to deal with longitudinal data analysis 
such as Generalized Estimating Equations (GEE).  
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3.15.5.1 Generalized Estimating Equations method: 
GEEs cover the generalized linear model and extend to analyse the repeated 
correlated measurements. This method is considered a marginal longitudinal 
approach that attempts -through two equations- to draw a conclusion of how the 
mean of the dependent variable changes across visits, while at the same time, is 
eliminating the nuisances of covariances among the observations within subjects 
separately in order to validate the regression coefficient estimates significantly. It has 
more power to detect an association of interest, either at population level or 
individual level, can deal with missing values and with a small number of equally 
distanced visits (homogeneously separated) as well as does not require dependent 
variable to be normally distributed. GEEs are “pooled” analyses of within-subject and 
between-subject relationships, both of which represent imperative aspects to 
estimate IMBDSME effect. Lastly, GEE method was used to estimate the treatment 
effect for each single outcome (Zeger et al., 1988). 
Analysis were performed through several models to estimate the effect size of 
IMBDSME intervention on primary and secondary outcomes. Basically, all models 
used model 1 where the outcomes’ score was the dependent variable and the 
interaction between trial groups and trial visits was the independent variable 
(unadjusted to the baseline). Then, adjustments were considered for baseline values 
of the outcome score by adding the trial visits to model 1 (model 2); as in model 2 
with adjustments for age and gender (model 3); as on model 3 with the adjustments 
for HbA1c (model 4); as in model 4 with the adjustments for diabetes-related 
medications (model 5).  
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The electronic records of 2786 patients who attended the trial sites were screened. 
Those who did not meet the eligibility criteria were 2384 (85.6%) as large proportion 
were diagnosed with different disorders and chronic conditions apart from T2DM 
due to the diverse range of patients who attend both trial sites as was explained in 
(3.9.2.1) and (3.9.2.2). What is more, those who were diagnosed with T2DM were 
supposed to meet the eligibility of having an uncontrolled level of HbA1c as was listed 
in section (3.2.4). Of those who were eligible, 402 (14.4%) potential participants, 215 
(53.5%) were unobtainable and only 187 (46.5%) were approached and invited to 
participate. Of those who were approached, 36 (19.2%) patients declined to 
participate where 151 (80.8%) agreed to participate and were recruited in the trial. 
All in all, the overall recruitment rate in this trial was 151/187 (80.8%). However, 
despite the flexibility of offering the completion of baseline assessment on phone at 
a time convenient for participants, three participants 3/151 (2%) withdrew during 
baseline assessment due to lengthy assessment which they perceived to be a burden. 
The rest 148 (98%) were randomised and allocated to two trial groups. Moreover, 
during follow up period, seven participants were lost for different reasons mentioned 
in the following section (4.1.1). The statistics of patients who were screened, 
excluded, invited and agreed to participate or declined within each stratum are 
presented in Table 7. 
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Std. Err. 95% CI3 
Assessed n= 2786 
PHH 808 (29%) 70.1 667.6 to 948.3 
JUH 1978 (71%) 151.4 1674.8 to 2281.1 
Excluded n= 2384 
PHH 694 (29.1%) 60.1 573.6 to 814.3 
JUH 1690 (70.9%) 128.0 1433.8 to 1946.1 
Eligible n= 402 
PHH 114 (28.4%) 14.2 85.50 to 142.4 
JUH 288 (71.6%) 28.6 230.7 to 345.2 
Couldn't be Invited n= 215 (215/402= 53%) 
PHH 54 (25.1%) 5.7 42.5 to 65.4 
JUH 161 (74.9%) 18.4 124.1 to 197.8 
Invited n= 187 (187/402=47%) 
PHH 60 (32.1%) 6.3 47 to 72 
JUH 127 (67.9%) 16.6 97 to 156 
Results of invitation of n=187 
Declined n= 36 
(36/187=19.2%) 
Recruited n= 151 
(151/187=80.8%) 
PHH 17 (47.2%) 43 (28.5%) 
JUH 19 (52.8%) 108 (71.5%) 




3 CI: Confidence Interval 
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Principally, randomisation was designed to equalize the number of participants 
within both trial groups. Nevertheless, due to different sizes of randomization blocks 
in the randomization list, it resulted in the intervention group being slightly larger 
(n=77) than the control group (n=71), representing 51% and 47% of the sample 
respectively. CONSORT flow diagram of recruitment stages and allocation of eligible 
participants within RCT arms is presented below in Figure 10. At second visit, data 
were unobtainable from two participants (2.6%) in intervention group because 
researcher was unable to approach, contact or meet them at clinic. While in the 
control group, data were unobtainable from one participant (1.4%) due to the same 
reason. In the third visit, the percentages of lost to follow up increased within 
intervention group and control group, standing at 6.5% (5/77) and 2.8% (2/71) 
respectively. Further two participants were unapproachable, and one participant 
died during follow up period, therefore, their data were unobtainable in the 
intervention group. While in the control group, another participant was 
unapproachable. All in all, ten participants were lost in trial after signing the consent 
from and those represented no more than 6.6% of those who were recruited. 
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4.1.1 CONSORT Flow Diagram of recruitment process and allocation within RCT: 
 






















Assessed for eligibility (n=2786) 
Excluded (n=2571) 
 Did not meet inclusion criteria (n=2384) 
 Declined to participate (n=36) 
 Unobtainable (n=215) 
 
 Unobtainable (n= 1) 
 Follow up assessment (n= 69)  
 Unobtainable (n= 1)  
 Follow up assessment (n= 70) 
 
 
Allocated to Control group (n= 71) 
 Received the usual clinical care (n= 71) 
 Unobtainable (n= 2) 
 Follow up assessment (n= 75)  
 Process evaluation interview (n= 15) 
 
Allocated to intervention group (n= 77) 
 Received educational booklet & phone 
calls from 2 weeks of Enrollment (n= 77) 
 Unobtainable (n= 2) 
 Dead (n= 1) 





 Consented Participants (n= 151) 
 Will be included in Analysis (n=71)  Will be included in Analysis (n=77) 
Baseline assessment (n= 151) 
 Completed baseline (n= 148) 
 Withdrawn during baseline (n= 3) 
Randomized (n= 148) 
 
Second Visit (after 3 months) 
 






Enrollment (First visit) 
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4.2 Data and randomisation list check: 
4.2.1 Data check: 
The entered raw data on the electronic SPSS database were checked with the original 
documentation using the anonymised Case Report Forms (CRFs). There were 151 
cases with approximately 665 responses for each case. All of them were checked by 
researcher who found 256 single input mismatching the original documentation. The 
mismatched responses were corrected. Entry error rate was 0.26% with 95% CI (0.17 
- 0.38%) using 256/100415 for the whole dataset. The error rate was less than 0.5% 
and this means that any difference between the trial groups of 0.5% may be 
accounted for the entry error. Nevertheless, this difference is unlikely to affect the 
clinical effect size. 
4.2.2 Randomisation outcome check: 
The numbered randomisation list contained a block identifier number, stratum of 
two sites, participant number, unique randomisation code for each participant and 
his/her allocation in a trial group. Moreover, the list was developed based on 
different sizes of even blocks of four, six and eight to recruit a total of 464 participants 
from two trial sites; 232 participants from each This long list was generated in case 
researcher could not secure a second trial site for individual recruitment purposes. 
The sequence of 148 participants who were allocated according to the outcome of 
the randomisation online service was compared with the initially uploaded 
randomisation list and were identical. 
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4.3 Participants’ allocation: 
As seen in Table 8 below, participants were allocated to both trial groups equally 
within each trial site stratum according to the process of randomisation. Recruited 
participants from JUH were (70.2%) of the whole trial sample, while (29.8%) were 
recruited from PHH due to the low number of patients with T2DM who attended 
PHH. Participants who withdrew during baseline assessment were attending JUH and 
they are described under pre-randomisation group. 
Allocation within Trial 
Arms 
 
Trial Settings  
Intervention 
group n (%) 
Control 




Total n (%) 
Jordan University Hospital 53 (35%) 50 (33 %) 3 (2%) 106 (70.2%) 
Prince Hamza Hospital 24 (16%) 21 (14%) 0 45 (29.8%) 
Total 77 (51%) 71 (47%) 3 (2%) 151 (100%) 
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4.4 Baseline data: 
4.4.1 Demographic characteristics: 
Demographic characteristics for all participants and by trial groups are presented at 
Table 9. The data of the three participants (2%) who chose to withdraw before the 
procedure of randomisation are described under pre-randomization trial group. 
Median of age of participants in this trial sample was 56 (IQR4, 50 – 61) and the mean 
was 55 ± (7.58). Of those, 86 participants were females who constituted the majority 
(57%) of the sample. As a result, 78 participants were housewives, which was the 
highest among job categories (51.7%). Similarly, housewives were the majority in 
each trial group; 38 participants in TAU group (53.6%) and 40 participants in 
IMBDSME group (52%). Fifth of the sample 34 participants (22.5%) were retired and 
did not have a specific job at the point of recruitment. Regarding marital status, 116 
participants (76.8%) of the sample were married. Another figure, 61 participants 
(40.4%) of the sample finished their elementary education. Furthermore, active 
smokers were almost third (29.8%) of the sample whom more than two third of them 
were males. Lastly, all participants have a median of income of 350 (IQR, 250 – 500) 
Jordanian Dinars JD5. Researcher used significance statistical tests to compare 
baseline characteristics whether demographics or comorbidities between IMBDSME 
group and TAU group, and based on the statistically non-significant results, 
researcher concluded that trial groups were homogenous and comparable at the 
point of recruitment. 
 
4 IQR: Inter Quartile Range 
5 1 JD = 1.41 USD 
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56 (50 – 61) 
 
56 (50 – 61) 
 
56 (50 – 62) 
 























































































6 Inter Quartile Range (75%-25%) 
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Education level 























































350 (250 – 500) 
 
350 (200 – 500) 
 







7 Inter Quartile Range 
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Medications 
Metformin only  
Metformin + Sulfonylureas 
Metformin + Sulfonylureas + Pre-Mixed insulin 
Metformin + Sulfonylureas + Long acting 
Metformin + Short acting insulin + Long acting 
Metformin + Pre-Mixed insulin 
Metformin + Sulfonylureas + DPP-4 inhibitor8 
Metformin + Pre-Mixed insulin + DPP-4 inhibitor  
Metformin + Sulfonylureas + Pre-Mixed inhibitor  




















































Table 9 Demographic Characteristics for all Participants and by Trial Groups 
 
 
8 Inhibitors of Dipeptidyl Peptidase 4 
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4.4.2 Comorbidities and Anthropometric measurements: 
The presence of comorbidities and measurements of anthropometric parameters 
within trial sample and trial groups are demonstrated in detail in Table 10. In terms 
of comorbidities, and although the variations between trial groups were not 
statistically significant, more participants in the IMBDSME group were diagnosed 
with retinopathy and lipoedema than of those who were in the TAU group. Whereas 
in the TAU group, more participants were diagnosed with hypertension and 
nephropathy than participants in the IMBDSME group. 
The glycaemic level (HbA1c) was slightly more controlled in TAU group 9.73 ± (1.51) 
than participants in IMBDSME group 9.82 ± (1.7), whom have been diagnosed with 
T2DM longer than participants in TAU, standing at median of 10 (IQR, 5-16) years and 
median of 9 (IQR, 5-15) years respectively. In contrast, participants in TAU group have 
had uncontrolled and higher level of lipoedema such as triglycerides and cholesterol 
levels, standing at median of 181 (IQR, 134 – 219) and mean of 185.7 ± (53.2) 
respectively, than participants in the IMBDSME group who had median of 162 (IQR, 
104 – 272) and mean of 178.2 ± (50.2) respectively. Lastly, systolic and diastolic blood 
pressure readings and body mass index were similar between trial groups.  
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HbA1c (Glycaemic level) 
Mean ± (SD) 
 
9.75 ± (1.60) 
 
9.73 ± (1.51) 
 
9.82 ± (1.7) 
 


















































































































Diabetes Duration (before transformation) 
Median (IQR9) 
Diabetes Duration (Square root Transformation) 
Mean ± (SD10) 
 
10 (5 – 15) 
 
3.11 ± (1.23) 
 
9 (5 – 15) 
 
3.01 ± (1.2) 
 
10 (5 – 16) 
 








t test P=0.42 
Body Mass Index (Before transformation) 
Median (IQR) 
Body Mass Index (After log transformation) 
Mean ± (SD) 
 
31 (26.4 – 35) 
 
3.43 ± (0.22) 
 
31 (25.3 – 35.2) 
 
3.42 ± (0.23) 
 
31 (27.2 – 35) 
 
3.45 ± (0.21) 
 
29 (24.8 -33.4) 
 




Systolic Blood Pressure 
Mean ± (SD) 
 
134.4 ± (19.3) 
 
134.3 ± (20.9) 
 
134.6 ± (18.3) 
 
130 ± (21.2) 
Independent t 
test P=0.57 
Diastolic Blood Pressure 
Mean (SD) 
 
76.1 ± (11.6) 
 
76.8 ± (13.3) 
 





Triglycerides (Before transformation) 
Median (IQR) 
Triglycerides (After log transformation) 
Mean ± (SD) 
 
174 (121 – 255) 
 
5.16 ± (0.60) 
 
181 (134 – 219) 
 
5.2 ± (0.50) 
 
162 (104 – 272) 
 
5.12 ± (0.62) 
 
235(229 – 242) 
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Cholesterol 
Mean ± (SD) 
 
182.3 ± (51.6) 
 
185.7 ± (53.2) 
 
178.2 ± (50.2) 
 
226 ± (59.4) 
Independent t 
test P=0.46 
Low Density Lipoprotein (LDL)  
Mean ± (SD) 
 
118.2 ± (41.8) 
 
120.8 ± (42.0) 
 





High Density Lipoprotein (HDL)  
Mean ± (SD) 
 
40.9 ± (12.4) 
 
41.1 ± (14.1) 
 
40.7 ± (11.3) 
 
44 ± (9.9) 
Independent t 
test P= 0.88 
Table 10 Comorbidities and Anthropometric measurements for all Participants and by Trial Groups at Baseline 
 
 
9 IQR: Inter Quartile Range (75%-25%) 
10 SD: Standard Deviation 
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4.4.2.1 Differences between trial sites: 
As mentioned in (3.9.4), trial sites differ in treatment regimen and sponsors. This fact 
may explain the variations in the prescribed diabetes-related in both trial sites (JUH 
and PHH). In details, more than third (36.1%) of participants who attended JUH were 
treated for T2DM using the combination of metformin plus the short and long acting 
insulin, whereas it was not prescribed to any of participants who attended PHH. On 
the other hand, more than quarter (26.7%) of participants who attended PHH were 
treated using the combination of metformin and pre-mixed insulin, whereas 19.1% 
of participants who attended JUH were prescribed this combination.  
Without a doubt, the result of HbA1c is greatly informed by the treatment plan that 
includes diabetes-related medications where patients with T2DM are commonly 
treated by different regimens (Hirst et al., 2014). Those medications lower HbA1c in 
different ways, which explain the need for different regimens to achieve an 
individually tailored HbA1c goal. This may explain the statistically significant 
difference (P value = 0.015) in HbA1c between trial sites where participants who 
attended PHH had higher mean of HbA1c 10.2 ± (1.8) than participants who attended 
JUH 9.5 ± (1.5). All details are presented in Table 11. 
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HbA1c  10.2 ± (1.8) 9.5 ± (1.5) 9.8 ± (1.6) 
Metformin only  
Metformin + Sulfonylureas 
Metformin + Sulfonylureas + Pre-Mixed insulin 
Metformin + Sulfonylureas + Long acting 
Metformin + Short acting insulin + Long acting 
Metformin + Pre-Mixed insulin 
Metformin + Sulfonylureas + DPP-4 inhibitor 
Metformin + Pre-Mixed insulin + DPP-4 inhibitor  
Metformin + Sulfonylureas + Pre-Mixed inhibitor  































Total  45 (100%) 105 (100%) 150 (100%) 
Table 11 Medications and HbA1c level for all participants across Trial sites 
  
 
11 PHH (Prince Hamza Hospital) 
12 JUH (Jordan University Hospital) 
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4.4.3 IMB components, quality of life and self-care behaviours: 
IMB components, diabetes-dependent quality of life, and self-care behaviours were 
measured at baseline and are presented from Table 12 to Table 15. As mentioned 
before in section (2.1), “I” letter stands for information (knowledge), “M” for 
motivation whether social or personal and “B” for related-behaviour self-efficacy. 
Participants in the TAU group tended to have higher scores in all IMB components 
than participants in the IMBDSME group, except personal motivation where both 
trial groups had nearly similar scores. The variations in baseline scores between trial 
groups were not statistically significant as shown in Table 12, Table 13 and Table 15. 
Using the Audit for Diabetes-Dependent Quality of Life (ADDQOL) scale, participants 
in both groups had a median of 1 (0 – 2) in the first question, a median of -2 (-2 -- -1) 
in the second question and a median of -2.1(-3.3 - -1.2) for the diabetes-specific 18-
items. According to the ADDQOL scale responses, a middle score of one for the first 
question means they averagely chose a “good” level of quality of life in general, while 
for the second question, a score of -2 means they averagely chose that their lives 
would be “much better” without T2DM. Total score of ADDQOL that measured the 
impact of T2DM on particular life aspects through 18-items was higher within 
participants in the TAU group than participants in the IMBDSME group. Moreover, 
the level of participants’ satisfaction on the received TAU did not statistically 
significantly vary between trial groups, whereas it statistically significantly varied 
between trial sites. Regardless of the trial groups allocation, participants who 
attended PHH had a lower level of satisfaction (23.1) compared to participants who 
attended JUH (26.1) with P value < 0.004.  
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Overall, mean score of measuring the performance of self-care behaviours such as 
diet modification, physical activity and medications management were broadly 
comparable in both trial groups. Those scales have been summed after weighting 
adjustments for each scale and the total is presented in a dummy variable called total 
of Diabetes Self-Care Behaviours (DSCB). Generally, participants in TAU group scored 
higher in performing diet modification 3.14 ± (1.3) and lower in performing physical 
exercise 1.14 ± (1.1) than IMBDSME group who scored 2.8 ± (1.3) and 1.32 ± (1.37) 
respectively at baseline. 
Characteristics of diabetes 












Mean ± (SD) 
 
6.63 ± (1.2) 
 
6.75 ± (1.0) 
 




Mean ± (SD) 
 
3.4 ± (0.4) 
 
3.39 ± (0.4) 
 






0.77 (0.6 – 0.9) 
 
0.78 (0.6 – 0.9) 
 





Mean ± (SD) 
 
3.64 ± (0.45) 
 
3.65 ± (0.45) 
 




Mean ± (SD) 
 
2.87 ± (0.57) 
 
2.89 ± (0.48) 
 
2.85 ± (0.64) 
Independent t 
test P=0.72 
Table 12 Baseline Data of Diabetes Knowledge, Motivation and Self-Efficacy. SKILLD: Spoken Knowledge in Low 
Literacy in Diabetes scale; DES: Diabetes Empowerment Scale; MOS: Medical Outcomes Trial; DES+MOS: Total 
score of combining DES with MOS.PDSMS: Perceived Diabetes Self-Management Scale. 
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Diabetes-Dependent 














1 (0 – 2) 
 
1 (0 – 2) 
 








-2 (-2 -- -1) 
 
-2 (-2 - -2) 
 








-2.1(-3.3 - -1.2) 
 











26 (21.5 – 30) 
 
26 (22 – 30) 
 





Table 13 Baseline Data of Audit of Diabetes Dependent Quality of Life (ADDQOL) and Diabetes Treatment 
Satisfaction Questionnaire (DTSQs) 








DTSQs at Baseline 
Mean ± (Standard Deviation) 
 
25.2 ± (5.9) 
 
23.1 ± (6.7) 
 
26.1 ± (5.4) 
Independent t 
test P=0.01 



















Mean ± (Standard Deviation) 
 
3 ± (1.3) 
 
3.14 ± (1.3) 
 
2.8 ± (1.3) 
Independent t 
test P=0.13 
Physical Activity (SDSCA) 
Mean ± (Standard Deviation) 
 
1.24 ± (1.24) 
 
1.14 ± (1.1) 
 






Mean ± (Standard Deviation) 
 
8 ± (1.3) 
 
8.0 ± (1.41) 
 
8.1 ± (1.3) 
Independent t 
test P=0.76 
Total of DSCB 
Mean ± (Standard Deviation) 
 
10.67 ± (3.02) 
 
10.66 ± (2.70) 
 
10.67 ± (3.6) 
Independent t 
test P=0.86 
Table 15 Baseline Data of Diabetes Self-Management Behaviours. SDSCA; Summary of Diabetes Self-Care 
Activities Scale; MARS, Medications Adherence Rating Scale; DSCB, Diabetes Self-Care Behaviours. 
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4.4.4 Missing Data: 
Table 16 below shows the percentages of missing data across baseline variables in 
this trial. At baseline, and as part of the routine clinic practice, weight was not 
measured for 24.3% of this sample, and researcher was unable to calculate BMI for 
43.7% of the sample due to the absence of height measurements in the medical 
records. Moreover, blood pressure was not measured for 31.8% of all participants, 
while lipid profile such as HDL, LDL, triglycerides and cholesterol were not measured 
for 36.5%, 38.5%, 27.7% and 27.7% respectively. All other parameters were collected 
for all participants (148) who finished baseline assessment and allocated to one of 
trial groups. Anthropometric measurements such as weight, height and blood 
pressure were not always measured either due to the unavailability of equipment or 
were not requested by the treating physician. Likewise, many results of blood tests 
at baseline such as lipid profile and glycaemic indicators did not exist in the electronic 
database due to various technical difficulties. According to Pedersen et al. (2017), 
this type of missing data is a clear example of the Missing Completely At Random 
(MCAR) and supported the notion of using multiple imputation as researcher 
proposed in section (3.14.2). 
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Gender 0 151 0.0% 2 0 1 
Job 2 149 1.4% 5 1 5 
Age 1 150 0.7% 28 30 65 
Marital Status 2 149 1.4% 4 0 3 
Educational level 2 149 1.4% 4 0 3 
Smoking status 2 149 1.4% 3 0 2 
Income 2 149 1.4% 39 50 3000 
Alcohol 2 149 1.4% 1 0 0 
Diabetes Duration 2 149 1.4% 32 0.5 35 
Hypertension 2 149 1.4% 2 0 1 
Lipoedema 2 149 1.4% 2 0 1 
Heart Disease 2 149 1.4% 2 0 1 
Nephropathy 2 149 1.4% 2 0 1 
Retinopathy 2 149 1.4% 2 0 1 
Neuropathy 2 149 1.4% 2 0 1 
weight 36 115 24.3% 68 49 150 
BMI 66 85 43.7% 84 20 55.8 
Systolic pressure 47 104 31.8% 20 90 190 
Diastolic pressure 47 104 31.8% 13 50 115 
Blood sugar 57 94 38.5% 80 97 492 
HDL 54 97 36.5% 46 17 94 
LDL 57 94 38.5% 69 45 213 
Triglycerides 41 110 27.7% 99 47 630 
Cholesterol 41 110 27.7% 83 70 312 
Medications 1 150 0.7% 10 1 16 
HbA1c 0 151 0.0% 47 8.1 15.1 
SKILLD 2 149 1.4% 14 3.5 9.5 
DES 2 149 1.4% 130 1.86 5 
MOS 3 148 2.0% 26 1.62 5 
PDSMS 3 148 2.0% 24 9 38 
SDSCA Diet 3 148 2.0% 25 0 6.25 
SDSCA activity 3 148 2.0% 11 0 6.5 
MARS 3 148 2.0% 7 4 10 
ADDQOL 1st Question 3 148 2.0% 7 -3 3 
ADDQOL 2nd Question 3 148 2.0% 5 -3 1 
ADDQOL Total 3 148 2.0% 107 -8.2 0 
DTSQs 3 148 2.0% 26 9 36 
DTSQs 2nd Question 3 148 2.0% 7 0 6 
DTSQs 3rd Question 3 148 2.0% 7 0 6 
Table 16 Percentages of MCAR Missing Data at Baseline for all Participants (n=151) before Randomisation. 
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Data on weight was available to 83% of participants who attended JUH, while only 
60% of those who attended PHH have been measured for weight. Moreover, systolic 
and diastolic blood pressure readings were available for 75.5% of participants who 
attended JUH, and available only for 53.3% of participants who attended PHH. This 
variation was due to the availability of equipment and facilities. In JUH, the required 
equipment and a dedicated registered nurse were available for anthropometric 
measurement purposes, whereas in PHH, none of the attendees were measured for 
anthropometrics unless it was asked by the treating physician because the 
equipment were not available in the clinic and were shared with other clinics. Details 
and percentages are presented in Table 17 below. 
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Variables Prince Hamza 
Hospital n=45 (29.8%) 
Jordan University 
Hospital n=106 (70.2%) 






























































Table 17 Percentages of Missing data of Anthropometric Measurements across trial settings at Baseline 
  
 
13BMI: Body Mass Index 
 SBP: Systolic Blood Pressure 
 DBP: Diastolic Blood Pressure 
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4.5 Missing data within trial outcomes: 
In this trial, primary and secondary outcomes were measured at three-month 
(second visit) and six-month (third visit) after collecting baseline data as was 
described in section (3.11). As is the case in many clinical trials, missing data were 
presented repeatedly across all trial visits due to several reasons such as not 
attending, or the unavailability of the blood tests results in the medical records and 
anthropometric measurements equipment in the clinic. All missing data regardless 
of the quantity of missingness were treated using multiple imputation as explained 
in section (3.14.2). 
It was key factor for this trial that participants should attend their clinic appointments 
for data collection purposes, and in order to collect primary and secondary outcomes 
by the independent assessors. Although it was also clinically relevant, participants 
who attended all the pre-planned clinical appointments were diagnosed with T2DM 
for a mean duration of 11.61 ± (8.06) years while who did not attend the pre-planned 
clinic appointments tend to have T2DM for a mean duration of 9.52 ± (7.06) years, 
this relationship was not statistically significant. However, participants who attended 
JUH were statistically significant (P=0.026) more likely to attend their clinic 
appointments (83%), whereas (33.3%) of participants who attended PHH did not 
attend their clinic appointment as presented in Table 18.  
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Variables Did not attend their clinic 
appointments n=33 
(21.9%) 






Hospital, n (%) 
15 (33.3%) 30 (66.7%) 45 (29.8%) 
Jordan University 
Hospital, n (%) 
18 (17.0%) 88 (83.0%) 106 (70.2%) 
Duration of T2DM by 
years at baseline, 
mean ± (SD)14 
9.52 ± (7.06) 11.61 ± (8.06) 11.2 ± (7.9) 
Table 18 Characteristics of Participants who attended their clinic appointments versus who did not 
In this trial, as mentioned before in trial management section (3.10), independent 
assessors collected the primary and secondary outcomes at three-month and six-
month visits. Both (two assessors) managed to attend trial settings to meet the 
recruited participants from trial groups to collect outcomes face to face. However, 
some participants did not show up for their clinic appointments and assessors were 
advised by the researcher to contact those participants by phone to collect the trial 
outcomes if they were willing to continue voluntarily with the trial. Independent 
assessors chose and prioritised to collect the primary outcomes over the secondary 
outcomes due to time constraints as secondary outcomes scales were longer and 
consumed considerable time and efforts. Overall, percentages of missing data within 
primary outcomes were less than of those within secondary outcomes. 
Statistics of all participants and their status according to the trial visits and by trial 
groups are presented in Table 19. In general, 97.2% and 93.5% of TAU group and 
 
14T2DM: Type 2 Diabetes Mellitus 
 SD: Standard Deviation 
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IMBDSME group respectively completed their primary outcomes either face to face 
or on phone at three-month or six-month.  
Percentages of participants who completed their primary outcomes on phone are 
presented in Table 20. From the details, 32 participants (21.6%) of the trial sample 
were called on phone to collect their primary outcomes; nine participants (6.1%) at 
three-month and 23 participants (15.6%) at six-month points because they were not 
approachable at the clinic on the pre-planned appointment. Of those who were 
called at three-month point, six of them were allocated at IMBDSME group. Whereas, 
of those who were called at six-month time point, 14 of them were allocated in TAU 
group. Using chi-square statistical tests, the relationship of being allocated to a 
certain trial group and participants’ status according to trial visits or the fact of 
collecting their primary outcomes on phone was not statistically significant different. 
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group, n=3 (2%) 
Total, n=151 
(100%) 
Completed the trial either face to face or on phone 69 (97.2%) 72 (93.5%) 0 141 (93.4%) 
Withdrawn at First Visit before Randomisation 0 0 3 (100%) 3 (2%) 
Can't be reached at Second Visit 1 (1.4%) 2 (2.6%) 0 3 (2%) 
Can't be reached at Third Visit 1 (1.4%) 2 (2.6%) 0 3 (2%) 
Deceased at Third Visit 0 1 (1.3%) 0 1 (0.6%) 
Table 19 Percentages of participants and their status according to the trial visits for all participants and by trial groups. 
 
Participants who completed primary outcomes on phone and didn't complete 
secondary outcomes 






At three-month visit 3 (4.2%) 6 (7.8%) 9 (6.1%) 
At six-month visit 14 (19.7%) 9 (11.7%) 23 (15.6%) 
Total  17 (24%) 15 (19.5%) 32 (21.6%) 
Table 20 Percentages of participants who completed their primary outcomes on phone for all participants and by trial groups 
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4.5.1 Primary outcomes: 
Percentages of missing data of primary outcomes for all participants and across trial 
groups at three-month and six-month are presented below in Table 21, Table 22 and 
Table 23. It is notable that the highest percentage of drop out was among IMBDSME 
group at six-month because five participants (6.5%) could not be approached by the 
independent assessors whom one of those participants were female and died during 
the trial data collection period. 
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Primary outcomes for all 
participants (n=148) 






SDSCA Diet 3 145 2.0% 21 1 6.25 
SDSCA Activity 3 145 2.0% 9 0 4 
MARS 3 145 2.0% 6 5 10 
Six-month 
SDSCA Diet 7 141 4.7% 20 1 6.3 
SDSCA Activity 7 141 4.7% 10 0 5 
MARS 7 141 4.7% 6 5 10 
Table 21 Percentages of Missing Data of primary outcomes at for all Participants SDSCA; Summary of Diabetes 
Self-Care Activities Scale; MARS, Medications Adherence Rating Scale. 
 
Primary outcomes of 
TAU group (n=71) 






SDSCA Diet 1 70 1.4% 20 1 6.25 
SDSCA Activity 1 70 1.4% 7 0 3.5 
MARS 1 70 1.4% 6 5 10 
Six-month 
SDSCA Diet 2 69 2.8% 17 1.25 6.25 
SDSCA Activity 2 69 2.8% 7 0 3.5 
MARS 2 69 2.8% 6 5 10 
Table 22 Percentages of Missing Data of primary outcomes at for Participants of TAU group. SDSCA; Summary of 
Diabetes Self-Care Activities Scale; MARS, Medications Adherence Rating Scale. 
 
 
Primary outcomes of 
IMBDSME group (n=77) 






SDSCA Diet 2 75 1.4% 16 1.75 6.25 
SDSCA Activity 2 75 1.4% 9 0 4 
MARS 2 75 1.4% 4 7 10 
Six-month 
SDSCA Diet 5 72 6.5% 17 1 5.5 
SDSCA Activity 5 72 6.5% 10 0 5 
MARS 5 72 6.5% 4 7 10 
Table 23 Percentages of Missing Data of primary outcomes at for Participants of IMBDSME group. SDSCA; 
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4.5.2 Secondary outcomes 
Percentages of missing data of secondary outcomes for all participants and across 
trial groups are presented below from Table 24, Table 25 and Table 26. Similar to 
baseline missing data, several blood tests and anthropometric measurements data 
were the highest compared to other variables to be missed. At three-month, BMI and 
blood pressure readings were missed in more than 85% of the trial sample, whereas 
lipid profile results were missed in more than 55%, and glycaemic level was the least 
missing, standing at 30% of the whole sample. Indeed, all other outcomes 
measurements that measured diabetes patients’ knowledge, motivation, self-
efficacy, satisfaction on the perceived treatment and their quality of life were missed 
in 15 participants (10.1%) of the sample because they did not show up during their 
clinic appointment. At six-month, the percentages of missing data increased 
moreover to approach 100% among BMI and blood pressure readings. While lipid 
profile results were not available in around 65% of the trial sample whom almost 40% 
of them have not had any glycaemic indicators readings such as HbA1c and fasting 
glucose level. While missing data doubled for those other secondary measurements 
to reach up to 20.3% of the trial sample.  
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Secondary outcomes for 
all participants (n=148) 






Weight 127 21 85.8% 19 50 156 
BMI 134 14 90.5% 14 20.8 41.4 
Systolic pressure 127 21 85.8% 9 105 190 
Diastolic pressure 127 21 85.8% 8 60 100 
HbA1c 45 103 30.4% 56 4.9 16 
Blood sugar 62 86 41.9% 79 51 716 
HDL 93 55 62.8% 31 22 103 
LDL 101 47 68.2% 39 44 249 
Triglycerides 84 64 56.8% 61 45 736 
Cholesterol 83 65 56.1% 54 81 346 
Medications 11 137 7.4% 10 1 16 
SKILLD 15 133 10.1% 13 4 10 
DES 15 133 10.1% 69 2.65 4.67 
MOS 15 133 10.1% 21 1 5 
PDSMS 15 133 10.1% 19 17 38 
ADDQOL 1st Question 15 133 10.1% 5 -1 3 
ADDQOL 2nd Question 15 133 10.1% 5 -3 1 
ADDQOL Total 15 133 10.1% 113 -7 .17 
DTSQc 15 133 10.1% 21 -4 18 
DTSQc 2nd Question 15 133 10.1% 6 -2 3 
DTSQc 3rd Question 15 133 10.1% 6 -2 3 
Six-month 
Weight 148 0 100.0% 0 . . 
BMI 148 0 100% 0 . . 
Systolic Pressure 148 0 100.0% 0 . . 
Diastolic Pressure 148 0 100.0% 0 . . 
Hba1c 57 91 38.5% 53 5.1 13.5 
Blood Sugar 70 78 47.3% 69 77 455 
HDL 99 49 66.9% 33 21 120 
LDL 107 41 72.3% 35 49 195 
Triglycerides 95 53 64.2% 45 47 970 
Cholesterol 95 53 64.2% 46 96 273 
Medications 16 132 10.8% 9 1 16 
SKILLD 30 118 20.3% 12 4.5 10 
DES 30 118 20.3% 55 2.5 4.5 
MOS 30 118 20.3% 20 1.6 5 
PDSMS 30 118 20.3% 23 15 40 
ADDQOL 1st Question 30 118 20.3% 6 -2 3 
ADDQOL 2nd Question 30 118 20.3% 5 -3 1 
ADDQOL Total 30 118 20.3% 97 -6.6 .24 
Table 24 Percentages of Missing Data of Secondary outcomes at for all Participants 
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According to trial groups, percentages of missing data between trial groups in all 
secondary outcomes were nearly parallel of those for the whole sample. 
Nevertheless, the percentages of missing data at three-month in secondary 
outcomes such as diabetes patients’ knowledge, motivation, self-efficacy, 
satisfaction on the perceived treatment and their quality of life for TAU group was 
lower 7.6% in comparison to 12.9% in IMBDSME group. In contrast, the percentages 
of missing data in the aforementioned measurements at six-month for TAU group 
was higher 22.5% in comparison to 18.2% in IMBDSME group. All the previous 
variations between trial groups in terms of missing data were not statistically 
significant. All details are illustrated in Table 25 and Table 26 below. 
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Secondary outcomes for 
TAU group (n=71) 






Weight 60 11 84.5% 11 61 156 
BMI 64 7 90.1% 7 22.95 41.4 
Systolic pressure 60 11 84.5% 7 105 190 
Diastolic pressure 60 11 84.5% 4 65 100 
HbA1c 21 50 29.5% 34 4.9 16 
Blood sugar 29 42 40.8% 38 65 543 
HDL 45 26 63.3% 21 22 103 
LDL 50 21 70.4% 19 44 221 
Triglycerides 40 31 56.3% 30 86 467 
Cholesterol 40 31 56.3% 28 81 317 
Medications 5 66 7.04% 10 1 16 
SKILLD 5 66 7.6% 10 4 8.5 
DES 5 66 7.6% 49 2.6 4.4 
MOS 5 66 7.6% 18 1 4.8 
PDSMS 5 66 7.6% 13 17 32 
ADDQOL 1st Question 5 66 7.6% 5 -1 3 
ADDQOL 2nd Question 5 66 7.6% 5 -3 1 
ADDQOL Total 5 66 7.6% 61 -6.5 -0.4 
DTSQc 5 66 7.6% 18 -4 17 
DTSQc 2nd Question 5 66 7.6% 5 -2 3 
DTSQc 3rd Question 5 66 7.6% 5 -1 3 
Six-month 
Weight 71 0 100.0% 0 . . 
BMI 71 0 100.0% 0   
Systolic pressure 71 0 100.0% 0 . . 
Diastolic pressure 71 0 100.0% 0 . . 
Hba1c 26 45 36.6% 36 5.1 13.5 
Blood Sugar 34 37 47.8% 34 77 455 
HDL 46 25 64.7% 17 26 120 
LDL 50 21 70.4% 18 49 195 
Triglycerides 45 26 63.3% 23 47 523 
Cholesterol 45 26 63.3% 25 112 273 
Medications 9 62 12.6% 8 1 16 
SKILLD 16 55 22.5% 10 4.5 9.5 
DES 16 55 22.5% 34 2.5 4.4 
MOS 16 55 22.5% 18 1.6 5 
PDSMS 16 55 22.5% 16 15 33 
ADDQOL 1st Question 16 55 22.5% 5 -1 3 
ADDQOL 2nd Question 16 55 22.5% 4 -3 0 
ADDQOL Total 16 55 22.5% 50 -6.5 0.23 
Table 25 Percentages of Missing Data of Secondary outcomes at for TAU group Participants 
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Secondary outcomes for 
IMBDSME group (n=77) 






Weight 67 10 87.0% 10 50 104 
BMI 70 7 90.9% 7 20.8 38.2 
Systolic pressure 67 10 87.0% 5 110 155 
Diastolic pressure 67 10 87.0% 7 60 100 
HbA1c 24 53 31.1% 36 5.4 12.7 
Blood sugar 33 44 42.8% 42 51 716 
HDL 48 29 62.3% 22 23 73 
LDL 51 26 66.2% 23 50 249 
Triglycerides 44 33 57.1% 33 45 736 
Cholesterol 43 34 55.8% 31 98 346 
Medications 6 71 7.7% 8 7 16 
SKILLD 10 67 12.9% 8 6.5 10 
DES 10 67 12.9% 44 2.6 4.6 
MOS 10 67 12.9% 15 2.3 5 
PDSMS 10 67 12.9% 18 18 38 
ADDQOL 1st Question 10 67 12.9% 4 0 3 
ADDQOL 2nd Question 10 67 12.9% 5 -3 1 
ADDQOL Total 10 67 12.9% 60 -7 0.17 
DTSQc 10 67 12.9% 16 0 18 
DTSQc 2nd Question 10 67 12.9% 6 -2 3 
DTSQc 3rd Question 10 67 12.9% 6 -2 3 
Six-month 
Weight 77 0 100.0% 0 . . 
BMI 77 0 100% 0 . . 
Systolic pressure 77 0 100% 0 . . 
Diastolic pressure 77 0 100% 0 . . 
Hba1c 31 46 40.2% 31 5.6 12 
Blood Sugar 36 41 46.7% 39 110 420 
HDL 53 24 68.7% 20 21 76 
LDL 57 20 74.0% 17 55 132 
Triglycerides 50 27 64.9% 25 87 970 
Cholesterol 50 27 64.9% 23 96 251 
Medications 7 70 9.0% 9 1 16 
SKILLD 14 63 18.2% 8 6 10 
DES 14 63 18.2% 35 3.0 4.4 
MOS 14 63 18.2% 17 2.6 5 
PDSMS 14 63 18.2% 18 16 40 
ADDQOL 1st Question 14 63 18.2% 6 -2 3 
ADDQOL 2nd Question 14 63 18.2% 5 -3 1 
ADDQOL Total 14 63 18.2% 54 -4.6 0 
Table 26 Percentages of Missing Data of Secondary outcomes at for IMBDSME group Participants  
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4.6 Statistics of primary and secondary outcomes  
It is clear from the information in the sections above that percentages of missing data 
of primary outcomes were less than those of the secondary outcomes at three-
month and six-month. As per CONSORT statement, all trial outcomes whether 
primary or secondary needs to be statistically summarized for each group using 
proportions or means and standard deviations together with the effect size using 
odds ratio and their confidence intervals. Thus, means and standard deviations of 
trial outcomes with missing data are presented within Table 27 and Table 29below 
and presented after imputing missing data within Table 28 and Table 30. Presenting 
outcomes before and after imputing missing data was recommended by (Altman, 
2009). While effect size of IMBDSME for each outcome is presented separately within 
estimation models later in this chapter. Conducting sensitivity analysis is 
recommended to support conclusions based on the results from the planned analysis 
after handling missing outcomes. 
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Primary Outcomes Before 
Imputing Missing Data 













Diet (SDSCA) 3.14 ± (1.3) 2.82 ± (1.3) 2.95 ± (1.1) 3.56 ± (1.10) 2.84 ± (1.1) 3.31 ± (1.02) 
Physical Activity (SDSCA) 1.14 ± (1.1) 1.32 ± (1.37) 1.18 ± (0.94) 1.55 ± (1.15) 1.20 ± (0.78) 1.6 ± (1.07) 
Medications adherence (MARS) 8.0 ± (1.41) 8.1 ± (1.3) 8.37 ± (1.29) 9.02 ± (0.92) 8.27 ± (1.25) 8.94 ± (0.9) 
Total of DSCB 10.66 ± (2.63) 10.67 ± (3.36) 10.79 ± (2.27) 12.51 ± (2.90) 10.64 ± (2.21) 12.28 ± (2.64) 
Table 27 Summary of Primary Outcomes before Imputing Missing Data.  
Primary Outcomes After Imputing 
Missing Data 













Diet (SDSCA) 3.14 ± (1.3) 2.82 ± (1.2) 2.95 ± (1.1) 3.55 ± (1.10) 2.84 ± (1.1) 3.30 ± (1.0) 
Physical Activity (SDSCA) 1.14 ± (1.1) 1.32 ± (1.4) 1.18 ± (0.95) 1.55 ± (1.14) 1.21 ± (0.78) 1.6 ± (1.1) 
Medications adherence (MARS) 7.99 ± (1.4) 8.1 ± (1.3) 8.4 ± (1.3) 9.02 ± (0.88) 8.28 ± (1.25) 8.95 ± (0.9) 
Total of DSCB 10.66 ± (2.70) 10.67 ± (3.56) 10.78 ± (2.28) 12.49 ± (2.90) 10.65 ± (2.24) 12.26 ± (2.69) 
Table 28 Summary of Primary Outcomes after Imputing Missing Data. SDSCA; Summary of Diabetes Self-Care Activities Scale; MARS, Medications Adherence Rating Scale; DSCB, Diabetes Self-
Care Behaviours.  
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Secondary Outcomes Before 
Imputing Missing Data 













Glycaemic level (HbA1c) 9.70 ± (1.5) 9.81 ± (1.7) 9.21 ± (2.4) 8.72 ± (1.59) 8.97 ± (1.85) 8.72 ± (1.55) 
Diabetes Knowledge (SKILLD) 6.75 ± (1.0) 6.51 ± (1.34) 6.86 ± (1.1) 8.36 ± (0.81) 6.7 ± (1.03) 8.37 ± (0.86) 
Social Motivation (MOS) 3.9 ± (0.79) 3.83 ± (0.83) 4.01 ± (0.7) 4.3 ± (0.66) 3.97 ± (0.68) 4.19 ± (0.56) 
Personal Motivation (DES) 3.4 ± (0.43) 3.4 ± (0.46) 3.51 ± (0.44) 3.74 ± (0.52) 3.48 ± (0.50) 3.91 ± (0.38) 
Total of DES+MOS 3.65 ± (0.45) 3.62 ± (0.46) 3.76 ± (0.43) 4.02 ± (0.43) 3.73 ± (0.43) 4.05 ± (0.34) 
Self-Efficacy (PDSMS) 2.89 ± (0.48) 2.85 ± (0.64) 3.02 ± (0.44) 3.59 ± (0.57) 2.99 ± (0.47) 3.62 ± (0.59) 
Quality of Life (Q1) 0.87 ± (1.3) 0.82 ± (1.2) 1.29 ± (1.15) 1.82 ± (0.76) 1.05 ± (1.06) 1.9 ± (0.95) 
Quality of Life (Q2) -1.7 ± (0.88) -1.56 ± (0.98) -1.97 ± (0.89) -1.0 ± (1.0) -1.84 ± (0.74) -0.90 ± (0.96) 
Quality of Life (ADDQOL) -2.3 ± (1.4) -2.38 ± (1.63) -2.92 ± (1.38) -1.98 ± (1.35) -2.63 ± (1.82) -1.99 ± (1.18) 
DTSQs 25.4 ± (6.0) 25 ± (6.01) 7.52 ± (4.32) 11.4 ± (3.4) ------ ----- 
Table 29 Summary of Secondary Outcomes before Imputing Missing Data. SKILLD: Spoken Knowledge in Low Literacy in Diabetes scale; DES: Diabetes Empowerment Scale; MOS: Medical 
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Secondary Outcomes After 
Imputing Missing Data 













Glycaemic level (HbA1c) 9.73 ± (1.32) 9.81 ± (1.67) 9.2 ± (2.4) 8.73 ± (1.57) 8.93 ± (1.85) 8.72 ± (1.55) 
Diabetes Knowledge (SKILLD) 6.75 ± (0.89) 6.51 ± (1.27) 6.80 ± (1.05) 8.39 ± (0.79) 6.7 ± (1.01) 8.31 ± (0.85) 
Social Motivation (MOS) 3.90 ± (0.78) 3.83 ± (0.86) 3.98 ± (0.66) 4.3 ± (0.65) 4.0 ± (0.68) 4.21 ± (0.56) 
Personal Motivation (DES) 3.40 ± (0.5) 3.42 ± (0.47) 3.5 ± (0.43) 3.7 ± (0.52) 3.46 ± (0.49) 3.94 ± (0.38) 
Total of DES+MOS 3.65 ± (0.45) 3.62 ± (0.46) 3.75 ± (0.43) 4.01 ± (0.43) 3.74 ± (0.43) 4.04 ± (0.34) 
Self-Efficacy (PDSMS) 2.89 ± (0.48) 2.85 ± (0.64) 3.02 ± (0.44) 3.57 ± (0.57) 3.03 ± (0.47) 3.61 ± (0.59) 
Quality of Life (Q1) 0.87 ± (1.3) 0.82 ± (1.2) 1.28 ± (1.1) 1.79 ± (0.81) 1.14 ± (1.1) 1.9 ± (0.94) 
Quality of Life (Q2) -1.7 ± (0.86) -1.56 ± (0.97) -1.95 ± (0.89) -1.0 ± (0.99) -1.79 ± (0.79) -0.91 ± (0.95) 
Quality of Life (ADDQOL) -2.3 ± (1.54) -2.37 ± (1.62) -2.9 ± (1.14) -1.97 ± (1.36) -2.62 ± (1.75) -1.96 ± (1.22) 
DTSQ 25.2 ± (6.2) 24.69 ± (6.13) 7.5 ± (4.3) 11.6 ± (3.14) ------ ----- 
Table 30 Summary of Secondary Outcomes after Imputing Missing Data. SKILLD: Spoken Knowledge in Low Literacy in Diabetes scale; DES: Diabetes Empowerment Scale; MOS: Medical 
Outcomes Trial; PDSMS: Perceived Diabetes Self-Management Scale; Audit of Diabetes Dependent Quality of Life (ADDQOL) and Diabetes Treatment Satisfaction Questionnaire (DTSQs). 
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4.7 Primary outcomes: 
As mentioned before in section (3.12.2), primary outcomes were measuring the 
performance of diet modification, physical activity and medications management. 
Subscales of SDSCA were used to measure diet and physical activity behaviours, and 
MARS was used to measure medications management. All three self-management 
behaviours were computed in one variable called Diabetes Self-Care Behaviours 
(DSCB). The differences in mean scores between each trial group at baseline, three-
month and six-month visits as well as 95% confidence intervals and P values are 
presented in a table for each self-management behaviour and their total. Each one 
was modelled separately using GEE before and after imputation and results were 
almost similar. However, and due to the trivial variation in means between imputed 
and non-imputed data as shown above in Table 27, Table 28, Table 29 and Table 30, 
inferential statistics is presented for the imputed dataset in the following sections. 
4.7.1 Diet Self-Care behaviour: 
Participants in the IMBDSME group had higher mean scores 3.55 ± (1.1) and 3.30 ± 
(1.02) at three-month and six-month visits respectively than baseline mean score 
2.82 ± (1.3). While participants in the TAU group had lower mean score 2.95 ± (1.1) 
and 2.84± (1.1) for the same time points than baseline score 3.14 ± (1.3). In fact, 
participants in TAU group had a higher baseline mean score by 0.32 (95% CI, -0.74 – 
0.09) than IMBDSME group. However, at three-month time point, diet score 
increased by 0.6 (95%CI 0.24 to 0.96), and 0.46 (95% CI 0.11 to 0.81) at second and 
third visits respectively for participants in IMBDSME group than those in the TAU 
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group. These differences were statistically significant as all p-values were less than 
0.01 – except baseline- and demonstrated in the table below and Figure 11.  
Diet Self-Care Behaviour 
(SDSCA) 
Mean±(SD)  




Baseline 3.14 ± (1.3) 2.82 ± (1.3) -0.32 (-0.74 – 0.09) 0.13 
Three-month 2.95 ± (1.1) 3.55 ± (1.1) 0.60 (0.24 – 0.96) 0.001 
Six-month 2.84 ± (1.1) 3.30 ± (1.0) 0.46 (0.11 – 0.81) 0.01 




Figure 11 Mean Scores of Diet Self-Care behaviour for Trial Groups across Visits and their Values 
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4.7.1.1 Modelling GEE: 
As mentioned before in section (3.15.5.1), analysis was performed through several 
models to estimate the effect size of IMBDSME intervention on diet score. P values, 
coefficients, risk ratios and their 95% CI of diet score for both trial groups for all 
models are presented below at Table 32. 
From the details in the table below, it is clear that using model one produced an 
underestimated effect size of IMBDSME intervention at three-month and six-month 
visits due to the non-adjustment of the baseline values of diet score. While after 
adjustment in model two, the estimated coefficient increased to 0.92 (95%CI, 0.57 to 
1.28) and 0.78 (95%CI, 0.40 to 1.17) statistically significant at three-month and six-
month visits respectively. With further adjustments for other covariates as in model 
five, estimated points increased statistically significant to 0.97 (95%CI, 0.58 to 1.36) 
and 0.85 (95%CI, 0.31 to 1.39) at three-month and six-month visits respectively. All 
GEE models were statistically significant where P value of the models was less than 
0.001. Participants who received IMBDSME intervention were 2.51 (95%CI, 1.76 to 
3.59) and 2.19 (95%CI, 1.39 to 3.47) times more likely to have higher mean score in 
diet scale at three-month and six-month respectively when the score is adjusted to 
the baseline (model 2). This increase was statistically significant. While participants 
in the TAU group were high likely to have lower score in diet scale by 17% (95%CI, 7% 
to 36%) and 46% (95%CI, 1% to 46%) at three-month and six-month respectively 
before adjustment, and this change was statistically non-significant. However, after 
adjusting for the baseline scores, gender, age, HbA1c and diabetes-medications, 
participants who received IMBDSME intervention were 2.64 (95%CI, 1.65 to 4.20) 
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and 2.34 (95%CI, 1.37 to 4.01) times more likely to have higher score in diet scale at 
three-month and six-month respectively. The results were statistically significant. 
Nevertheless, participants in the TAU group were 19% (95%CI, 9% to 40%) and 35% 
(95%CI, 5% to 56%) likely to have lower score in diet scale at three-month and six-

















  TAU  IMBDSME  
Diet (SDSCA) Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 -0.19 (-0.44 to 0.07) 0.83 (0.64 to 1.07) 0.15 0.73 (0.49 to 0.98) 2.08 (1.62 to 2.70) 0.001 
 2 -0.19 (-0.44 to 0.07) 0.83 (0.64 to 1.07) 0.15 0.92 (0.57 to 1.28) 2.51 (1.76 to 3.59) 0.001 
 3 -0.19 (-0.44 to 0.07) 0.83 (0.64 to 1.07) 0.15 0.92 (0.57 to 1.30) 2.52 (1.76 to 3.60) 0.001 
 4 -0.24 (-0.53 to -0.05) 0.79 (0.59 to 1.05) 0.10 1.0 (0.60 to 1.40) 2.72 (1.82 to 4.06) 0.001 
 5 -0.21 (-0.51 to 0.08) 0.81 (0.60 to 1.09) 0.16 0.97 (0.58 to 1.36) 2.64 (1.65 to 4.20) 0.001 
6-month 1 -0.30 (-0.60 to 0.01) 0.74 (0.54 to 1.01) 0.57 0.48 (0.16 to 0.82) 1.62 (1.16 to 2.26) 0.005 
 2 -0.30 (-0.60 to 0.01) 0.74 (0.54 to 1.01) 0.57 0.78 (0.33 to 1.24) 2.19 (1.39 to 3.47) 0.001 
 3 -0.30 (-0.62 to 0.01) 0.74 (0.54 to 1.01) 0.57 0.78 (0.33 to 1.24) 2.19 (1.39 to 3.47) 0.001 
 4 -0.43 (-0.81 to -0.05) 0.65 (0.44 to 0.95) 0.03 0.85 (0.32 to 1.37) 2.64 (1.78 to 3.90 0.002 
 5 -0.44 (-0.83 to -0.05) 0.65 (0.44 to 0.95) 0.03 0.85 (0.31 to 1.39) 2.34 (1.37 to 4.01) 0.002 
Table 32 Coefficients and Risk Ratios of Diet score of Trial Groups for all Models and their CI (Confidence Interval). 
Model 1 is unadjusted to the baseline.                                                                                                                                 
Model 2 adjusted to the baseline.                                                                                                                                          
Model 3 as in model 2 with adjustments for age and gender.                                                                                              
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                       
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.7.2 Physical Activity Self-Care behaviour: 
Participants in the IMBDSME group reported higher scores 1.55 ± (1.14) and 1.60 ± 
(1.10) than baseline score compared to participants in the TAU group 1.18 ± (0.95) 
and 1.21 ± (0.78) at three-month and six-month respectively. Although participants 
in the IMBDSME group had a higher baseline score than participants in the TAU 
group, the increase across trial visits was higher among participants who received 
IMBDSME intervention. In details, mean score of physical activity increased by 0.37 
(95% CI, 0.03 – 0.72) and 0.39 (95% CI, 0.07 – 0.71) at three-month and six-month 
respectively for participants in the IMBDSME group than those in the TAU group. 
Differences were statistically significant and p values were less than 0.05 except for 
baseline mean scores and presented in the table below and illustrated in Figure 12. 
Physical Activity Self-
Care Behaviour (SDSCA) 
Mean±(SD)  




Baseline 1.14 ± (1.10) 1.32 ± (1.40) 0.18 (-0.22 – 0.59) 0.37 
Three-month 1.18 ± (0.95) 1.55 ± (1.14) 0.37 (0.03 – 0.72) 0.04 
Six-month 1.21 ± (0.78) 1.60 ± (1.10) 0.39 (0.07 – 0.71) 0.02 
Table 33 Physical Activity score for both Trial Groups after imputation across all Trial Visits 
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Figure 12 Mean Scores of Physical Activity Self-Care Behaviour for Trial Groups across visits and their values 
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4.7.2.1 Modelling GEE: 
Similar to diet self-care behaviour, analysis was performed through several models 
to estimate the effect size of IMBDSME intervention on physical activity score. P 
values, coefficients, risk ratios and their 95% CI of physical activity score for both trial 
groups for all models are presented below at Table 34. 
From the detail in the table belowabove, it shows that the only statistically significant 
coefficient was only within model 1 among participants in the IMBDSME group. 
Estimated coefficients were 0.23 (95%CI, 0.03 to 0.43) and 0.28 (95% CI, 0.06 to 0.50) 
compared to the estimated coefficients of those in the TAU group standing at 0.04 
(95% CI, -0.18 to 0.25) and 0.07 (95% CI, -0.14 to 0.29) at three-month and six-month 
respectively. This means that the estimated coefficient was overestimated before 
adjustment at model 1 for IMBDSME group. While after adjustments to the baseline 
scores in model 2, the estimated coefficients for participants in the IMBDSME group 
were not statistically significant and decreased to 0.19 (95% CI, -0.10 to 0.48) and 
0.21 (95% CI, -0.10 to 0.51) at three-month and six-month respectively. Nonetheless, 
estimated coefficients for participants in the TAU group in model 2 did not change 
from the estimates in model 1 at three-month and six-month, thus, risk ratios 
remained the same. All other GEE models were statistically not significant because P 
values were larger than 0.05 even after further adjustments for other covariates.  
Indeed, in model 1 at three-month visit, participants in the IMBDSME group were 
25% (95% CI, 3% to 53%) statistically significant more likely to improve their physical 
activity behaviour, whereas participants in the TAU group were 4% (95% CI, -16% to 
29%) more likely to improve their physical activity behaviour, but this increase was 
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not statistically significant. However, after adjustment to the baseline score (model 
2), the probability for participants in the IMBDSME group was not statistically 
significant and decreased from the value in model 1 to be 21% (95% CI, -10% to 62%) 
more likely to improve their physical activity behaviour, while the probability for 
participants in the TAU group was the same value in model 1. Similar trend was seen 
at six-month visit, in model 1, the probability for participants in the IMBDSME group 
was statistically significant and they were 32% (95% CI, 6% to 65%) more likely to 
improve their physical activity behaviour, whereas the probability for participants in 
TAU was 7% (95% CI, -14% to 34%) but was not statistically significant. After 
adjustment in model 2, the probability for participants in IMBDSME group was not 
statistically significant and decreased to be 23% (95% CI, -9% to 67%) more likely to 
improve their physical activity behaviour, while the probability for participants in the 
TAU group did not change and was the same in model 1. 
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.04 (-0.18 to 0.25) 1.04 (0.84 to 1.29) 0.74 0.23 (0.03 to 0.43) 1.25 (1.03 to 1.53) 0.026 
 2 0.04 (-0.18 to 0.25) 1.04 (0.84 to 1.29) 0.74 0.19 (-0.10 to 0.48) 1.21 (0.90 to 1.62) 0.21 
 3 0.04 (-0.18 to 0.25) 1.04 (0.84 to 1.29) 0.74 0.19 (-0.10 to 0.48) 1.21 (0.90 to 1.62) 0.21 
 4 -0.01 (-0.27 to 0.25) 0.99 (0.76 to 1.28) 0.94 0.24 (-0.09 to 0.56) 1.27 (0.91 to 1.76) 0.16 
 5 -0.004 (-0.27 to 0.26) 1.00 (0.76 to 1.30) 0.97 0.21 (-0.18 to 0.55) 1.24 (0.89 to 1.72) 0.21 
6-month 1 0.07 (-0.14 to 0.29) 1.07 (0.86 to 1.34) 0.52 0.28 (0.06 to 0.50) 1.32 (1.06 to 1.65) 0.012 
 2 0.07 (-0.14 to 0.29) 1.08 (0.87 to 1.34) 0.51 0.21 (-0.10 to 0.51) 1.23 (0.91 to 1.67) 0.18  
 3 0.07 (-0.14 to 0.29) 1.08 (0.87 to 1.34) 0.51 0.21 (-0.10 to 0.51) 1.23 (0.91 to 1.67) 0.19 
 4 0.16 (-0.09 to 0.41) 1.17 (0.91 to 1.51) 0.22 0.16 (-0.18 to 0.50) 1.17 (0.83 to 1.65) 0.36 
 5 0.17 (-0.07 to 0.42) 1.19 (0.93 to 1.52) 0.17 0.13 (-0.21 to 0.47) 1.14 (0.81 to 1.60) 0.45 
Table 34 Coefficients and Risk Ratio of Physical Activity score of Trial Groups for all Models and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline.                                                                                                                                                  
Model 2 adjusted to the baseline.                                                                                                                                                              
Model 3 as in model 2 with adjustments for age and gender.                                                                                                           
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                   
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.7.3 Medications Management Self-Care behaviour: 
Participants in the IMBDSME group reported higher scores 9.02 ± (0.88) and 8.95 ± 
(0.90) than baseline scores compared to participants in the TAU group 8.40 ± (1.30) 
8.28 ± (1.25) at three-month and six-month visits respectively. According to the 
baseline score, participants in IMBDSME group had a higher baseline score by 0.07 
(95% CI, -0.37 – 0.5) than TAU group. However, after delivering IMBDSME, MARS 
score increased by 0.65 (95% CI, 0.28 – 1.01) and 0.67 (95% CI, 0.30 – 1.04) at second 
and third visits respectively for participants in IMBDSME group than those in the TAU 
group. These differences were statistically significant as all p-values were less than 








Baseline 7.99 ± (1.40) 8.1 ± (1.30) 0.07 (-0.37 – 0.5) 0.76 
Three-month 8.40 ± (1.30) 9.02 ± (0.88) 0.65 (0.28 – 1.01) 0.001 
Six-month 8.28 ± (1.25) 8.95 ± (0.90) 0.67 (0.30 – 1.04) 0.001 
Table 35 Medications’ Management Scale Score for both Trial Groups after Imputation across Trial Visits 
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4.7.3.1 Modelling GEE: 
As mentioned before in section (3.15.5.1), researcher used several models to 
estimate the effect size of IMBDSME intervention on medications’ management self-
care behaviour. Coefficients, risk ratios and their 95% CI of MARS score for both trial 
groups for all models are presented below at Table 36. It shows that MARS score 
increased statistically significant for both trial groups at three-month and six-month 
visit before and after adjustment to baseline score.  
Participants in the IMBDSME group had an estimated coefficient increase of 0.97 
(95% CI, 0.69 to 1.24) and 0.90 (95% CI, 0.63 to 1.16) before adjustments (model 1) 
at three-month and six-month respectively. Where after adjustment to the baseline 
(model 2), the estimated coefficients for those who received IMBDSME intervention 
reduced at to be 0.58 (95% CI, 0.19 to 0.97) and 0.61 (95% CI, 0.23 to 0.99) at three-
month and six-month visits respectively. Hence, the estimate coefficient was 
overestimated in model 1 for IMBDSME group. However, after adjustment for other 
covariates in model 5, participants who received IMBDSME intervention had the 
same coefficients of model 2 except for six-month visit where it statistically 
significant decreased to 0.46 (95% CI, 0.02 to 0.90).On the other hand, estimated 
coefficients for those in TAU group were statistically significant across all models at 
three-month and six-month visits except for model 4 and 5 at six-month time point. 
They did not change considerably across models and were around 0.39 to 0.37 at 
three-month visit, and from 0.29 to 0.27 at six-month visit.  
Additionally, participants in the IMBDSME group in model 1 were statistically 
significant 2.63 (95% CI, 2.00 to 3.44) and 2.45 (95% CI, 1.88 to 3.18) times more likely 
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to practice medications management at three–month and six-month visits 
respectively. While those in the TAU group were only 1.47 (95% CI, 1.11 to 1.96) and 
1.33 (95% CI, 1.01 to 1.76) times more likely to practice medications management at 
three–month and six-month visits respectively. While after baseline adjustment, the 
probabilities of IMBDSME group decreased to almost at 1.80 (95% CI, 1.21 to 2.64) 
and 1.84 (95% CI, 1.25 to 2.69) at three–month and six-month visits respectively and 
did not change for participants in TAU group from values before adjustments. After 
adjusting for all covariates, the probability for participants in IMBDSME group 
remained the same at three-month visit and decreased to 1.59 (95% CI, 1.02 to 2.49) 
at six-month visit where it was not statistically significant. While for participants in 
TAU group, the probabilities decreased to 1.45 (95% CI, 1.07 to 1.97) and 1.32 (95% 
CI, 0.96 to 1.81) at three-month and six-month visits respectively and was only 
statistically significant at three-month visit.  
 
187 

















 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.39 (0.10 to 0.67) 1.47 (1.11 to 1.96) 0.008 0.97 (0.69 to 1.24) 2.63 (2.00 to 3.44) 0.001 
 2 0.39 (0.10 to 0.67) 1.47 (1.11 to 1.96) 0.008 0.58 (0.19 to 0.97) 1.80 (1.21 to 2.64) 0.004 
 3 0.39 (0.10 to 0.67) 1.47 (1.11 to 1.96) 0.008 0.58 (0.19 to 0.97) 1.80 (1.21 to 2.64) 0.001 
 4 0.36 (0.50 to 0.68) 1.44 (1.05 to 1.97) 0.02 0.60 (0.17 to 1.03) 1.82 (1.16 to 2.79) 0.006 
 5 0.37 (0.07 to 0.68) 1.45 (1.07 to 1.97) 0.02 0.58 (0.17 to 0.99) 1.80 (1.18 to 2.70) 0.006 
6-month 1 0.29 (0.01 to 0.57) 1.33 (1.01 to 1.76) 0.04 0.90 (0.63 to 1.16) 2.45 (1.88 to 3.18) 0.001 
 2 0.29 (0.01 to 0.57) 1.33 (1.01 to 1.76) 0.04 0.61 (0.23 to 0.99) 1.84 (1.25 to 2.69) 0.002 
 3 0.29 (0.01 to 0.57) 1.33 (1.01 to 1.76) 0.04 0.61 (0.23 to 0.99) 1.84 (1.25 to 2.69) 0.001 
 4 0.29 (-0.02 to 0.60) 1.34 (0.98 to 1.82)  0.07 0.46 (0.03 to 0.90) 1.59 (1.03 to 2.46) 0.04 
 5 0.27 (-0.04 to 0.59) 1.32 (0.96 to 1.81) 0.09 0.46 (0.02 to 0.90) 1.59 (1.02 to 2.49) 0.04 
Table 36 Coefficients and Risk Ratio of MARS score of Trial Groups for all Models and their CI (Confidence Interval)                                                                      
Model 1 is unadjusted to the baseline.                                                                                                                                  
Model 2 adjusted to the baseline.                                                                                                                                         
Model 3 as in model 2 with adjustments for age and gender.                                                                                         
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                  
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.7.4 Total of Diabetes Self-Care behaviours (DSCB): 
Participants in the IMBDSME group reported higher scores 12.49 ± (2.90) and 12.26± 
(2.69) than baseline scores compared to participants in the TAU group 10.78 ± (2.28) 
and 10.65 ± (2.24) at three-month and six-month visits respectively. The difference 
between baseline scores for both groups were almost nil due to the fact that this 
variable were derived and computed from the three self-care behaviours after 
weighting adjustments for each one separately. To explain in detail, the mean score 
of the total of three self-care behaviours for IMBDSME participants increased 
statistically significant by 1.71 (95% CI, 0.84 – 2.59) and 1.61 (95% CI, 0.76 – 2.46) at 
three-month and six-month visits respectively than participants in the TAU group. All 
mean scores for trial groups at each trial visits and their CI are demonstrated in below 
and Figure 14. 
Total of Diabetes Self-
Care Behaviours (DSCB) 
Mean±(SD)  





Baseline 10.66 ± (2.70) 10.67 ± (3.56) 0.007 (-0.98 – 0.99) 0.98 
Three-month  10.78 ± (2.28) 12.49 ± (2.90) 1.71 (0.84 – 2.59) 0.001 
Six-month 10.65 ± (2.24) 12.26± (2.69) 1.61 (0.76 – 2.46) 0.001 
Table 37 Mean Score of the Total of Diabetes Self-Care Behaviours for both Trial Groups after Imputation across 
Trial Visits and their Confidence Intervals (CI) 
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Figure 14 Mean Scores of the Total of Diabetes Self-Care Behaviours for Trial Groups across visits and their P values 
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4.7.4.1 Modelling GEE: 
The same approach of estimating IMBDSME intervention effect size on previous 
primary outcomes was used with the total of diabetes self-care behaviours. 
Researcher performed GEE using five models to estimate the coefficients among 
participants in the IMBDSME group. Coefficients, P values, risk ratios and their 95% 
CI of MARS score for both trial groups for all models are presented below at Table 
38. It shows that estimated coefficients, and accordingly, risk ratios in all models 
increased statistically significant in the IMBDSME group, whereas those in the TAU 
group changed minimally and were not statistically significant. At three-month visit, 
the increase in DSCB score among IMBDSME group was overestimated due to being 
modelled before the adjustment of the baseline score. However, after adjustment, 
the point estimate decreased to be 1.70 (95% CI, 0.90 to 2.51) instead of 1.82 (95% 
CI, 1.26 to 2.39) that was in model one. While after the adjustment for other 
covariates, estimates increased to be 1.87 (95% CI, 1.01 to 2.73) in model four and 
1.78 (0.93 to 2.62) after adjustment for the diabetes-related medications. With this, 
participants in IMBDSME group were statistically significant 5.5 (95% CI, 2.46 to 
12.27)) times more likely to perform all self-care behaviours after baseline score 
adjustment (model two) than participants in TAU group. This probability increased to 
5.91 (95% CI, 2.53 to 13.8) after adjustment for all other clinically related covariates 
(model five). At six-month visit, the increase in DSCB score among IMBDSME group 
was 1.61 (95% CI, 0.74 to 2.47) after the adjustment of the baseline score which did 
not change hugely from the point estimate before the adjustment 1.59 (95% CI, 0.93 
to 2.25). Whereas after adjustment for other covariates, the point estimate 
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decreased to be 1.50 (95% CI, 0.55 to 2.44) and 1.48 (95% CI, 0.54 to 2.42) in model 
four and five respectively. Lastly, participants in IMBDSME group were statistically 
significant 4.98 (95% CI, 2.1 to 11.85) times more likely to perform all self-care 
behaviours after baseline score adjustment (model two) than participants in TAU 
group. This probability decreased to 4.38 (95% CI, 1.71 to 11.2) after adjustment for 
all other clinically related covariates (model five). 
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.11 (-0.45 to 0.69) 1.13 (0.63 to 2.00) 0.69 1.82 (1.26 to 2.39) 6.19 (3.53 to 10.9) 0.001 
 2 0.12 (-0.46 to 0.69) 1.13 (0.63 to 2.00) 0.69 1.70 (0.90 to 2.51) 5.5 (2.46 to 12.27) 0.001 
 3 0.12 (-0.46 to 0.69) 1.12 (0.63 to 2.00) 0.69 1.70 (0.90 to 2.51) 5.5 (2.47 to 12.27) 0.001 
 4 -0.04 (-0.70 to 0.62) 0.96 (0.50 to 1.85) 0.90 1.87 (1.01 to 2.73) 6.50 (2.74 to 15.4) 0.001 
 5 0.001 (-0.68 to 0.68) 1.00 (0.51 to 1.97) 0.99 1.78 (0.93 to 2.62) 5.91 (2.53 to 13.8) 0.001 
6-month 1 -0.014 (-0.57 to 
0.54) 
0.99 (0.56 to 1.72) 0.96 1.59 (0.93 to 2.25) 4.91 (2.54 to 9.50) 0.001 
 2 -0.014 (-0.57 to 
0.54) 
0.99 (0.56 to 1.72) 0.96 1.61 (0.74 to 2.47) 4.98 (2.1 to 11.85) 0.001 
 3 -0.015 (-0.57 to 
0.54) 
0.99 (0.56 to 1.72) 0.96 1.60 (0.74 to 2.47) 4.98 (2.1 to 11.83) 0.001 
 4 -0.01 (-0.64 to 0.62) 0.99 (0.53 to 1.86) 0.97 1.50 (0.55 to 2.44) 4.46 (1.73 to 11.5) 0.002 
 5 -0.02 (-0.66 to 0.61) 0.98 (0.52 to 1.85) 0.95 1.48 (0.54 to 2.42) 4.38 (1.71 to 11.2) 0.002 
Table 38 Coefficients and Risk Ratio of the total of Diabetes Self-Care Behaviours score of Trial Groups for all Models and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                               
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.8 Secondary Outcomes: 
As explained in detail above in section (3.13.3), secondary outcomes were to examine 
the effectiveness of IMBDSME intervention on the main three elements of IMB model 
(Information-Motivation-Behavioural skills), glycaemic level (HbA1c) and diabetes 
dependent quality of life at three-month and six-month endpoints. Those outcomes 
were measured using several scales except the glycaemic level where glycated 
haemoglobin blood test (HbA1c) was used for this purpose. The differences in mean 
scores between each trial group at baseline, three-month and six-month visits as well 
as 95% confidence intervals and P values are presented in tables for each secondary 
outcome. In addition, GEE modelling is presented for each outcome separately 
before and after imputation and results were broadly comparable as was the case 
with primary outcomes in section (4.7). However, inferential statistics is presented 
for the imputed dataset in the following sections. 
4.8.1 Knowledge of diabetes self-care behaviours:  
Participants in the IMBDSME group had higher mean scores of 8.36± (0.81) and 8.37± 
(0.86) than baseline mean score of 6.51± (1.34) at three-month and six-month visits 
respectively. While participants in TAU group had mean scores of 6.86 ± (1.1) and 6.7 
± (1.03) than baseline mean score of 6.75± (1.0) at three-month and six-month visits 
respectively. Although the change in scores at three-month and six-month visits were 
higher from baseline score for participants in IMBDSME group than participants in 
TAU group, participants in TAU group had higher baseline score of 6.75 ± (1.0) than 
those in IMBDSME group 6.51 ± (1.34) and this difference was not statistically 
significant. The differences between trial groups were statistically significant and 
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were 1.48 (95% CI, 1.14 – 2.01) and 1.64 (95% CI, 6.45 – 6.98) at three-month and 
six-month visits respectively as all p-values were less than 0.001 as presented in Table 
39 and Figure 15. However, effect size of the IMBDSME intervention on the level of 
knowledge is estimated in GEE modelling in the next section. 








Baseline 6.75 ± (1.0) 6.51 ± (1.34) -0.24 (-0.63 – 
0.15) 
0.22 
Three-month 6.86 ± (1.1) 8.36 ± (0.81) 1.48 (1.14 – 2.01) 0.001 
Six-month 6.7 ± (1.03) 8.37 ± (0.86) 1.64 (6.45 – 6.98) 0.001 
Table 39 Mean scores of SKILLD scale for both trial groups across trial visits after imputation with the differences 
and their 95% confidence interval differences 
 
 
Figure 15 Mean Scores of SKILLD for both trial groups across trial visits and their P values  
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4.8.1.1 Modelling GEE: 
Similar to primary outcomes, secondary outcomes were modelled using GEE 
approach in five models to estimate the effect size of IMBDSME intervention on the 
level of diabetes self-management knowledge. P values, estimated coefficients, risk 
ratios and their 95% CI of SKILLD score for both trial groups for all models are 
presented below at Table 40. Generally, estimated coefficients and risk ratios were 
statistically significant for participants in the IMBDSME group in all models where P 
value was less than 0.001 at three-month and six-month visits, while they were not 
statistically significant for participants in TAU group. 
Details in the table below shows that estimated coefficient for participants in 
IMBDSME group decreased from 1.79 (95% CI, 1.53 to 2.05) to 1.72 (95% CI, 1.36 to 
2.08) at three-month visit, and increased from 1.80 (95% CI, 1.52 to 2.07) to 1.85 
(95% CI, 1.46 to 2.25) at six-month visit after baseline score adjustment. While after 
adjustment for other covariates in model five, estimated coefficient increased 
minimally to 1.74 (95% CI, 1.38 to 2.09) and 1.89 (95% CI, 1.48 to 2.29) at three-
month visit and six-month respectively. On the other hand, estimates for participants 
in TAU group decreased from 0.07 (95% CI,-0.17 to 0.32) to 0.04 (95% CI, -0.22 to 
0.31) and from -0.06 (95% CI,-0.34 to 0.23) to -0.11 (95% CI, -0.39 to 0.17) after 
adjusting for other covariates in model five at three-month and six-month 
respectively. Participants who received IMBDSME intervention were 5.57 (95% CI, 
3.89 to 7.99) and 6.39 (95% CI, 4.30 to 9.49) times more likely to be knowledgeable 
on diet modification, physical activity and medications management at three-month 
and six-month visits respectively when the score is adjusted to the baseline (model 
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2). While participants in TAU group were 7% (95% CI, -16% to 37%) more likely to be 
knowledgeable on diet modification, physical activity and medications management 
at three-month, and less likely by 6% (95% CI, -29% to 26%) to have knowledge on 
the same self-management behaviours at six-month visit.  After adjusting for other 
covariates in model five, the probabilities increased for participants who received 
IMBDSME intervention to be 5.67 (95% CI, 3.96 to 8.12) and 6.61 (95% CI, 4.41 to 
9.92) at three-month and six-month visits respectively. However, it decreased further 
from model two for participants in TAU group to be 4% (95% CI, -20% to 36%) more 
likely to have knowledge on self-management behaviours at three-month visit, and 
less likely by 11% (95% CI, -32% to 18%) to have knowledge on those behaviours.  
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.07 (-0.17 to 0.32) 1.07 (0.84 to 1.37) 0.57 1.79 (1.53 to 2.05) 5.99 (4.60 to 7.79) 0.001 
 2 0.07 (-0.17 to 0.32) 1.07 (0.84 to 1.37) 0.57 1.72 (1.36 to 2.08) 5.57 (3.89 to 7.99) 0.001 
 3 0.07 (-0.17 to 0.31) 1.07 (0.84 to 1.37) 0.57 1.72 (1.36 to 2.08) 5.57 (3.89 to 7.97) 0.001 
 4 0.04 (-0.22 to 0.31) 1.04 (0.80 to 1.36) 0.75 1.74 (1.37 to 2.10) 5.68 (3.95 to 8.18) 0.001 
 5 0.04 (-0.22 to 0.31) 1.04 (0.80 to 1.36) 0.76 1.74 (1.38 to 2.09) 5.67 (3.96 to 8.12) 0.001 
6-month 1 -0.06 (-0.34 to 0.23) 0.94 (0.71 to 1.26) 0.69 1.80 (1.52 to 2.07) 6.03 (4.57 to 7.96) 0.001 
 2 -0.06 (-0.35 to 0.23) 0.94 (0.71 to 1.26) 0.69 1.85 (1.46 to 2.25) 6.39 (4.30 to 9.49) 0.001 
 3 -0.06 (-0.35 to 0.23) 0.94 (0.71 to 1.26) 0.69 1.85 (1.46 to 2.25) 6.39 (4.30 to 9.47) 0.001 
 4 -0.07 (-0.36 to 0.21) 0.93 (0.70 to 1.23) 0.61 1.89 (1.48 to 2.30) 6.59 (4.38 to 9.90) 0.001 
 5 -0.11 (-0.39 to 0.17) 0.89 (0.68 to 1.18) 0.44 1.89 (1.48 to 2.29) 6.61 (4.41 to 9.92) 0.001 
Table 40 Coefficients and Risk Ratio of SKILLD score for both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                               
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.8.2 Motivation toward Diabetes self-care behaviours: 
As mentioned in detail in section (3.13.3.2), motivation level toward performing 
diabetes self-management behaviours was measured using two scales; Diabetes 
Empowerment Scale (DES) and Medical Outcomes Study (MOS). Total score of both 
scales was used to evaluate the motivation level for participants in this trial across 
visits.  
As illustrated in Table 41 and Figure 16, participants in the IMBDSME group had 
higher mean scores in DES-MOS than baseline mean score 4.01 ± (0.43) and 4.04 ± 
(0.34) compared to participants in the TAU group 3.75 ± (0.43) and 3.74 ± (0.43) at 
three-month and six-month visits respectively. The difference was not statistically 
significant in baseline mean scores between trial groups and was 0.02 (95% CI, -0.17 
to 0.12), where the baseline scores were 3.65 ± (0.45) and 3.62 ± (0.46) for TAU group 
and IMBDSME group respectively. While the differences in DES-MOS mean scores 
between trial groups were statistically significant at three-month visit 0.26 (95% CI, 
0.10 – 0.41) and 0.31 (95% CI, 0.15 – 0.47) at six-month visit. P values were less than 
0.001 at both visits.  








Baseline 3.65 ± (0.45) 3.62 ± (0.46) -0.02 (-0.17 – 0.12) 0.74 
Three-month 3.75 ± (0.43) 4.01 ± (0.43) 0.26 (0.10 – 0.41) 0.001 
Six-month 3.74 ± (0.43) 4.04 ± (0.34) 0.31 (0.15 – 0.47) 0.001 
Table 41 Mean scores of DES-MOS for both trial groups across trial visits after imputation with the differences 
and their 95% confidence interval differences 
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Figure 16 Mean Scores of DES-MOS for both trial groups across trial visits and their P values 
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4.8.2.1 Modelling GEE: 
As presented in Table 42, estimates of the effect size of IMBDSME intervention on 
the level of motivation toward performing diabetes self-management behaviours 
were modelled using GEE. P values, estimated coefficients, risk ratios and their 95% 
CI of DES-MOS score for both trial groups for all models are presented below. In 
general, all estimated coefficients and risk ratios were statistically significant for 
participants in the IMBDSME group in all models where P value was less than 0.001 
at three-month and six-month visits, while they were not statistically significant for 
participants in TAU group as P value was more than 0.06. 
Participants who received IMBDSME intervention had an estimated coefficient of 
0.38 (95% CI, 0.27 to 0.49) at three-month and increased to 0.40 (95% CI, 0.29 to 
0.52) at six-month visit before any adjustment in model one, while after the 
adjustment to the baseline scores, estimated coefficient decreased to 0.28 (95% CI, 
0.13 to 0.43) and 0.32 (95% CI, 0.15 to 0.48) at three-month and six-month visits 
respectively. Moreover, the estimates did not differ considerably after adjusting for 
other covariates at model five from estimates at model two where it was the same 
at three-month visit and increased 0.01 at six-month visit. In terms of probability, 
participants who received IMBDSME intervention were 33% (95% CI, 14% to 54%) 
and 37% (95% CI, 17% to 61%) more likely to be motivated toward performing 
diabetes self-management behaviours at three-month and six-month visits after 
baseline scores adjustment. Similar to the estimates, probabilities in model five 
remained the same as model two at three-month visit and increased 2% at six-month 
visit. 
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For participants in TAU group, estimates coefficients were the same before and after 
adjustments to the baseline scores and were 0.10 (95% CI, -0.004 to 0.20) and 0.08 
(95% CI, -0.04 to 0.21) at three-month and six-month visits. These estimates 
decreased to 0.08 (95% CI, -0.03 to 0.19) at three-month visits and increased to 0.10 
(95% CI, -0.02 to 0.21) at six-month visit after adjusting for other covariates in model 
five. All estimates and risk ratios for participants in TAU group were not statistically 
significant.  
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.10 (-0.003 to 0.20) 1.10 (0.99 to 1.22) 0.06 0.38 (0.27 to 0.49) 1.46 (1.31 to 1.67) 0.001 
 2 0.10 (-0.004 to 0.20) 1.10 (1.00 to 1.22) 0.06 0.28 (0.13 to 0.43) 1.33 (1.14 to 1.54) 0.001 
 3 0.10 (-0.004 to 0.20) 1.10 (1.00 to 1.22) 0.06 0.28 (0.13 to 0.43) 1.33 (1.14 to 1.54) 0.001 
 4 0.09 (-0.02 to 0.19) 1.09 (0.98 to 1.21) 0.11 0.27 (0.12 to 0.41) 1.31 (1.13 to 1.51) 0.001 
 5 0.08 (-0.03 to 0.19) 1.09 (0.97 to 1.21) 0.14 0.28 (0.13 to 0.43) 1.33 (1.14 to 1.53) 0.001 
6-month 1 0.08 (-0.04 to 0.21) 1.09 (0.96 to 1.23) 0.18 0.40 (0.29 to 0.52) 1.49 (1.33 to 1.67) 0.001 
 2 0.08 (-0.04 to 0.21) 1.09 (0.96 to 1.23) 0.18 0.32 (0.15 to 0.48) 1.37 (1.17 to 1.61) 0.001 
 3 0.08 (-0.04 to 0.21) 1.09 (0.96 to 1.23) 0.18 0.32 (0.15 to 0.48) 1.37 (1.17 to 1.61) 0.001 
 4 0.08 (-0.03 to 0.19) 1.09 (0.97 to 1.21) 0.15 0.34 (0.20 to 0.49) 1.41 (1.22 to 1.63) 0.001 
 5 0.10 (-0.02 to 0.21) 1.10 (0.99 to 1.23) 0.09 0.33 (0.19 to 0.47) 1.39 (1.21 to 1.61) 0.001 
Table 42 Coefficients and Risk Ratio of DES-MOS score for both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                               
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.8.3 Diabetes self-management self-efficacy: 
As was explained in (3.13.3.3), perceived self-efficacy to perform diabetes self-
management behaviours was measured to evaluate the element of behavioural 
skills, which is part of IMB model through using the Perceived Diabetes Self-
Management Scale (PDSMS). As illustrated in Table 43 and Figure 17, participants in 
the IMBDSME group experienced higher mean scores 3.57 ± (0.57) and 3.61 ± (0.59) 
than baseline mean score compared to participants in TAU group 3.02 ± (0.44) and 
3.03 ± (0.47) at three-month and six-month visits respectively. The difference in 
baseline mean scores for trial groups was 0.03 (95% CI, -0.22 – 0.15) and was not 
statistically significant. Baseline mean score for participants in IMBDSME group 2.85 











Baseline 2.89 ± (0.48) 2.85 ± (0.64) -0.03 (-0.22 – 
0.15) 
0.72 
Three-month 3.02 ± (0.44) 3.57 ± (0.57) 0.54 (0.37 – 0.73) 0.001 
Six-month 3.03 ± (0.47) 3.61 ± (0.59) 0.58 (0.37 – 0.79) 0.001 
Table 43 Mean scores of PDSMS for both trial groups across trial visits after imputation with the differences and 
their 95% confidence interval differences 
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Figure 17 Mean Scores of PDSMS for both trial groups across trial visits and their P values 
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4.8.3.1 Modelling GEE: 
As presented in Table 44, estimated coefficients of the effect size of IMBDSME 
intervention on the level of self-efficacy were modelled using GEE approach in five 
models. It consisted of P values, estimated coefficients, risk ratios and their 95% CI 
for both trial groups for all models. Generally speaking, estimated coefficients and 
their risk ratios for participants in the IMBDSME group were statistically significant in 
all models at three-month and six—month visits. What is more, they were statistically 
significant for participants in the TAU group in model two and three at three-month 
visit but not statistically significant at six-month visit.  
Participants who received IMBDSME intervention had an estimated coefficients at 
three-month and six-month visits of 0.71 (95% CI, 0.55 to 0.87) and 0.75 (95% CI, 0.58 
to 0.91) respectively before baseline score adjustment, while after adjustment in 
model two, they decreased to be decreased to 0.58 (95% CI, 0.38 to 0.78) and 0.61 
(95% CI, 0.38 to 0.83) at same endpoints above. However, the estimate coefficients 
in model two increased in model five at three-month visit to be 0.61 (95% CI, 0.40 to 
0.82) and decreased at six-month to be 0.55 (95% CI, 0.32 to 0.78). On the other 
hand, participants in TAU group had the same estimated coefficient before and after 
adjustment of the baseline score 0.13 (95% CI, 0.01 to 0.24) at three-month visit and 
decreased to 0.10 (95% CI, -0.03 to 0.23) in model five but was not statistically 
significant.  
Regarding probability, participants who received IMBDSME intervention were 
statistically significant more likely by 79% (95% CI, 46% to 118%) and 83% (95% CI, 
47% to 129%) to experience an increase in self-efficacy at three-month and six-month 
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visits after adjusting baseline mean score (model two). The probabilities in model 
two increased to 84% (95% CI, 50% to 127%) at three-month visit and decreased to 
73% (95% CI, 38% to 117%) at six-month visit after adjusting for all covariates in 
model 5. However, the probability for participants in TAU group was 14% (95% CI, 1% 
to 28%) more likely to experience an increase in self-efficacy after baseline score 
adjustments and it was the only statistically significant figure. 
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.13 (0.01 to 0.24) 1.14 (1.01 to 1.28) 0.03 0.71 (0.55 to 0.87) 2.03 (1.72 to 2.40) 0.001 
 2 0.13 (0.01 to 0.24) 1.14 (1.01 to 1.28) 0.03 0.58 (0.38 to 0.78) 1.79 (1.46 to 2.18) 0.001 
 3 0.13 (0.01 to 0.24) 1.14 (1.01 to 1.28) 0.03 0.58 (0.38 to 0.78) 1.79 (1.46 to 2.18) 0.001 
 4 0.10 (-0.03 to 0.22) 1.10 (0.97 to 1.25) 0.12 0.59 (0.39 to 0.80) 1.81 (1.48 to 2.23) 0.001 
 5 0.10 (-0.03 to 0.23) 1.10 (0.97 to 1.25) 0.15 0.61 (0.40 to 0.82) 1.84 (1.50 to 2.27) 0.001 
6-month 1 0.14 (-0.01 to 0.30) 1.15 (0.99 to 1.34) 0.08 0.75 (0.58 to 0.91) 2.11 (1.79 to 2.49) 0.001 
 2 0.14 (-0.01 to 0.30) 1.15 (0.99 to 1.34) 0.08 0.61 (0.38 to 0.83) 1.83 (1.47 to 2.29) 0.001 
 3 0.14 (-0.01 to 0.30) 1.15 (0.99 to 1.34) 0.08 0.61 (0.38 to 0.83) 1.83 (1.47 to 2.29) 0.001 
 4 0.12 (-0.04 to 0.30) 1.12 (0.96 to 1.31) 0.14 0.59 (0.36 to 0.82) 1.80 (1.43 to 2.26) 0.001 
 5 0.15 (-0.01 to 0.30) 1.16 (0.99 to 1.35) 0.06 0.55 (0.32 to 0.78) 1.73 (1.38 to 2.17) 0.001 
Table 44 Coefficients and Risk Ratios of PDSMS score for both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                               
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
208 
PhD Thesis September 2020 Student ID 4220143 
 
4.8.4 Glycaemic level (HbA1c): 
As mentioned in section (3.13.3.4), glycated haemoglobin blood test (HbA1c) was 
used to evaluate the glycaemic level for all participants at baseline, three-month and 
six-month visits. As per the American Diabetes Association (ADA) guidelines, this 
blood test is usually arranged each three-month by the treating physician, and each 
six-month if their HbA1c level improved. As mentioned in (4.4.2.1), fundamentally, 
prescribing diabetes-related medications is informed greatly by the result of HbA1c. 
Those medications were determined and prescribed according to the utilised 
treatment regimens and the availability in each trial sites, in which each has different 
sponsor. Therefore, and in addition to estimate the effect size of IMBDSME 
intervention on Hba1c levels between trial groups, researcher investigated the 
effectiveness between trial groups for each trial site due to the fact that the 
difference in HbA1c between trial sites was statistically significant at baseline as was 
presented in (4.4.2.1). At baseline, participants who attended PHH had higher mean 
of HbA1c 10.2 ± (1.8) than participants who attended JUH who had a mean of HbA1c 
of 9.5 ± (1.5) and this difference was statistically significant (P0.015). 
4.8.4.1 Glycaemic level (HbA1c) in both sites: 
Participants in the IMBDSME group had lower mean of HbA1c 8.73 ± (1.57) and 8.72 
± (1.55) at three-month and six-month, respectively, than baseline mean value 9.81 
± (1.67) as is presented below in Table 45 and Figure 18. Although participants in TAU 
group had lower mean of HbA1c 9.21 ± (2.40) and 8.97 ± (1.85) at three-month and 
six-month respectively than baseline value 9.73 ± (1.32), the improvement in HbA1c 
among participants who received IMBDSME intervention was higher than those who 
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did not receive in TAU group. Based on the mean values of HbA1c, the differences 
between trial groups across baseline, three-month and six-month visits were not 
statistically significant despite the variations in the level of improvement in HbA1c 
between TAU group and IMBDSME group. All P values were more than 0.05. 
Nevertheless, the true effect size of the IMBDSME intervention on HbA1c level is 
modelled using GEE approach in the next section. 
Glycaemic level 
(HbA1c) for both sites 
Mean±(SD)  




Baseline 9.73 ± (1.32) 9.81 ± (1.67) 0.08 (-0.44 – 0.61) 0.75 
Three-month 9.21 ± (2.40) 8.73 ± (1.57) -0.48 (-1.26 – 0.30) 0.23 
Six-month 8.97 ± (1.85) 8.72 ± (1.55) -0.25 (-0.95 – 0.45) 0.76 
Table 45 Mean of HbA1c for both trial groups across trial visits after imputation with the differences and their 
95% confidence interval differences 
 
 
Figure 18 Mean of HbA1c for both trial groups across trial visits and their P values  
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4.8.4.2 Modelling GEE: 
Using GEE approach, the estimates of the effect size of IMBDSME intervention on 
HbA1c level was statistically significant in model one before the adjustment of 
baseline score -1.09 (95% CI, -1.56 to -0.62) and -1.00 (95% CI, -1.50 to -0.49) at three-
month and six-month respectively as shown in Table 46. However, estimates 
coefficients at the same model for participants in TAU group were -0.50 (95% Ci, -
1.04 to 0.04) at three-month and -0.70 (95% CI, -1.20 to --0.18) at six-month. Estimate 
points for those in TAU group at three-month was not statistically significant (P = 
0.07) but was statistically significant at six-month visit (P= 0.01). These estimates 
were overestimated due to the non-adjustment of the baseline score. While after the 
adjustment, all estimates were not statistically significant even after the adjustment 
for other covariates such as gender, age and medications for both trial groups at 
three-month and only for IMBDSME group at six-month visit. While for TAU group at 
six-month visit, they had statistically significant estimates of -0.70 (95% CI, -1.20 to -
-0.18) after adjustment of the baseline (model two) and -0.65 (95% CI, -1.17 to --0.14) 
after adjustment for gender, age and medications at model four. P values were less 
than 0.01 at both models. Consequently, participants in TAU group were more likely 
by 50% (95% CI, 16% to 70%) at model two and three, and 48% (95% CI, 13% to 69%) 
at model four to have a reduced level of HbA1c than participants in the IMBDSME 
group at six-month visit. 
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(HbA1c) for all 
 TAU  IMBDSME  
Mod
el 
Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 -0.50 (-1.04 to 0.04) 0.61 (0.35 to 1.04) 0.07 -1.09 (-1.56 to -0.62) 0.34 (0.21 to 0.54) 0.001 
 2 -0.50 (-1.04 to 0.04) 0.61 (0.35 to 1.04) 0.07 -0.59 (-1.31 to 0.13) 0.55 (0.27 to 1.14) 0.11 
 3 -0.49 (-1.03 to 0.05) 0.61 (0.36 to 1.05) 0.08 -0.61 (-1.32 to 0.11) 0.54 (0.27 to 1.12) 0.10 
 4 -0.46 (-1.02 to 0.10) 0.63 (0.36 to 1.10) 0.11 -0.62 (-1.34 to 0.10) 0.54 (0.26 to 1.10) 0.09 
6-month 1 -0.70 (-1.20 to --0.18) 0.50 (0.30 to 0.84) 0.01 -1.00 (-1.50 to -0.49) 0.37 (0.22 to 0.61) 0.001 
 2 -0.70 (-1.20 to --0.18) 0.50 (0.30 to 0.84) 0.01 -0.30 (-1.01 to 0.40) 0.74 (0.36 to 1.50) 0.40 
 3 -0.70 (-1.21 to --0.19) 0.50 (0.30 to 0.83) 0.01 -0.29 (-1.00 to 0.42) 0.75 (0.37 to 1.52) 0.43 
 4 -0.65 (-1.17 to --0.14) 0.52 (0.31 to 0.87) 0.01 -0.35 (-1.06 to 0.36) 0.70 (0.35 to 1.43) 0.33 
Table 46 Coefficients and Risk Ratios of HbA1c value for both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for diabetes-related medications 
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4.8.4.3 Improvement in HbA1c levels: 
The blood test (HbA1c) considers as an important indicator of glycaemic control for 
several reasons mentioned in section (3.13.3.4). American Diabetes Association 
(ADA) recommended a reasonable HbA1c goal for non-pregnant adults with T2DM is 
less than 7%. Thus, and in order to examine the effectiveness of IMBDSME 
intervention on HbA1c levels in three-month and six-month visits, participants in 
both trial groups were categorised by glycaemic level to either controlled (HbA1c<7) 
or uncontrolled (HbA1c >=7). And since all participants in this trial were screened and 
considered to be eligible by having an uncontrolled level of HbA1c of more than 8% 
at the point of recruitment, researcher can detect and compare the improvements 
in HbA1c between trial groups by examining the proportions of participants who had 
a controlled level of HbA1c at three-month and six-month visits. 
Of those who received IMBDSME intervention at three-month visit, seven 
participants (9.9%) improved their HbA1c and their mean level was 6.00 ± (1.04), 
while 70 participants (90.1%) had an uncontrolled level of HbA1c and their mean was 
9.15 ± (1.04). On the other hand, five participants (7.5%) of those who did not receive 
the IMBDSME intervention improved their HbA1c level and their HbA1c mean was 
5.97 ± (1.06), while the rest 66 (92.5%) had an uncontrolled level of HbA1c and their 
HbA1c mean level was 9.57 ± (1.07). For six-month visit, eight participants (10.2%) of 
those who received IMBDSME intervention improved their HbA1c and their mean 
level was 6.16 ± (1.05), while 69 participants (89.8%) had an uncontrolled level of 
HbA1c and their mean was 9.19 ± (1.04). On the other hand, six participants (8.1%) 
of those who did not receive the IMBDSME intervention improved their HbA1c level 
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and their HbA1c mean was 6.01 ± (1.07), while the rest 65 (91.9%) had an 
uncontrolled level of HbA1c and their HbA1c mean level was 9.35 ± (1.06). The 
comparison between trial groups was tabulated using Chi-Square statistical test and 
the differences were statistically significant at both three-month and six-month visits 
due to P value less than 0.001 as shown in Table 47. 
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 (HbA1c) for 
all attendees 









Mean±(SD) Frequency (%) Mean±(SD) Frequency (%) Mean±(SD) 
Three-month 66 (92.5%) 9.57 ± (1.07) 5 (7.5%) 5.97 ± (1.06) 70 (90.1%) 9.15 ± (1.04) 7 (9.9%) 6.00 ± (1.04) 0.001 
Six-month 65 (91.9%) 9.35 ± (1.06) 6 (8.1%) 6.01 ± (1.07) 69 (89.8%) 9.19 ± (1.04) 8 (10.2%) 6.16 ± (1.05) 0.001 
Table 47 Proportions of participants who had a controlled and uncontrolled level of HbA1c for both trial groups across trial visits. 
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4.8.4.4 Glycaemic level in PHH: 
Means of HbA1c for participants who attended JUH for both trial groups across trial 
visits are demonstrated in Table 48 and Figure 19. Participants in TAU group had 
higher mean level of HbA1c 10.2 ± (2.40) than baseline at three-month and then 
reduced at six-month visit to 9.62 ± (1.85). On the other hand, participants who 
received the IMBDSME intervention had lower mean levels of HbA1c of 9.58 ± (1.57) 
and 9.40 ± (1.55) at three-month and six-month visit respectively. Although HbA1c at 
baseline was higher for IMBDSME group 10.45 ± (1.67) than of those in TAU group 
9.99 ± (1.32), the difference was not statistically significant (P=0.40). Moreover, the 
differences between trial groups at three-month and six-month visits were not 
statistically significant (P=0.44) and (P=0.76) respectively. 
Glycaemic level 
(HbA1c) for PHH 
attendees 
Mean±(SD)  




Baseline 9.99 ± (1.32) 10.45 ± (1.67) 0.46 (-0.63 – 1.56) 0.40 
Three-month 10.2 ± (2.40) 9.58 ± (1.57) -0.61 (-2.21 – 0.99) 0.44 
Six-month 9.62 ± (1.85) 9.40 ± (1.55) -0.22 (-1.73 – 1.29) 0.76 
Table 48 Mean of HbA1c for both trial groups across trial visits for PHH attendees after imputation with the 
differences and their 95% confidence interval differences 
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Figure 19 Mean of HbA1c of PHH attendees for both trial groups across trial visits and their P values 
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4.8.4.5 Modelling GEE: 
In section (3.15.5.1), there is an explanation for the method of modelling trial primary 
and secondary outcomes across five models to accurately estimate coefficients to 
measure the effect size of IMBDSME intervention on those outcomes. However, in 
order to estimate coefficients and measure the effect size of the intervention on 
HbA1c levels in two different trial sites (PHH and JUH), the trial sites were included 
as an independent variable in each of these models for adjustment purposes. This 
aimed to calculate the estimate points according to trial sites after the adjustment to 
the baseline levels of HbA1c for each trial groups and trial sites. 
From the Table 49, estimated coefficients were statistically significant among 
participants in the IMBDSME group before the adjustment to baseline score (model 
one). They were -1.09 (95% CI, -1.81 to -0.37) and -1.10 (95% CI, -1.87 to -0.33) at 
three-month and six-month visits respectively. While after the adjustment to the 
baseline values (model two), estimated points decreased to -1.16 (95% CI, -2.50 to 
0.17) at three-month and increased to -0.77 (95% CI, -2.03 to 0.50) but were not 
statistically significant. Similar to other models, all estimated points were not 
statistically significant despite the further decrease at three-month visit to -1.31 (95% 
CI, -2.74 to 0.13) and the increase to -0.95 (95% CI, -2.21 to 0.31) in model four. On 
the other hand, estimated points for participants in the TAU group were 0.07 (95% 
CI, -1.07 to 1.21) at three-month and -0.33 (95% CI, -1.37 to 0.71) at six-month before 
the adjustment to the baseline value (model one). Those estimates continued to 
increase along with the models and were not statistically significant at both visits. 
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.07 (-1.07 to 1.21) 1.07 (0.34 to 3.36) 0.90 -1.09 (-1.81 to -0.37) 0.33 (0.16 to 0.69) 0.003 
 2 0.07 (-1.07 to 1.21) 1.07 (0.34 to 3.36) 0.90 -1.16 (-2.50 to 0.17) 0.31 (0.08 to 1.19) 0.09 
 3 0.11 (-1.04 to 1.26) 1.11 (0.35 to 3.51) 0.90 -1.19 (-2.54 to 0.16) 0.30 (0.08 to 1.17) 0.08 
 4 0.16 (-1.06 to 1.38) 1.17 (0.35 to 3.97) 0.80 -1.31 (-2.74 to 0.13) 0.27 (0.06 to 1.14) 0.08 
6-month 1 -0.33 (-1.37 to 0.71) 0.72 (0.25 to 2.03) 0.53 -1.10 (-1.87 to -0.33) 0.33 (0.15 to 0.72) 0.005 
 2 -0.33 (-1.37 to 0.71) 0.72 (0.25 to 2.03) 0.53 -0.77 (-2.03 to 0.50) 0.74 (0.36 to 1.50) 0.24 
 3 -0.37 (-1.40 to 0.66) 0.69 (0.25 to 1.93) 0.48 -0.72 (-2.00 to 0.55) 0.48 (0.14 to 1.71) 0.27 
 4 -0.26 (-1.25 to 0.73) 0.77 (0.29 to 2.08) 0.61 -0.95 (-2.21 to 0.31) 0.39 (0.11 to 1.36) 0.14 
Table 49 Coefficients and Risk Ratios of HbA1c for PHH attendees in both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
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4.8.4.6 Glycaemic level in JUH: 
Means of HbA1c for participants who attended JUH for both trial groups across trial 
visits are demonstrated in Table 50 and Figure 20. Participants who received the 
IMBDSME intervention had lower levels of HbA1c 8.33 ± (1.57) and 8.50 ± (1.55) at 
three-month and six-month visits than baseline 9.52 ± (1.67). Although participants 
in the TAU group had lower levels of HbA1c 8.83 ± (2.40) at three-month and 8.77 ± 
(1.85) at six-month visit than baseline 9.62 ± (1.32), the reduction in HbA1c levels 
among IMBDSME group was greater than for those in the TAU group at three-month 
visit. However, at six-month visit, participants in TAU group had a further reduction 
in HbA1c levels, while those in IMBDSME group had an increase in HbA1c levels. All 
differences between trial groups were not statistically significant across trial visits. 
Glycaemic level 
(HbA1c) for JUH attendee 
Mean±(SD)  




Baseline 9.62 ± (1.32) 9.52 ± (1.67) -0.10 (-0.68 – 
0.48) 
0.74 
Three-month 8.83 ± (2.40) 8.33 ± (1.57) -0.49 (-1.35 – 
0.36) 
0.25 
Six-month 8.77 ± (1.85) 8.50 ± (1.55) -0.27 (-1.07 – 
0.52) 
0.49 
Table 50 Mean of HbA1c for both trial groups across trial visits for JUH attendees after imputation with the 
differences and their 95% confidence interval 
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Figure 20 Mean of HbA1c of JUH attendees for both trial groups across trial visits and their P values 
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4.8.4.7 Modelling GEE: 
Similar to the modelling approach of HbA1c among participants who attended PHH 
in section (4.8.4.5), estimate coefficients were calculated by including trial sites as an 
independent variable in each of these models for adjustment purposes.  
From Table 51, estimated coefficients were statistically significant before the 
adjustment to the baseline values (model one) for participants in both groups at 
three-month and six-month visits. In details, participants who received IMBDSME 
intervention had coefficients of -1.65 (95% CI,-2.86 to -0.44) and -1.50 (95% CI, -2.72 
to -0.27) at three-month and six-month respectively, while participants in TAU group 
had coefficients of -0.73 (95% CI, -1.33 to -0.13) and -0.82 (95% CI,-1.39 to --0.24) for 
the same time points. After the adjustment to the baseline values, those coefficients 
for participants in IMBDSME group decreased to -1.72 (956% CI, -3.39 to -0.06) and 
was statistically significant (P=0.04), and decreased for participants in TAU group to 
-0.80 (95% CI, -2.09 to 0.49) but was not statistically significant (P=0.22) at three-
month visit. However, estimate coefficient was statistically significant at three-
month visit only for participants in the IMBDSME group in model four and was -1.82 
(95% CI, -3.44 to -0.20). Whereas at six-month visit, estimated coefficients increased 
for both trial groups, standing at -0.48 (-1.66 to --0.69) and -1.16 (-2.90 to 0.57) for 
TAU group and for IMBDSME group respectively and none of them were statistically 
significant after the adjustment in model two, three and four. Despite those results, 
estimates for participants in the IMBDSME group was higher -1.25 (95% CI, -2.87 to 
0.38) in comparison to those participants in TAU group -0.60 (95% CI, -1.74 to --0.55).  
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In terms of probability, for three-month visit, participants in the IMBDSME group 
were 84% (95% CI, 18% to 97%) more likely to have lower HbA1c values than baseline 
in comparison to participants in the TAU group who were 58% (-89% to 66%). These 
results were statistically significant for participants in IMBDSME group but were not 
for participants in TAU group. For six-month visit, although all probabilities were not 
statistically significant after adjusting for all covariates, participants in the IMBDSME 
group were 71% (95% CI, 47% to 94%) more likely to have lower HbA1c values than 
baseline in comparison to participants in the TAU group who were 45% (73% to 82%). 
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 TAU  IMBDSME  
Mod
el 
Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 -0.73 (-1.33 to -0.13) 0.48 (0.26 to 0.88) 0.02 -1.65 (-2.86 to -0.44) 0.19 (0.06 to 0.64) 0.01 
 2 -0.80 (-2.09 to 0.49) 0.45 (0.12 to 1.63) 0.22 -1.72 (-3.39 to -0.06) 0.18 (0.03 to 0.94) 0.04 
 3 -0.84 (-2.13 to 0.46) 0.43 (0.12 to 1.60) 0.21 -1.75 (-3.40 to -0.10) 0.17 (0.03 to 0.90) 0.04 
 4 -0.86 (-2.23 to 0.51) 0.42 (0.11 to 1.66) 0.22 -1.82 (-3.44 to -0.20) 0.16 (0.03 to 0.82) 0.03 
6-month 1 -0.82 (-1.39 to --0.24) 0.44 (0.25 to 0.79) 0.006 -1.50 (-2.72 to -0.27) 0.22 (0.07 to 0.76) 0.02 
 2 -0.48 (-1.66 to --0.69) 0.62 (0.19 to 2.00) 0.42 -1.16 (-2.90 to 0.57) 0.31 (0.06 to 1.77) 0.19 
 3 -0.44 (-1.61 to --0.73) 0.64 (0.20 to 2.07) 0.46 -1.08 (-2.78 to 0.62) 0.34 (0.06 to 1.86) 0.21 
 4 -0.60 (-1.74 to --0.55) 0.55 (0.18 to 1.73) 0.31 -1.25 (-2.87 to 0.38) 0.29 (0.06 to 1.47) 0.13 
Table 51 Coefficients and Risk Ratios of HbA1c for JUH attendees in both Trial Groups for all Models and their CI (Confidence Interval) across trial visits 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for diabetes-related medications 
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4.8.5 Audit of Diabetes Dependent Quality of Life (ADDQOL): 
As detailed in section (3.13.3.5), diabetes patients’ quality of life was measured using 
an Audit of Diabetes-Dependent Quality of Life (ADDQOL) scale. It consisted of two 
items regarding their quality of life in general at the beginning, and an additional 18 
items asking about certain aspects related to their DM. Each of those is examined 
and modelled separately below. 
4.8.5.1 Present Quality of Life: 
Participants in both trial groups were asked to describe their present quality of life 
status by choosing an option out of seven. These options: “Excellent” received score 
of +3, “Very good” received score of +2, “Good” received score of +1, “Neither good 
nor bad” received score of 0, “Bad” received score of -1, “Very bad” received score 
of -2, “Extremely bad” received score of -3. As shown in Table 52 and Figure 21, 
participants in the IMBDSME group had higher mean score of 1.79 ± (0.81) and 1.90 
± (0.97) at three-month and six-month visits respectively than baseline mean score 
0.82 ± (1.12). Although participants in the TAU group had higher baseline mean score 
by 0.06 (95% CI, -0.47 – 0.36), the difference was not statistically significant. They 
had mean scores of 1.28 ± (1.28) and 1.13 ± (1.08) at three-month and six-month 
visits respectively. As a result, the mean score of participants who received IMBDSME 
intervention was higher by 0.51 (95% CI, 0.17 – 0.86) and 0.77 (95% CI, 0.38 – 1.15) 
than of those who had TAU at three-month and six-month respectively, and those 
rises were statistically significant as P values were less than 0.05. 
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Baseline 0.87 ± (1.33) 0.82 ± (1.12) -0.06 (-0.47 – 0.36) 0.79 
Three-month 1.28 ± (1.28) 1.79 ± (0.81) 0.51 (0.17 – 0.86) 0.004 
Six-month 1.13 ± (1.08) 1.90 ± (0.97) 0.77 (0.38 – 1.15) 0.001 
Table 52 Mean of ADDQOL first question for both trial groups across trial visits after imputation with the 
differences and their 95% confidence interval 
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4.8.5.2 Modelling GEE: 
As presented in Table 53, estimated coefficients for the effect size of IMBDSME 
intervention were calculated using GEE approach through five models. It shows P 
values, estimated coefficients, risk ratios and their 95% CI of ADDQOL first question 
score for both trial groups for all models. Overall, estimated coefficients were 
statistically significant for all participants except at six-month for those who did not 
receive IMBDSME intervention. 
Estimates for participants in the IMBDSME group were 0.96 (95% CI, 0.68 to 1.25) 
and 1.07 (95% CI, 0.76 to 1.39) at three-month and six-month respectively before the 
adjustment of baseline score (model one). While after the adjustment at model two, 
estimates decreased to 0.57 (95% CI, 0.19 to 0.94) and 0.81 (95% CI, 0.37 to 1.26) at 
three-month and six-month visits respectively. With further adjustment at model 
five, it decreased to 0.53 (95% CI, 0.14 to 0.93) and 0.74 (95% CI, 0.32 to 1.16) for the 
same periods. On the other hand, estimates for participants who did not receive the 
IMBDSME intervention were the same before and after the adjustments and were 
0.40 (95% CI, 0.15 to 0.65) and 0.26 (95% CI, -0.07 to 0.59) at three-month and six-
month respectively. In model five, estimates decreased to 0.32 (95% CI, 0.02 to 0.62) 
and 0.14 (95% CI, -0.16 to 0.44) for the same periods and was not statistically 
significant at six-month. As regard the probability, participants in the IMBDSME 
group were more likely to have higher score of ADDQOL first question by 76% (95% 
CI, 21% to 156%) than participants in the TAU group who were likely to have a higher 
score by 49% (95% CI, 16% to 91%) after baseline score adjustment at three-month 
visit. In model five, the probability decreased to 70% (95% CI, 15% to 153%) and 38% 
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(95% CI, 2% to 86%) for participants in the IMBDSME group and TAU group 
respectively. both of which were statistically significant at three-month visit. At six-
month visit, participants in the IMBDSME group were 1.26 (95% CI, 0.45 to 2.52) 
times more likely to have higher score of ADDQOL first question than participants in 
the TAU group who were 29% likely to have higher score than baseline after the 
adjustment for the baseline score. In model five, and similar to three-month visit, 
probabilities decreased to 1.1 (95% CI, 0.38 to 2.2) and 15% (95% CI, -15% to 56%) 
for participants in the IMBDSME group and TAU group respectively and was only 
statistically significant for participants who received the IMBDSME intervention 
where P value was less than 0.001. 
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 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 0.40 (0.15 to 0.65) 1.49 (1.16 to 1.91) 0.002 0.96 (0.68 to 1.25) 2.62 (1.97 to 3.48) 0.001 
 2 0.40 (0.15 to 0.65) 1.49 (1.16 to 1.91) 0.002 0.57 (0.19 to 0.94) 1.76 (1.21 to 2.56) 0.003 
 3 0.40 (0.15 to 0.65) 1.49 (1.16 to 1.91) 0.002 0.57 (0.19 to 0.94) 1.76 (1.21 to 2.56) 0.003 
 4 0.33 (0.04 to 0.62) 1.39 (1.04 to 1.86) 0.03 0.54 (0.15 to 0.94) 1.72 (1.16 to 2.56) 0.01 
 5 0.32 (0.02 to 0.62) 1.38 (1.02 to 1.86) 0.04 0.53 (0.14 to 0.93) 1.70 (1.15 to 2.53) 0.01 
6-month 1 0.26 (-0.07 to 0.59) 1.29 (0.93 to 1.80) 0.12 1.07 (0.76 to 1.39) 2.92 (2.13 to 4.01) 0.001 
 2 0.26 (-0.07 to 0.59) 1.29 (0.93 to 1.80) 0.12 0.81 (0.37 to 1.26) 2.26 (1.45 to 3.52) 0.001 
 3 0.26 (-0.07 to 0.59) 1.29 (0.93 to 1.80) 0.12 0.81 (0.37 to 1.26) 2.26 (1.45 to 3.52) 0.001 
 4 0.11 (-0.19 to 0.41) 1.12 (0.82 to 1.51) 0.48 0.79 (0.36 to 1.21) 2.19 (1.44 to 3.34) 0.001 
 5 0.14 (-0.16 to 0.44) 1.15 (0.85 to 1.56) 0.35 0.74 (0.32 to 1.16) 2.10 (1.38 to 3.20) 0.001 
Table 53 Coefficients and Risk Ratios of ADDQOL first question for all participants in both Trial Groups for all Models and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                                
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.8.5.3 Quality of life without diabetes: 
The second item in ADDQOL scale was asking participants to describe how their 
quality of life would be without diabetes. The choices were from “very much better” 
received score of -3, “much better” received score of -2, “a little better” received a 
score of -1, “the same” received score of zero and “worse” received score of +1. As 
shown in Table 54 and Figure 22, participants in IMBDSME group had higher mean 
score -1.00 ± (1.36) and -0.91 ± (1.22) at three-month and six-month visits 
respectively than baseline score -1.56 ± (1.62). In contrast, participants in TAU group 
had lower score of -1.95 ± (1.14) and -1.79 ± (1.75) at three-month and six-month 
visits than baseline score of -1.7 ± (1.54). Although there was difference of 0.15 (95% 
CI, -0.16 – 0.45) in baseline score between trial groups, it was not statistically 
significant. However, there were statistically significant differences between trial 
groups at three-month visit and was 0.94 (95% CI, 0.62 – 1.27) and was 0.88 (95% CI, 










Baseline -1.7 ± (1.54) -1.56 ± (1.62) 0.15 (-0.16 – 0.45) 0.35 
Three-month -1.95 ± (1.14) -1.00 ± (1.36) 0.94 (0.62 – 1.27) 0.001 
Six-month -1.79 ± (1.75) -0.91 ± (1.22) 0.88 (0.56 – 1.21) 0.001 
Table 54 Mean of ADDQOL second question for both trial groups across trial visits after imputation with the 
differences and their 95% confidence interval 
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Figure 22 Mean of ADDQOL second question for both trial groups across trial visits and their P values 
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4.8.5.4 Modelling GEE: 
As presented in Table 55, estimated coefficients for the effect size of IMBDSME 
intervention on second question in ADDQOL scale were calculated as well as P values, 
risk ratios and their 95% CI using GEE approach for both trial groups in five models. 
Overall, estimated coefficients were statistically significant for all participants before 
and after the adjustment to the baseline mean score except for those who did not 
receive IMBDSME intervention at three-month visit in model five and six-month visit. 
It is clear that participants who received the IMBDSME intervention had positive 
estimated coefficients while all estimates for participants in the TAU group were 
negative values in all models. 
At three- month visit, participants in IMBDSME group had an estimate of 0.55 (95% 
CI, 0.35 to 0.75) before the adjustment in model one, whereas it increased to 0.80 
(95% CI, 0.48 to 1.11) after the adjustment to the baseline score in model two, and 
increased further in model five to 0.83 (95% CI, 0.47 to 1.19). In contrast, participants 
in TAU group had the same estimates before and after the adjustment to the baseline 
score of -0.25 (95% CI, -0.50 to -0.01) and decreased further at model four -0.29 (95% 
CI, -0.57 to -0.01) and at model five -0.27 (95% CI, -0.56 to -0.02). At six-month, 
participants in IMBDSME group had an estimate of 0.65 (95% CI, 0.41 to 0.88) before 
the adjustment to baseline score, increased to 0.74 (95% CI, 0.42 to 1.05) after the 
adjustment in model two and 0.72 (95% CI, 0.40 to 1.05) in model five. Similar to 
three-month visit, participants in TAU group had the same estimate before and after 
the adjustment of -0.09 (95% CI, -0.31 to 0.12) and decreased further to -0.07 (95% 
CI, -0.29 to 0.09) in model five.  
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Participants who received IMBDSME group were 1.22 (95% CI, 0.62 to 2.04) and 1.3 
(95% CI, 0.6 to 2.3) times more likely to had higher score of ADDQOL second question 
than baseline score in model two and model five respectively at three-month visit. 
At the same period, participants in TAU group were 22% (95% CI, 1% to 39%) and 
24% (95% CI, 2% to 43%) likely to have lower scores than baseline in model two and 
model five respectively. At six-month visit, participants in IMBDSME group were 1.09 
(95% CI, 0.53 to 1.86) and 1.06 (95% CI, 0.49 to 1.85) times more likely to have higher 
score than baseline in model two and model five respectively. While participants in 
TAU group were 9% (95% CI, -26% to 13%) and 6% (95% CI, -22% to 13%) likely to 












 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 -0.25 (-0.50 to -0.01) 0.78 (0.61 to 0.99) 0.047 0.55 (0.35 to 0.75) 1.73 (1.41 to 2.11) 0.001 
 2 -0.25 (-0.50 to -0.01) 0.78 (0.61 to 0.99) 0.047 0.80 (0.48 to 1.11) 2.22 (1.62 to 3.04) 0.001 
 3 -0.25 (-0.50 to -0.01) 0.78 (0.61 to 0.99) 0.047 0.80 (0.48 to 1.11) 2.22 (1.62 to 3.04) 0.001 
 4 -0.29 (-0.57 to -0.01) 0.75 (0.57 to 0.99) 0.048 0.83 (0.48 to 1.18) 2.30 (1.62 to 3.25) 0.001 
 5 -0.27 (-0.56 to -0.02) 0.76 (0.57 to 1.02) 0.07 0.83 (0.47 to 1.19) 2.30 (1.60 to 3.30) 0.001 
6-month 1 -0.09 (-0.31 to 0.12) 0.91 (0.74 to 1.13) 0.41 0.65 (0.41 to 0.88) 1.91 (1.51 to 2.42) 0.001 
 2 -0.09 (-0.31 to 0.12) 0.91 (0.74 to 1.13) 0.41 0.74 (0.42 to 1.05) 2.09 (1.53 to 2.86) 0.001 
 3 -0.09 (-0.31 to 0.12) 0.91 (0.74 to 1.13) 0.41 0.74 (0.42 to 1.05) 2.09 (1.53 to 2.86) 0.001 
 4 -0.10 (-0.29 to 0.09) 0.90 (0.75 to 1.09) 0.29 0.75 (0.43 to 1.07) 2.11 (1.53 to 2.92) 0.001 
 5 -0.07 (-0.29 to 0.09) 0.94 (0.78 to 1.13) 0.49 0.72 (0.40 to 1.05) 2.06 (1.49 to 2.85) 0.001 
Table 55 Coefficients and Risk Ratios of ADDQOL second question for all participants in both Trial Groups for all Models and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                                    
Model 2 adjusted to the baseline.                                                                                                                                                                                                           
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                           
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                                     
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.8.5.5 Diabetes-specific 18-items: 
Diabetes-specific 18-items were designed to ask participants to express the impact 
of diabetes on certain aspects of life. In addition, participants were asked to respond 
on each item by stating how important that aspect was in their life. The calculation 
of each item’s score and total score of ADDQOL was explained previously. 
As presented in Table 56 and Figure 23, participants in IMBDSME group had higher 
mean score -1.97 ± (1.36) and -1.96 ± (1.22) at three-month and six-month visits 
respectively than baseline score -2.37 ± (1.62). In contrast, participants in TAU group 
had lower score of -2.9 ± (1.14) and -2.6 ± (1.75) at three-month and six-month visits 
than baseline score of -2.3 ± (1.54). Although there was difference of -0.11 (95% CI, -
0.61 – 0.38) in baseline score between trial groups, it was not statistically significant. 
However, there were statistically significant differences between trial groups at 
three-month visit and was 0.91 (95% CI, 0.44 – 1.38) and was 0.65 (95% CI, 0.11 – 
1.19) at six-month visit where P values were less than 0.02.  
 
ADDQOL 
Total of 18 items 
Mean±(SD)  




Baseline -2.3 ± (1.54) -2.37 ± (1.62) -0.11 (-0.61 – 
0.38) 
0.66 
Three-month -2.9 ± (1.14) -1.97 ± (1.36) 0.91 (0.44 – 1.38) 0.001 
Six-month -2.6 ± (1.75) -1.96 ± (1.22) 0.65 (0.11 – 1.19) 0.019 
Table 56 Mean score of ADDQOL 18-itmes for both trial groups across trial visits after imputation with the 
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4.8.5.6 Modelling GEE: 
As presented in Table 57, estimated coefficients for the effect size of IMBDSME 
intervention on total score of ADDQOL 18-ietms scale were calculated as well as P 
values, risk ratios and their 95% CI using GEE approach for both trial groups in five 
models. Overall, and similar to the result of ADDQOL second question (4.8.5.3), 
estimated coefficients were statistically significant for all participants before and 
after the adjustment to the baseline mean score except for those who did not receive 
IMBDSME intervention at six-month visit. It is clear that participants who received 
the IMBDSME intervention had positive estimated coefficients while all estimates for 
participants in the TAU group were negative values in all models. 
At three-month visit, participants in IMBDSME group had an estimate of 0.40 (95% 
CI, 0.01 to 0.81) before the adjustment in model one, whereas it increased to 1.02 
(95% CI, 0.52 to 1.52) after the adjustment to the baseline score in model two, and 
increased further in model five to 1.15 (95% CI, 0.58 to 1.71). In contrast, participants 
in TAU group had the same estimates before and after the adjustment to the baseline 
score of -0.62 (95% CI, -0.91 to -0.32) and decreased further at model five to -0.63 
(95% CI, -0.97 to -0.29). At six-month, participants in IMBDSME group had an 
estimate of 0.41 (95% CI, 0.05 to 0.87) before the adjustment to baseline score, 
increased to 0.77 (95% CI, 0.11 to 1.43) after the adjustment in model two and 0.90 
(95% CI, 0.15 to 1.65) in model five. Similar to three-month visit, participants in TAU 
group had the same estimate before and after the adjustment of -0.36 (95% CI, -0.85 
to 0.13) and decreased further to -0.40 (95% CI, -0.96 to 0.16) in model five. 
237 
PhD Thesis September 2020 Student ID 4220143 
 
Participants who received IMBDSME group were 1.78 (95% CI, 0.68 to 3.58) and 2.15 
(95% CI, 0.79 to 4.55) times more likely to had higher mean total score of ADDQOL 
18-items than baseline score in model two and model five respectively at three-
month visit. At the same period, participants in TAU group were 46% (95% CI, 27% to 
60%) and 47% (95% CI, 25% to 62%) likely to have lower scores than baseline in model 
two and model five respectively. At six-month visit, participants in IMBDSME group 
were 1.16 (95% CI, 0.11 to 3.21) and 1.46 (95% CI, 0.16 to 4.22) times more likely to 
have higher mean score than baseline in model two and model five respectively. 
While participants in TAU group were 30% (95% CI, 14% to 57%) and 33% (95% CI, 
17% to 62%) likely to have lower scores than baseline in model two and five 
respectively and were not statistically significant. 
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Total of 18 
items 
 TAU  IMBDSME  
Model Coef (95% CI) Risk Ratio (95% CI) P- value Coef (95% CI) Risk Ratio (95% CI) P- value 
3-month 1 -0.62 (-0.91 to -0.32) 0.54 (0.40 to 0.73) 0.001 0.40 (0.01 to 0.81) 1.50 (0.99 to 2.25) 0.041 
 2 -0.62 (-0.91 to -0.32) 0.54 (0.40 to 0.73) 0.001 1.02 (0.52 to 1.52) 2.78 (1.68 to 4.58) 0.001 
 3 -0.62 (-0.91 to -0.32) 0.54 (0.40 to 0.73) 0.001 1.02 (0.52 to 1.52) 2.78 (1.68 to 4.59) 0.001 
 4 -0.66 (-1.00 to -0.32) 0.51 (0.36 to 0.73) 0.001 1.17 (0.60 to 1.73) 3.21 (1.83 to 5.63) 0.001 
 5 -0.63 (-0.97 to -0.29) 0.53 (0.38 to 0.75) 0.001 1.15 (0.58 to 1.71) 3.15 (1.79 to 5.55) 0.001 
6-month 1 -0.36 (-0.85 to 0.13) 0.70 (0.43 to 1.14) 0.15 0.41 (0.05 to 0.87) 1.51 (0.96 to 2.39) 0.048 
 2 -0.36 (-0.85 to 0.13) 0.70 (0.43 to 1.14) 0.15 0.77 (0.11 to 1.43) 2.16 (1.11 to 4.21) 0.02 
 3 -0.36 (-0.85 to 0.13) 0.70 (0.43 to 1.14) 0.15 0.77 (0.11 to 1.44) 2.17 (1.11 to 4.22) 0.02 
 4 -0.40 (-0.96 to 0.16) 0.67 (0.38 to 1.17) 0.16 0.91 (0.17 to 1.66) 2.49 (1.18 to 5.24) 0.02 
 5 -0.40 (-0.96 to 0.16) 0.67 (0.38 to 1.17) 0.16 0.90 (0.15 to 1.65) 2.46 (1.16 to 5.22) 0.02 
Table 57 Coefficients and Risk Ratios of ADDQOL 18-items for all participants in both Trial Groups for all Models and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline.                                                                                                                                                                                               
Model 2 adjusted to the baseline.                                                                                                                                                                                                       
Model 3 as in model 2 with adjustments for age and gender.                                                                                                                                                       
Model 4 as in model 3 with the adjustments for HbA1c.                                                                                                                                                                
Model 5 as in model 4 with the adjustments for diabetes-related medications. 
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4.9 Results conclusion: 
As presented above, primary and secondary outcomes were analysed thoroughly and 
effect size for each was calculated and repeated in different models using GEE 
method. However, effect sizes do not explain how the IMBDSME intervention worked 
nor give an explanation on the underlying process of the intervention. Indeed, some 
researchers argued that RCTs of social complex interventions are simplifying the 
cause-and-effect relationship, due to the insignificant attention being payed to the 
influence of context, implementers and participants’ acceptance (Clark et al., 2007). 
Others criticized and described RCTs which have poorly described interventions as 
the black box that need to be unpacked to allow expressive evaluation (Stephenson 
et al., 2003). Nonetheless, one of the main reasons behind RCTs is to ensure that 
differences between trial groups are seldom due to chance and not systematic. 
Therefore, and in addition to address these limitations, conducting process 
evaluation of complex interventions can inform future replication of either the trial 
interventions or the trial outcomes in a different context. Process evaluation of 
IMBDSME intervention is presented in the next section.  
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5 Process evaluation of IMBDSME intervention: 
According to MRC guidance on process evaluation of complex intervention, process 
evaluation aims to provide more insight to improve the understandings of the causal 
assumption underpinning the intervention and raise further questions for 
exploration. It helps to identify which parts of the complex intervention are more 
effective than others and learn how and why they have a particular effect on the 
outcomes. Principally, it is vital to know how intervention works to build an evidence 
base that will inform policy and practice (Moore et al., 2015). 
Researcher planned and designed process evaluation step of IMBDSME earlier before 
conducting the trial of examining the effectiveness of IMBDSME on the trial 
outcomes. However, at the time of designing process evaluation, the causal 
assumptions of IMBDSME intervention were already defined and described using a 
logic model by researcher in Figure 5. A logic model was used to clarify the 
development stages of IMBDSME intervention, the required materials and training, 
the structure in which the intervention should be delivered and both clinical and trial 
outcomes. Although Strange et al. (2006) recommended to report and analyse 
process evaluation data, qualitative data in particular, without being aware of the 
results of trial outcomes to allow for unbiased interpretations, it was not possible to 
postpone the analysis of the trial outcomes after process evaluation is completed 
because of several reasons; our main concern was the trial primary outcomes, done 
by one researcher and time constraints of the PhD program. 
In this trial, process evaluation was designed for further understanding on how 
essential elements of IMB model (patients’ Knowledge, Motivation, Behavioural 
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skills) worked together to affect the trial outcomes. To design process evaluation of 
IMBDSME, researcher looked-for appropriate theoretical framework to be utilised to 
inform the methods of data collection and the reporting of findings of process 
evaluation. According to MRC guidance, three main aspects of process evaluation 
need to be examined and they are; implementation, mechanism of impact and 
contextual factors. Firstly, implementation of IMBDSME and how the delivery was 
achieved and what was actually delivered in practice aimed largely to provide 
assurance on the internal validity by examining the quality (fidelity) and the quantity 
(dose) of the intervention. The Oxford Implementation Index framework was used to 
assess the implementation data in this trial (Montgomery et al., 2013). Secondly, 
mechanism of impact of the IMBDSME intervention and the understandings of how 
participants in the IMBDSME group responded and interacted with the received dose 
of the intervention through utilising theory-based evaluation approach. Thirdly, 
contextual factors that influenced the effectiveness of the IMBDSME that shaped 
what was implemented and shaped the conditions under which the mechanism of 
impact was processing. 
Reporting findings of process evaluation is challenging due to the absence of a unified 
reporting guidelines that can fit all the used approaches in process evaluation. Moore 
et al. (2015) in MRC guidance mentioned that work was in progress to develop 
CONSORT- SPI 2018 (Social and Psychological Intervention) at that time by (Grant et 
al.). It is an extension to CONSORT 2010 statement developed to help researchers in 
behavioural medicine reporting trials that consist of complex interventions. Although 
they stressed that the new prospect extension have more expansion on reporting 
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process evaluation, CONSORT-SPI statement did not point or direct researchers to 
adopt or utilise evaluation frameworks or theories to report process evaluation data. 
Instead, they integrated process evaluation items within the main trial sections 
without relating each type of data to whether they are for implementation aspect, 
mechanism of impact or contextual factors. In other words, there was no elaboration 
on the process evaluation aspects as expected. However, they were considered 
during reporting the findings of process evaluation in this trial. 
In this trial, researcher collected process evaluation data using quatitative methods. 
However, reporting full process evaluation is beyond the scope of this PhD. 
Therefore, researcher is presenting the quantitative data of the implementation 
aspect, acceptability of IMBDSME intervention and satisfaction with the treatment 
for both trial groups.  
243 
PhD Thesis September 2020 Student ID 4220143 
 
5.1 Implementation of IMBDSME: 
The Oxford Implementation Index (OII) is a framework that was developed by a team 
of systematic reviewers to extract implementation data in order to be comparable 
with other interventions’ implementation data across primary care trials. Researcher 
has adopted this index as it was suggested by the MRC and has the ground to make 
implementation data of IMBDSME trial comparable with other interventions for 
future systematic reviews. Domains of OII are as follow: 
5.1.1 Intervention design: 
Developers of OII endorsed that a clear description of the intervention need to be 
reported for all trial groups, IMBDSME and TAU groups. As a consequence, the 
description of the development of IMBDSME intervention and the theoretical model 
that underpinning the intervention are presented in chapter (2).  
In fact, both groups received TAU, but participants in the control group in which 
researcher called TAU group did not receive any intervention from the researcher 
during the delivery period (three-month) apart from the educational booklet at the 
end of the trial. The description of usual treatment of patients with T2DM (TAU) is 
presented in section (3.9.4) for both trial sites and illustrated in a table to ease the 
comparability between both hospitals. 
5.1.2 Intervention delivery: 
The delivery of the intervention was done by the researcher who is a qualified 
registered diabetes nurse in Jordan. Neither of the independent outcome’s assessors 
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nor any of the research team intervened in delivering any parts or components of the 
IMBDSME.  
As per dosage of the IMBDSME intervention, knowledge, motivation and behavioural 
skills were three main determinants of the IMB model and formed the theoretical 
assumption of IMBDSME intervention. However, they were not equally delivered to 
all participants in this trial and participants in the IMBDSME group did not receive the 
same dose as it was an individualized DSME intervention.  
As mentioned in section (3.11), the delivery of the IMBDSME intervention started by 
handing the intervention booklet to all participants who were allocated to IMBDSME 
group without any exclusion as a result of randomisation. The booklet consisted of 
an educational toolkit (PRIDE) to provide the required knowledge to perform DSCB. 
More details on the process of adapting and translating (PRIDE) is mentioned in 
section (2.2.2). Theoretically, knowledge on DSCB were sent to all participants 
through (PRIDE) toolkit, nevertheless, this does not mean that knowledge on all DSCB 
were delivered to those participants. In fact, the spotted difference was in the 
frequency and length of the delivered interventional phone calls in the IMBDSME 
group due to different participants’ wishes and interests. During the interventional 
phone calls, Knowledge of PRIDE toolkit were discussed and delivered using MI and 
BAP to initiate a behavioural change. Therefore, as the proposed IMBDSME 
intervention was an individualized DSME, a deviation between the proposed dose of 
IMBDSME intervention and the actual implemented dose cannot be detected. 
Efforts were exercised to monitor the adherence to the IMBDSME intervention 
through weekly logs. Six participants completed their weekly logs and returned them 
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on three-month visit while others did not bring the logs either because they failed to 
recall completing them or they underestimated the importance of completing the 
logs and thought that performing DSCB is the ultimate goal of the intervention. The 
presence of one researcher who conducted the trial and delivered the intervention 
limited the ability to collect data from other resources such as clinicians or 
independent observers to monitor participants’ adherence to IMBDSME. 
5.1.3 Participants’ uptake of IMBDSME intervention: 
Data on the frequency of the interventional phone calls and their length for all 
participants in the IMBDSME group were collected and are presented in Table 58. 
Mean of frequency of delivered phone calls was 6.21 ± (1.74) calls while the average 
length for all interventional phone calls per participant was 74.0 ± (1.55) minutes and 
the average length of each phone call was 12.2 ± (1.82) minutes. 
Delivered dose of phone calls  Mean±(SD) Minimum Maximum 
Frequency 6.21 ± (1.74) 2 10 
Length of all calls (minutes) 74.0 ± (1.55) 29 108 
Average length of each call 12.2 ± (1.82) 8.4 16.7 
Table 58 Frequency and length of the delivered Interventional phone calls for IMBDSME group. 
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After data analysis, an inferential regression analysis conducted to investigate the 
correlation between the frequencies of interventional phone calls and mean score of 
performing DSCB. Receiving a frequency of five interventional phone calls was a 
statistically significant predictor to increase the mean score of DSCB by an estimated 
coefficient of 0.49 (95% CI, 0.04 to 0.94) where P value 0.032. Mean score of 
performing DSCB for those who received five interventional phone calls or more 
among IMBDSME group increased from 12.19 (95% CI, 11.6 to 12.8) at baseline to 
14.1 (95% CI, 13.6 to 14.7) at three-month visit. Statistically, those who received five 
phone call, or more were more likely to have an increase in mean score of choosing 
heathier diet by an estimated coefficient of 0.21 (95% CI, 0.001 to 0.439) where P 
value 0.049. Mean score of diet for those who received five interventional phone 
calls or more among IMBDSME group increased from 2.81 (95% CI, 2.5 to 3.1) at 
baseline to 3.55 (95% CI, 3.3 to 3.8) at three-month visit. On the other hands, neither 
length of calls nor the average length of a single call as independent variables was 
statistically significant correlated with any of the trial outcomes.  
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5.2 Mechanism of impact: 
IMBDSME intervention was an individualised tailored DSME and focused on patients’ 
needs and concerns. Globally, there is a collective lack of agreement on the definition 
of patient-centred care and its intended outcomes; for example, patients’ 
satisfaction (Mead and Bower, 2000). Generally, although patient-centred 
interventions such as IMBDSME were consistently correlated with enhanced 
patients’ satisfaction, it did not clarify the mechanism of impact of an intervention 
and how it influenced behaviour change.(Shrivastava et al., 2013 , Al Shahrani and 
Baraja, 2014). Therefore, moving beyond measuring satisfaction, in particular, how 
participants in the IMBDSME group accepted and interacted with the received dose 
of IMBDSME intervention can elucidate the IMBDSME mechanism of impact (Moore 
et al., 2015). Acceptability measurement needs to cover all IMBDSME dimensions 
including the approach of delivery. Thus, researcher designed an acceptability 
questionnaire to examine participants’ reactions toward IMBDSME intervention to 
all participants in the IMBDSME group.  
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5.2.1 Acceptability and Treatment Satisfaction Questionnaires: 
Two questionnaires were administered to measure the acceptability and the degree 
of satisfaction on the delivered intervention among all participants in the 
intervention group; the self-developed acceptability questionnaire and the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ). As mentioned in section (3.10), 
independent assessors collected the trial outcomes as well as participants’ responses 
of acceptability and satisfaction measurements of IMBDSME after completing the 
delivery of intervention at three-month visit. DTSQ was used to measure satisfaction 
with treatment for participants in both IMBDSME and TAU groups at baseline and 3-
month visit, while the self-developed acceptability questionnaire was used only in 3-
month visit. Table 59 demonstrates when each questionnaire was used. 
Table 59 Timeline of Acceptability and satisfaction questionnaires within the trial. 
  












DTSQS X       
DTSQC    X    
Intervention Acceptability 
Questionnaires*¥2 
   X    
Process Evaluation 
Interviews 
   X    
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5.2.1.1 The Diabetes Treatment Satisfaction Questionnaire (DTSQ): 
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was firstly developed to 
measure the satisfaction of patients with DM with the treatment regimens in the 
clinics. The originally-developed questionnaire by Bradley (1994) is now referred as 
the status version DTSQs in order to differentiate it from the recently developed  
DTSQc “the change version”. DTSQs is commonly used to measure satisfaction of 
patients with T2DM at baseline, while DTSQc was used to measure the change in the 
level of satisfaction at the follow-up visit from baseline. It has been developed to 
overcome the potential ceiling effects when respondents choose the maximum level 
of satisfaction at baseline, and is more relevant for trials that including an 
intervention (Bradley, 1994). Nowadays, it is widely used in clinical trials and has 
been recommended by WHO and IDF for the routine clinical monitoring and 
assessing diabetes care outcomes. It has been shown to be useful in trials that 
examined new treatments such as insulin pump and diabetes education programs 
(Lewis, 1994 , Bradley et al., 1992). Lastly, DTSQ is an assessment tool of eight items. 
Each item of DTSQs was scored on a scale from six to zero, while DTSQc items were 
scored from -3 to 3. The total score was calculated by summing six items (one, four, 
five, six, seven and eight) to produce the overall satisfaction on the treatment. For 
DTSQs, it ranged from a low score of zero to a high score of 36, while on DTSQc total 
score ranged from a minimum of -18 to a maximum of 18. Items two and three were 
asking about the perceived frequency of hyperglycaemia and hypoglycaemia 
respectively and were treated as separate units in data analysis in both DTSQs and 
DTSQc. 
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5.2.1.2 The acceptability questionnaire:  
The acceptability questionnaire was a multidimensional and purposely-modified 
instrument of the one developed by Long et al. (2005). Their instrument used to 
measure the acceptability and explore patients’ view on the telephone care centre 
support that has been delivered to patients with T2DM to improve their glucose level. 
Their intervention was delivered in the Pro-Active Call-Centre Treatment Support 
(PACCTS) randomized controlled trial where they recruited patients from 47 general 
practices in England (Young et al., 2005). Hence, researcher chose their instrument 
due to utilising a similar approach in this clinical trial where the IMBDSME was mainly 
delivered over interventional phone calls.  
The developed questionnaire consisted of 26 items asking the IMBDSME group 
participants about different aspects of the delivered IMBDSME over phone calls. Each 
item scored on a five-points scale where five points indicated that participant 
strongly agreed, and one-point score indicated that they strongly disagreed with the 
provided statement. Participants have had the opportunity to choose neutral that 
scored three points if they neither agreed nor disagreed with the statement.  
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5.2.2 Analysis and Results of Acceptability and DTSQ Data: 
The utilised data in this chapter are purely quantitative. The collected data were 
handled and analysed using the same approach that was used with the trial outcomes 
by STATA. However, the responses of the acceptability of IMBDSME intervention 
were not imputed and was handled per protocol. This was because they were 
collected only from the participants who received the intervention regardless of the 
received dose. Data handling and analysis are mentioned in sections 3.14 and 3.15. 
5.2.2.1 The Diabetes Treatment Satisfaction Questionnaire (DTSQ): 
As explained in section (5.2.1.1), patients’ satisfaction of the received treatment was 
measured using the status version at baseline (DTSQs) and the change in the level of 
satisfaction was measured using the change version (DTSQc) at three-month visit. 
Nevertheless, researcher is presenting the level of satisfaction with treatment at 
three-month by summing the change score and the baseline status score for all 
participants. During analysis, DTSQs and DTSQc were each treated and presented as 
three sections; total of items (one, four, five, six, seven, and eight) and this measured 
the overall level of satisfaction with treatment, 2nd item measured the frequency of 
hyperglycaemia and 3rd item measured the frequency of hypoglycaemic episodes. 
All participants who were randomised (148) completed the DTSQ at baseline visit and 
response rate was 89.9% at three-month visit. Of all participants from both trial 
groups, 15 participants did not complete DTSQc; five participants in the TAU group 
and ten in the IMBDSME group. 
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As for the overall score of DTSQ, participants in the IMBDSME group reported higher 
mean score 36.2 ± (7.06) than baseline scores 24.7 ± (6.08) compared to participants 
in the TAU group who had a mean score of 33.4 ± (7.01) at three-month visit and 25.0 
± (6.3) at baseline. Although participants in IMBDSME group had lower mean score 
than TAU group by -0.38 (95% CI, -2.33 – 1.57) at baseline, the difference between 
both groups at baseline was non-statistically significant (P=0.7), while it changed to 
become statistically significant (P=0.02) after delivering the IMBDSME intervention 
at three-month visit and was 2.85 (95% CI, 0.41 – 5.28). All details are presented in 
Table 60 and Figure 24. 
 
Figure 24 Mean score of DTSQ status for both trial groups at baseline and three-month. 
For the 2nd item, participants had nearly same mean score in both trial groups where 
there was non-statistically significant difference at baseline and three-month visits 
because P value was more than 0.05. Participants in TAU group and IMBDSME group 
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had mean score of 4.23 ± (1.59) and 4.24 ± (1.49) respectively at baseline and the 
difference was minor and was -0.02 (95% CI, -0.50 – 0.47). Similarly, at three-month 
visit, participants in TAU group and IMBDSME group had mean score of 5.56 ± (1.73) 
and 5.55 ± (1.98) respectively and the difference was parallel to the baseline and was 
-0.02 (95% CI, -0.63 – 0.59). It can be seen there was an increase in the mean score 
at three-month from the baseline for both trial groups, however, it cannot be 
rationalized as an effect of the IMBDSME intervention. 
For the 3rd item, although participants in the IMBDSME group had higher mean score 
of 1.87 ± (1.64) than participants in the TAU group who had mean score of 1.57 ± 
(1.37) at baseline, the difference was non-statistically significant and was 0.20 (95% 
CI, -0.29 – 0.70). However, it is clear that participants in both groups had higher mean 
score at three-month. Of those who received the IMBDSME group, their mean score 
was 3.18 ± (1.86) and was higher than participants who did not receive the IMBDSME 
intervention (TAU) group who had 3.10 ± (1.86) at three-month visit. The difference 
was -0.08 (95% CI, -0.69 – 0.53) between trial groups but was non-statistically 
significant due to be P=0.80. 
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Mean score of all 
 sections of DTSQ 
DTSQ overall score 
Mean±(SD) 
DTSQ score 2nd item 
Mean±(SD) 
DTSQ score 3rd item 
Mean±(SD) 
TAU IMBDSME TAU IMBDSME TAU IMBDSME 
Baseline 25.0 ± (6.3) 24.7 ± (6.08) 4.23 ± (1.59) 4.24 ± (1.49) 1.57 ± (1.37) 1.87 ± (1.64) 
Difference (95% CI) 
and P value 
-0.38 (95% CI, -2.33 – 1.57), P=0.70 -0.02 (95% CI, -0.50 – 0.47), P=0.94 0.20 (95% CI, -0.29 – 0.70), P=0.42 
Three-month 33.4 ± (7.01) 36.2 ± (7.06) 5.56 ± (1.73) 5.55 ± (1.98) 3.18 ± (1.86) 3.10 ± (1.86) 
Difference (95% CI) 
and P value 
2.85 (95% CI, 0.41 – 5.28), P=0.02 -0.02 (95% CI, -0.63 – 0.59), P=0.95 -0.08 (95% CI, -0.69 – 0.53), P=0.80 
Table 60 Mean score of all sections of DTSQ for both Trial groups at baseline and three-month visit 
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5.2.2.1.1 Modelling GEE for DTSQ: 
In order to calculate the effect size of IMBDSME intervention on the level of 
treatment satisfaction, Generalised Estimating Equation (GEE) was applied to analyse 
the DTSQ data. Researcher conducted GEE approach only to the DTSQ overall score 
due to the presence of statistically significant difference between trial groups at 
three-month visit. As explained above about the utilisation of GEE approach, 
researcher applied model one and two within GEE to calculate the estimated 
coefficients for DTSQ score before and after adjusting the baseline score. 
As presented below, participants in the IMBDSME group had a higher mean score of 
11.35 (95% CI, 10.54 to 12.15) than mean score of 7.6 (95% CI, 6.55 to 8.63) for 
participants in the TAU group at three-month visit in model one before adjustment 
for the baseline score, whereas after the adjustment, the net increase in the mean 
score of DTSQ for participants in the IMBDSME group was 3.76 (95% CI, 2.44 to 5.07) 





 TAU  IMBDSME  
Model Coef (95% CI) P- 
value 
Coef (95% CI) P- value 
3-month 1 7.6 (6.55 to 8.63) 0.001 11.35 (10.54 to 12.15) 0.001 
 2   3.76 (2.44 to 5.07) 0.001 
Table 61 Coefficients of DTSQ overall score for all participants in both Trial Groups and their CI (Confidence Interval) 
Model 1 is unadjusted to the baseline                                                                                                                                           
Model 2 Adjusted to the baseline. 
256 
PhD Thesis September 2020 Student ID 4220143 
 
5.2.2.2 The acceptability questionnaire: 
Sixty-nine participants responded to the acceptability questionnaire and response 
rate was 89.6%. Those who did not complete the acceptability questionnaire were 
eight participants and they did not attend their three-month visit and could not be 
reached by phone by the independent assessors. 
At three-month visit, “Appropriate call timing for me” and “It was useful to complete 
weekly logs” items were either agreed or strongly agreed by around 76% of 
participants who responded to the acceptability questionnaire. In detail, 16% were 
neutral and 8% disagree or strongly disagree that interventional phone calls timing 
was appropriate for them. However, 17% disagree or strongly disagree that weekly 
logs were useful for them and 6% were neutral. 
Items where participants chose neutral by 12% and 7% were “Staff knowledgeable 
about diabetes” and “I recommend it to my colleagues” respectively. Moreover, 6% 
disagreed to recommend IMBDSME intervention to their colleagues. However, other 
items of acceptability questionnaire (22 items) were rated by choosing strongly 
agreed or agreed by all participants. Cronbach Alpha was calculated using STATA and 
was 0.49 for the 26 items combined. All proportions of participants who chose the 
rating are presented in below. 
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Aspect (n=69) Strongly 
Agree (%) 
Agree (%) Neutral (%) Disagree (%) Strongly 
disagree (%) 
Friendly and helpful 65 35    
Appropriate call timing for me  44 32 16 7 1 
Staff knowledgeable about diabetes 49 39 12   
Staff provide me with useful advice 52 48    
Happy to speak with the same staff regularly 54 46    
Like telephone contact for specialist advice  55 45    
Amount of time on phone acceptable 61 39    
It was useful to complete weekly logs 36 41 6 13 4 
Happy with the care received 54 46    
Easy to understand advice 55 45    
The advice given was relevant to me 48 52    
Sufficient time to ask questions and seek advice 46 54    
Talk about relevant things to me  55 45    
Acceptable to receive phone advice 54 46    
Staff on phone enhanced my confidence  56 44    
Feel much better after receiving the advice by call  58 42    
I recommend it to my colleagues 46 41 7 6  
Feel more knowledgeable about my diabetes now 55 45    
Have taken the advice on board 55 45    
Feel more in control of my diabetes  64 35  1  
Prefer to see health professional 49 51    
Increased my awareness 56 44    
3 months long enough to make a behaviour change 58 42    
It should be applied in the hospital  61 39    
Number of phone calls was acceptable 56 44    
Having choice over the phone calls frequency was important 56 44    
Table 62 Proportions of participants who rated the acceptability items at three-month visit. 
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5.3 Conclusion: 
To conduct process evaluation in this trial, researcher collected quantitative to 
provide an insight on how participants interacted with IMBDSME intervention and 
made an impact. However, only quantitative data were presented that were related 
to the process of implementation and mechanism of impact of IMBDSME 
intervention. 
The Oxford Implementation Index (OII) was used to report the aspect of 
implementation of process evaluation. It included reporting the IMBDSME design, 
delivery and participants’ uptake. Results revealed that participants who received 
five interventional phone calls or more had a statistically significant rise in their DSCB 
mean score and their healthier diet score at three-month visit from the baseline. 
Satisfaction with treatment and acceptability questionnaires were used to examine 
participants’ reactions toward IMBDSME intervention in order to get more vision on 
the mechanism of impact aspect of process evaluation. From the results after the 
adjustment of baseline scores for both trial groups, mean score of the overall level 
of satisfaction with the treatment (DTSQ) was statistically significant higher by a clear 
of 3.76 (95% CI, 2.44 to 5.07) for participants who were allocated to the IMBDSME 
group than participants in the TAU group. By the same token, almost 90% of 
participants in the IMBDSME group responded to the acceptability self-developed 
questionnaire where they agreed or strongly agreed that IMBDSME intervention was 
acceptable on 22 items that were related to either the intervention design or the 
delivery.  
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6 Discussion: 
In this chapter, the reader is given an insight to a critical discussion based on the trial 
results. Across scientific studies, different approaches are followed in writing the 
discussion section where writer is meant to delve into the meaning, explain the 
findings and how it relates to the wide literature. To enhance the quality and 
transparency of reporting, CONSORT statement were followed as was reported 
earlier in (3.2.3). In their guidelines, Moher et al. (2012) supported Horton (1995) 
who criticised authors for their use of rhetorkkkic more often to support their trials 
results to be “saleable” in the discussion section. Instead, they recommended to 
create a gracious argument of pros and cons of the trial and its results. They 
suggested to follow a structured discussion to draw a justified conclusion. Their 
proposed structure to discuss trial results was an appropriated example from the 
Annals of Internal Medicine journal and is briefed in Table 63. Their proposed 
structure did not include a section on the strengths side of the trial. However, similar 
structure is followed here with the addition of the trial strengths along with the 
limitations in regard to the trial design. Then trial results are interpreted within the 
IMB model context and were compared with other results in literature before 
explaining the trial implication on research and clinical settings in the conclusion. 
Suggested structure for discussion from CONSORT statement 
• A brief summary of the key results. 
• Suggesting potential mechanisms and justifications. 
• Weaknesses of the current study and what methods used to decrease them. 
• Differences with relevant findings from other studies in literature  
• A summary on the clinical and research implications of the trial in the 
conclusion. 
Table 63 Structure for Discussion section adopted from the Annals of Internal Medicine journal  
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6.1 Principal results of the trial: 
To our knowledge, this is the first randomised clinical trial that aimed to examine the 
effectiveness of delivering an IMB model-based educational intervention (IMBDSME) 
and assess outcomes at three-month and six-month time points. Briefly, principal 
results of the effectiveness of IMBDSME on primary and secondary outcomes are 
presented in the following sections. 
6.1.1 Effectiveness on Primary outcomes: 
Primary outcomes were the changes in diet, physical activity, and medications 
management self-care behaviours. In comparison to participants in TAU group, 
analysis revealed that participants in IMBDSME group had statistically significant 
higher scores in diet and medications management self-care behaviours at three-
month and six-month visits than baseline scores after adjusting for all covariates. In 
addition, they had higher scores for physical activities self-care behaviour at both 
visits than baseline score, but the changes were not statistically significant. The three 
self-care behaviours were summed after weighting adjustments to create a total 
score for performing Diabetes Self-Care Behaviours (DSCBs) as mentioned in (3.13.2). 
Those who were in IMBDSME group had statistically significant higher scores at 
three-month and six-month visits than baseline score in comparison to participants 
in TAU group for all DSCBs. 
6.1.2 Effectiveness on secondary outcomes: 
Secondary outcomes were the changes in levels of knowledge, motivation, self-
efficacy of diabetes self-care behaviours, glycaemic levels (HbA1c) and quality of life. 
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Overall, participants who received IMBDSME intervention had statistically significant 
higher scores in knowledge, motivation and self-efficacy determinants than baseline 
scores in comparison to participants in TAU group at three-month and six-month 
visits after adjusting for all covariates. In addition, the reductions in HbA1c for 
participants in IMBDSME group were greater in comparison to participants in TAU 
group than baseline values at three-month visit but was not statistically significant. 
Whilst at six-month visit, participants in TAU group had greater reduction in HbA1c 
than baseline values in comparison to participants in IMBDSME group and the 
reduction was statistically significant. Further analysis to investigate the effect of 
different treatment regimens in trial sites on HbA1c reductions for all participants in 
both trial groups revealed that the reduction in HbA1c values for those who attended 
JUH was greater than of that for those who attended PHH at three-month and six-
month visits after adjusting for all covariates. The reduction in HbA1c values was only 
statistically significant at three-month visit for participants in IMBDSME group who 
were attending JUH site.  
For diabetes-related quality of life, participants in both trial groups responded to 
ADDQOL questionnaire, which consisted of three parts as it was explained in 
(3.13.3.5). Participants in IMBDSME group had higher scores than baseline scores in 
comparison to participants in TAU group at all parts of ADDQOL questionnaire at 
three-month and six-month visits after adjusting for all covariates.  
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6.2 Strength and weakness of the trial: 
Strengths and weaknesses characteristics of the trial are discussed in the following 
sections in relation to multiple aspects such as trial design, recruitment and 
randomisation. Sections are provided with arguments over the advantages and 
disadvantages of the trial design, challenges during the recruitment process and how 
they could have been addressed, and safeguarding randomisation procedure as well 
as comparing the figures here with international published figures. 
6.2.1 Trial design: 
As was well-explained why RCT experiment design was chosen in section (3.2.2). It 
was reported that it was used to examine the effectiveness of IMBDSME intervention 
on performing DSCB as It is considered the gold standard of evidence in clinical 
research. It was hypothesised that participants who received IMBDSME intervention 
should have performed DSCB more frequent than participants who only received the 
usual treatment. However, Polit (2008) and Privitera (2017) agreed that on the fact 
that high valued RCT must include three essential and fundamental characteristics to 
conclude whether to accept or reject the research hypothesis; random sampling, 
manipulation and control. These three characteristics were utilized in this trial as was 
described in detail in chapter 3. Briefly, in this trial, high level of control was exerted 
to control who were eligible to be recruited and to be allocated randomly within trial 
groups to reduce systematic bias. This resulted in two comparable groups as all 
measured confounders did not statistically significant vary at baseline. Subsequently, 
a group received the IMBDSME intervention as an addition to the usual treatment 
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(Intervention group), and the other received the usual treatment only (control 
group).  
During planning stage, several measures were considered to increase the internal 
validity of the trial. These measures were important elements to the success of this 
trial and were highly effective as evidenced by the improvements in primary 
outcomes for those who received the IMBDSME intervention and had positive 
consequences on their quality of life and HbA1c. One of these measures is the 
adoption of wide inclusion criteria and minimise the exclusion criteria. It was 
suggested that 68.4% of patients with T2DM could be eligible when applying the 
criteria. Thus, it was broad to cover around two third of all patients who were 
diagnosed with T2DM. The criteria were carefully developed to reflect the real clinical 
practice. It aimed to recruit a representative sample of the population to minimize 
the threats to external validity of the trial. More about eligibility and exclusion 
criteria are described in (3.2.4). While the trial design met the three essential 
characteristics for high-quality RCT additionally with the discussed measures above, 
this trial can be seen as high valued RCT. However, some threats that might have 
affected the quality of this trial can be spotted and are presented in the following 
discussion. 
To begin, as it was shown above in trial design, two groups were used to examine the 
effectiveness of IMBDSME intervention where all participants in both groups 
received the Treatment As Usual (TAU), and it can be seen that participants in one of 
the groups received the IMBDSME intervention as an addition while participants in 
the other group received nothing extra. This description is not far from the  Freedland 
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et al. (2011) description for behavioural intervention trials. They claimed that most 
trials that examined the superiority of an intervention by comparing them to 
standard or usual care group deserve careful scrutiny because they do not eliminate 
differential attention as threats to internal validity. They elaborated on this point by 
stating that those in TAU group were contacted and followed up by the trialist, thus, 
received more attention that could expose them to some sort of clinical experience 
and was in reality TAU additionally with more attention. Or from another angle, it 
can be claimed that participants in IMBDSME group who received more care should 
simply have better outcomes because they received an extra attention and not 
because it was an IMB model based DSME. This claim can be raised for any RCT that 
use two arms where one of which is control group. They suggested that three-arm 
trials can help to eliminate the effect of the attention. However, a multiple arms RCT 
was proposed to address this claim in the early stage of this trial because It has the 
power to provide more specific information about the effectiveness of a new 
intervention and compare it with other current intervention as well as the TAU group 
and can refute the latter claim (Baron et al., 2013). However, design and data analysis 
of multiple arms RCT are more complicated due to the numbers of potential 
comparisons between groups and sample size calculations. Therefore, the idea of 
conducting multiple groups RCT was inconceivable within the timeline. 
Another point for discussion regarding the trial design is the fact that this trial was 
an individualised RCT while MRC framework state that individualised RCTs are not 
appropriate if the intervention is directed to be applied in a practice or organizational 
level. Therefore, they recommended that the clustered designs are particularly 
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suitable to evaluate those interventions. They added that cluster design increases 
the feasibility of conducting a true experiment and reduces the chance of exchanging 
information between participants from both trial groups due to the nature of the 
clustered design where the trial sites are randomly allocated to any of the trial arms. 
However, a cluster randomised design was not appropriate because of two reasons. 
First, the nature of the intervention required an individualised design because 
IMBDSME intervention was an individualised DSME. Second, each trial site has 
different treatment regimen and different sponsor. Consequently, this may serve 
different populations who may differ in their personal characteristics that may end 
up with a group imbalance and bias leading to an incomparable trials’ groups. Even 
though matching strategy may help to deal with group imbalance, it has its own 
limitation because we cannot identify all confounding factors before conducting the 
trial; thus, a remaining imbalance continues to be existed. Moreover, sharing and 
exchanging information between participants is inevitable in clinical research but it 
is more likely to occur in individualised designs. Clustered randomised trials require 
higher level of power, larger sample size, higher costs and complexity during analysis 
stage and these requirements cannot be afforded within PhD degree. Nevertheless, 
the individualised design is similar to other trials that examined the effectiveness of 
DSME in the literature and this is vital because it allows others to combine results 
from other trials for systematic reviews and meta-analyses purposes. Moreover, 
Torgerson (2001) recommended that clustered design should not be used unless 
there is a significant reason to adopt it. All in all, and by referring back to the research 
question of interest and the scope of this research in section (1.7.8), and following a 
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critically thinking process during the planning stage about several methods of 
randomization and control measures of trials, it was concluded that this trial had to 
be an individualized randomized controlled trial with parallel random allocation of 
participants to Treatment-As-Usual (TAU) and intervention group IMBDSME on 1:1 
basis. 
Another point to be mentioned that following MRC framework expansively in 
developing and evaluating IMBDSME intervention requires several studies, research 
team and adequate fund which is not feasible within PhD program. Nevertheless, all 
relevant MRC framework phases were conducted to answer the research question. 
6.2.2 Randomisation: 
Another measure is the randomisation procedure where an online randomisation 
software was used to allocate the recruited participants. At the point of recruitment, 
nobody was aware of the allocation until the participants’ sequence number was 
entered on the software to reveal that participants’ allocation. The software followed 
the order of a sequentially numbered list that was developed by an independent 
researcher and consisted of simple randomised blocks that were stratified according 
to the trial site. As was explained in (4.2.2), participants’ allocation was compared 
with the uploaded randomisation list after the trial and were identical. What is more, 
significance statistical tests were utilised to compare baseline characteristics and 
comorbidities between trial groups, and the results showed that there were no 
significant relationships between IMBDSME group and TAU group at baseline. 
Although Altman (1985) stressed that using significance tests to compare baseline 
characteristics to assess that the probability of the variation in baseline between trial 
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groups is illogic. His claim was based on the actual fact behind conducting 
randomisation where it guarantees a variation to a highly extent in baseline since it 
necessarily occurred due to chance rather than bias. Despite this fact about 
randomisation, baseline data were compared using significance statistical tests due 
to the presence of a threat that may weaken this RCT. This threat is the non-
concealment of participants’ allocation in trial groups from people who operated the 
trial, which is known as blinding. As a result of the statistically non-significant findings 
at baseline, researcher concluded that trial groups were homogenous and 
comparable at the point of recruitment. Therefore, it can also be concluded that 
randomisation procedure was safeguarded. 
The threat of non-concealment of participants’ allocation could not be avoided in this 
trial because this was conducted solely by the student who randomised, delivered 
the IMBDSME intervention and analysed the collected data. Participants’ allocation 
was known for him and could not be concealed. Although participants were 
randomised to trial groups, randomisation procedure does not guarantee to 
neutralize any differential assessment of trial outcomes. Therefore, two independent 
assessors were asked to collect trial outcomes who agreed and participated 
voluntarily. Although their involvement increased the likelihood of eliminating any 
biased estimates of treatment effects between trial groups, data analysis of the trial 
outcomes was done by the same student. Theoretically, it means that the estimated 
treatment effects could be biased due to fact of having access to trial outcomes 
during analysis. 
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6.2.3 Sample size: 
Adding to the previous measures is the values that were involved in calculating the 
trial sample size. Alpha level of 0.05 and a power of 80% consider as ideal for most 
trials (Suresh and Chandrashekara, 2012). Those were used to calculate a sample size 
to detect a small difference of effect size between trial groups on the primary 
outcomes to avoid falling into Type II or β error. The calculated sample size was 200 
and was not accomplished during the period of recruitment. One of the major 
reasons was for the fact of being tied in a recruitment interview. The engagement in 
a recruitment interview with a consented participant prevented from accessing other 
eligible potential participants who left the trial site without invitation. As can be seen, 
recruiting the required sample size was more difficult than expected and reaching 
the planned sample size failed within the envisaged timescale of the trial. Therefore, 
the trial was underpowered. 
More than the required sample size could have been achieved (317 participants) in 
this trial based on simple calculation. Referring back to the recruitments’ statistics in 
Table 7, if we assume that another independent researcher invited those who were 
unapproachable (215) at that time and assume that same proportion of whom 
consented in this trial (80.8%) applies, we would have recruuited (215*80.8%= 173) 
more participants. Thus, the total number of recruited participants could have 
changed to be 324 (173+151) at baseline. Likewise, if we assume that 2% of those 
173 chose to withdraw at baseline (173*2%= 4) the number of those who could have 
been randomised to trial groups is (173-4=169) added to those who were randomised 
148, the total would be 317 participants. Their baseline data could have been 
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collected over phone calls prior randomisation if it was not possible to be collected 
in trial site. 
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6.2.4 Recruitment: 
According to patients’ screening statistics, results showed that 85.6% of the screened 
patients were not eligible to be invited to participate in this trial. In fact, this high 
percentage appears to contradict the suggested proportion of (68.4%) of patients 
with T2DM whom were predicted to be eligible for invitation in section (3.2.4). This 
incongruity between proportions occurred because the suggested proportion was 
estimated from a dataset that was collected in 2012 in the National Centre for 
Diabetes where all attendees were diagnosed with T2DM. The initial plan for this trial 
was to be conducted at the national centre for diabetes but due to the high number 
of clinical studies there, research team had to choose outpatient’s clinics at other 
two hospitals as mentioned in (3.9.2). In both trial sites, a considerable proportion of 
attendees have had a broad range of disorders and chronic conditions, for example, 
heart failure, renal diseases or haematological disorders. Endocrinology outpatients’ 
clinics in JUH focus on endocrinology-related disorders where diabetes is the core of 
their competency, while outpatients’ clinics in PHH are not specialised clinics and 
they receive patients with different chronic conditions without focusing on a 
particular disorder such as diabetes. If any of those patients in PHH required further 
consultation on their diabetes condition, they normally would be referred to an 
endocrinologist which is lengthy process and can take months. This might explain the 
lower rate of attendance within PHH outpatients’ clinics (29%) of those who were 
screened as it seems not preferable because it is not speciality-focused in contrast to 
JUH outpatients’ clinics which were attended by large proportion (71%) of those who 
were screened. On the other side, lower rate of attendance facilitated approaching 
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and inviting more eligible patients with T2DM in PHH in comparison to JUH relatively. 
This can be seen by the percentage of those who were approached out of those who 
were eligible in PHH (60 participants invited /114 eligible participants =53%) 
compared to the percentage in JUH (127 participants invited /288 eligible 
participants = 44.1%) in Table 7. Being tied up with a participant during recruitment 
interview where they completed baseline data had a detrimental effect in both trial 
sites on recruitment rate because it prevented from accessing other eligible patients 
who used to leave the clinic once they finish their consultation to queue up in 
pharmacy. Subsequently, higher number of eligible participants were not invited in 
JUH compared to PHH. All the aforementioned factors were critical in the 
recruitment process and limited the ability to recruit the required sample size of 200 
participants within three months. 
As mentioned previously, recruitment rate was (80.8%) where (151) participants 
consented and were recruited out of those who were approached and eligible 187 
from both trial sites. However, 200 participants were required according to the 
sample size calculation and 76% of the original sample size was achieved (151) 
participants. Failing to meet the original sample size is a frequent problem in many 
trials as was described by Walters et al. (2017) following the results of their review. 
They conducted a comprehensive review of the consent and recruitment of 151 
publicly funded RCTs in UK and published by the UK NIHR from 2004 to the end of 
2016. The majority of the reviewed trials were two-armed, parallel groups and 
multicentre trials and reported that 79% of the reviewed studies recruited around 
80% of their original sample size and 56% achieved their final target sample size. They 
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added that a median of 70% (IQR 51%–87%) of eligible patients consented and were 
randomised. Apart from the achieved proportion of 76% of the required sample size 
in this trial, recruitment’s statistics were slightly better than the published figures 
above where 80.8% of those who were invited consented and recruited and 79.7% 
were randomised. 
6.2.4.1 Discussing risk: 
A potential problem with recruitment is that participants who were allocated to 
intervention group have been invited for the fact they had an uncontrolled glycaemic 
level (HbA1c >8%) where some of them have not approached that level before. It was 
crucial to relief their potential anxiety and not to endanger any fears from the high 
glucose level and its related complications by simplifying the language of 
communication. It has been stressed on the PIS about the medications side effects 
such as hypoglycaemia and the importance of managing glucose level to avoid them. 
During the recruitment interview, researcher has handled the risk of having an 
uncontrolled glycaemic level by stressing on the high possibility of reversing the surge 
of glucose level and its complications such as neuropathic pain, rather than conveying 
a message of threat of having an uncontrolled diabetes. In fact, many patients were 
aware of the risk of uncontrolled diabetes and its complications from other relatives 
or friends’ earlier experiences. Researcher has found that using a positive approach 
is very helpful to facilitate the enrolment into DSME programmes, for example, 
emphasizing on the benefits of being physically active on general well-being, rather 
than focusing on diabetes complications such as blinding or haemodialysis that may 
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alienate them from enrolment during recruitment interviews (Gillies and Entwistle, 
2012). 
Some of the eligible patients who did not meet the inclusion criteria or have been 
allocated to control group were asking for an advice on managing glycaemic level and 
obesity during the recruitment interview. They were given a simple superficial 
guidance related to maintaining activity and healthy food choices and were referred 
to their physician if they were concerned about their medications or health status. 
6.2.5 Retention rate: 
As is the case with most trials, sample size decreases during follow up due to 
dropouts. Those who were lost to follow up were ten participants and the reasons 
for dropouts were mentioned in (4.1) and the sample size calculation to determine 
how many participants needed to be recruited is explained in (3.2.3.1.2). Those ten 
participants represented for an attrition rate of 6.6% from those who had valid 
primary outcomes data for analysis. This proportion was less by almost one third of 
the proportion that was used during sample size calculation which was 15%. In other 
words, retention rate was 93.4% and valid primary outcomes data were available 
from 141 participants at six-month endpoint. This rate was higher than the reported 
median retention rate of 89% (IQR 79–97%) by Walters et al. (2017) in literature. 
Their results were published after reviewing the retention rate of 151 publicly funded 
RCTs in UK and published by the UK NIHR from 2004 to the end of 2016. They noted 
that recruitment success is improving slightly within RCTs compared with previous 
figures on recruitment covering the period 1994-2002 that were published by 
McDonald et al. (2006). Although this trial was not funded, it proves once again that 
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the considered measures during planning stage including the recruitment criteria had 
successful consequences on the trial results. 
Another arrangement that enhanced the retention rate in this trial is the timepoints 
of data collection. Primary and secondary outcomes were measured at baseline, 
three-month visit and six-month visit to detect the changes in questionnaires’ scores 
overtime. Three months interval between visits was the most common interval for 
attending follow ups and to renew their medications’ prescription for patients with 
T2DM. This arrangement facilitated meeting them to collect their responses on the 
trial outcomes in both trial sites to increase participants retention. Their biomedical 
results were collected whenever possible during data collection stage from electronic 
records. 
One more procedure that took place to enhance attendance and showing up for 
collecting outcomes was the appointments reminders. Participants were reminded 
in both groups about their prospective treatment appointments on phone calls to 
confirm there was no change on the second and third appointments. Whenever any 
change had occurred, it was updated on the participants’ CRF and the research diary 
with their new appointment to follow them up. In addition, participants had the 
flexibility to schedule their interventional phone calls based on their preferences. All 
efforts were made to ensure that participants were engaged with the IMBDSME 
intervention by stressing the importance of performing DSCA to improve their 
glycaemic level. It was proposed to tackle any reason that could undermine 
participants’ adherence to the IMBDSME intervention unless it contradicts with the 
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6.2.6 Trial measures: 
In order to produce valid results, it is essential to use reliable and valid measurements 
tools in RCTs when assessing baseline and trial outcomes. Although the used 
measures were validated and known to be reliable in previous studies as mentioned 
in (3.13.2) and (3.13.3), response bias exists wherever self-reported measures are 
used especially when double blinded practice cannot be exercised as is the case in 
this trial and all human behaviours RCTs. It can be seen from the preceding section 
(3.13) that the used measurements were all self-reported measures except for the 
HbA1c blood test, the results were supplied by the hospitals laboratories. It 
introduces further threat to the internal validity of any RCT due to the effect they can 
prompt on participants’ responses such as Hawthorne effect or measurement 
reactivity. Hawthorne effect can be described as the possibility of affecting trial 
results or participants’ behaviour as a consequence of being observed (Capellan et 
al., 2017). Another special case of Hawthorne effect is the measurement reactivity 
that focuses on the processes by which administering measurements repeatedly is 
leading to the improvements in the participants’ behaviour being measured (French 
and Sutton, 2010). To illustrate, the measurements or trial instruments may 
enlighten the trial participants of the targeted self-care behaviours, which in turn 
have an impact on the trial outcomes. Both, Hawthorne effect and measurement 
reactivity, might have been introduced in this trial as a result of using self-reported 
measurements. Holden (2001) claimed that this can create doubts as to whether or 
not the improvements in trial outcomes were solely due to delivering the 
intervention for those in the IMBDSME group. On the other hand, it may explain any 
277 
PhD Thesis September 2020 Student ID 4220143 
 
improvements in practising self-care behaviours among those in the TAU group, 
consequently, improvements in their HbA1c as we can notice in the results section 
(4.8.4.2). Elaboration on this point and additional discussion on trial results 
interpretation for IMBDSME and TAU groups are presented in the next section. 
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6.3 Interpretation of trial results: Strengths and weaknesses in relation to other 
studies, discussing particularly any differences in results 
In this trial, the behavioural change model (IMB) was used to design IMBDSME 
intervention and the delivery was designed based on its fundamental assumption. As 
mentioned in 2.1.2), authors of IMB model proposed that there are causal 
relationships between the primary determinants of any self-care behaviour; 
knowledge, motivation and behavioural skills, that can produce change in the level 
of practice of that behaviour. Here in this section, trial results are interpreted in light 
with the current literature to unfold how the utilisation of IMB model in designing 
the trial intervention (IMBDSME) affected the practice of the targeted DSCBs 
positively. Also, to attempt to explain the change in their practices among both 
IMBDSME group and TAU group with other trials that delivered behavioural change 
DSCB interventions in the literature. 
6.3.1 The utilisation of IMB model determinants: 
It was hypothesized that IMBDSME intervention can produce positive changes for 
those who received it in the performance of DSCBs (primary outcomes) at three-
month and six-month. The hypothesis was established because the delivered 
IMBDSME intervention aimed to improve the level of main determinants; diabetes 
knowledge, motivations, and behavioural skills’ self-efficacy, and sequentially, affect 
the performance of DSCBs, which would improve HbA1c level and quality of life. With 
respect to the trial’s results in (4.7) and (4.8), the statistically significant increase in 
the level of the three main determinants collectively for those in IMBDSME group has 
improved the primary outcomes, and as a result, improved quality of life and HbA1c 
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levels (secondary outcomes) at three-month and six-month from baseline. All 
outcomes for those in IMBDSME group were improved statistically significant except 
for HbA1c where it was only statistically significant at three-month for those who 
attended JUH. On the other hand, the change in the level of those determinants for 
those who did not receive the intervention in TAU group were not statistically 
significant at three-month and six-month from baseline and they changed slightly in 
the positive direction apart from the knowledge determinant that changed 
negatively at six-month. Consequently, the changes in primary and secondary 
outcomes for those participants were not statistically significant and were in various 
irrelevant orders either positive or negative changes at three-month and six-month 
from baseline. The surprising statistically significant improvement for those in TAU 
group was in medications management self-care behaviour at three-month. While as 
it looked as a spontaneous result of not receiving any intervention, both diet self-
care behaviour and quality of life level changed statistically significant adversely at 
six-month and three-month respectively for those at TAU group. 
From the perspective of linking the changes in DSCBs with the main determinants of 
IMB model, we can perceive that the magnitude and pattern of change at three-
month and six-month between trial groups could not be due to chance since the 
changes in the outcomes for IMBDSME group were statistically significant but were 
not the case in TAU group at both time points. The direct correlations between IMB 
determinants and trial outcomes were not measured cross-sectionally in this trial at 
any time points including baseline because it was irrelevant to the trial outcomes. 
However, although the differences at baseline between both groups were not 
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statistically significant in all variables, it was noticeable that those in TAU group had 
a slightly higher scores than those who were in IMBDSME group in the level of IMB 
determinants, primary outcomes except physical activity behaviour, quality of life, 
and HbA1c for those who attended JUH as presented in (4.4). Based on the account 
that all the recruited participants had different characteristics at baseline and were 
recruited from two settings each had a different treatment regimen, the only clear 
difference between both groups after three-month and six-month was that one 
received IMBDSME intervention and the other did not. All in all, this supports the 
claim that there is positive relationship between any self-care behaviours’ 
determinants and its level of performance, which was assumed by the developers of 
IMB model and was mentioned in (2.1.2) (Fisher and Fisher, 1993). Accordingly, it can 
be concluded that IMBDSME intervention made an improvement in the level of 
practicing DSCBs for those in IMBDSME group more than those in TAU group. 
Although participants in TAU group did not receive extra knowledge, motivation, or 
skills on DSCBs, the changes in those determinants were positive, however, were not 
statistically significant. This trend might be related to other reasons such as 
Hawthorne effect or measurement reactivity that might act as a hint to seek for 
further knowledge and learn behavioural skills that are related to DSCBs.   
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6.3.1.1 Improvement in knowledge: 
As mentioned earlier, knowledge level improved statistically significant for those in 
IMBDSME group at three-month and six-month from baseline. The improvement was 
believed due to being exposed to the Arabic-version of the educational booklet 
(PRIDE) that was handed to all those in IMBDSME group and discussed over 
interventional phone calls. These improvements were on a par with those reported 
in several systematic reviews and meta-analyses in literature about the effectiveness 
of DSME (Ricci-Cabello et al., 2014 , Mohamed et al., 2019 , Norris et al., 2001 , Norris 
et al., 2002). Norris et al. (2001) reported in their systematic review that several 
DSME trials showed statistically significant improvements in knowledge on DSCBs for 
both intervention and TAU groups on the short term less than six months but not on 
long term six months or higher. They added, those who received regular 
reinforcement on DSCBs showed a sustainable high level of knowledge on DSCBs on 
long term parallel with the performance of those in IMBDSME group in this trial. 
Similarly, Osborn et al. (2010) delivered an IMB-model based DSME in a brief one 
session and those in the intervention group had a statistically significant 
improvement in knowledge level at three-month. No data were reported on six-
month time point because their trial stopped due to funding matters.  
It is evident from the results reported by Phillips et al. (2018) that DSME interventions 
increase knowledge level about managing diabetes. They studied the relationship 
between diabetes knowledge and glycaemic control using qualitative study design 
where they administered multiple-choice test during interviews to assess diabetes 
knowledge. Although the reported relationship was not statistically significant 
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because their study was exceptionally underpowered as it was part of qualitative 
study, participants who have never received any diabetes education scored lower 
than those who have had any education about diabetes on the diabetes knowledge 
test. 
Most studies justified the improvement in knowledge level among TAU group due to 
contamination factor that was explained in (6.2.1). Contamination was possible in 
this trial because participants of both trial groups were recruited from each trial site, 
as a matter of fact, blinding participants is deemed infeasible in behavioural and 
education trials (Page and Persch, 2013). On the other hand, participants in TAU 
groups were incapable to recall the correct answer or knowledge as it can be 
concluded from the statistically significant decrease in knowledge level at six-month. 
What is more, the decrease might be attributed to the diminished influence of the 
measurement reactivity factor, which was mentioned in (6.2.6), for those in TAU 
group during follow-up because knowledge about DSCBs in this trial were self-
reported on SKILLD measurement tool that was consisted of ten open-ended 
questions as presented in (3.13.3.1). This type of measurement tool that use open-
ended questions assesses participants’ comprehensive on specific subject differently 
than multiple-choice questions that are common in DSME and behavioural research 
especially when it comes to measure the level of knowledge of diabetes (Campbell, 
2000). Open ended questions provide limited information as retrieval prompts. The 
retrieval of the knowledge or information on DSCBs from memory in a prompts-recall 
task mainly relies on recollection processes (Graesser et al., 2010). In contrast with 
process of answering open-ended questions, the process of answering multiple-
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choice questions is endorsed to some extent by automatic retrieval or familiarity 
because the correct answer is presented within the choices that frequently lead to 
successful identification of the correct answer (Yonelinas, 2002). Accordingly, 
participants’ performance on diabetes knowledge measurement tools in other trials, 
in particular TAU group, might have been aided by the concept of perceived 
familiarity that apply to multiple-choice questions, thus, high influence of 
measurement reactivity factor. While in this trial, the utilisation of SKILLD required 
participants to actively use and search their memory, and if they did not know the 
correct answer they often were unsuccessful due to the lack of cues or prompts in 
those questions, thus, low influence of measurement reactivity factor (Ozuru et al., 
2013).  
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6.3.1.2 Improvement in motivations: 
Similar to knowledge level in this trial, motivation level improved statistically 
significant for those in IMBDSME group at three-month and six-month visits after 
receiving IMBDSME intervention. The improvement was believed due to using 
Motivational Interviewing (MI) approach that include Brief Action Planning (BAP) and 
was described in (2.2.2.2). Most studies in literature did not measure the change in 
the level of motivation before and after DSME, and instead focused on comparing 
the performance of DSCBs or the level of HbA1c between those who received DSME 
that included MI and those who received the routine care or what is called control 
group. However, in this trial the changes in motivations level were measured using 
self-reported instruments that measured both the participants’ personal and social 
motivations at baseline, three-month and six-month as was introduced at (3.13.3.2). 
In literature, Siminerio et al. (2005) and Atak et al. (2008) compared the motivation 
level before and after receiving DSME intervention for both control and intervention 
group using Diabetes Empowerment Scale (DES) that was used in this trial. In both 
studies, DES score increased after receiving the DSME intervention from baseline in 
comparison to those who were in control group, but the differences between both 
groups were not statistically significant in both studies. Siminerio et al. (2005) 
justified the nonsignificant improvement due to the limited power to detect a 
difference from baseline to the end-of-study results, while Atak et al. (2008) justified 
the limited improvement in DES due to the inadequate and short DSME intervention. 
In addition, both studies neither utilised MI approach nor focused to improve the 
psychological outcomes in their DSME interventions. While in this trial, the IMBDSME 
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intervention was delivered using MI approach and focused on psychological factors, 
which might justify the statistically significantly improvement in DES score for those 
in IMBDSME group at three-month and six-month from baseline. Moreover, as is the 
case with most self-reported measures, DES score improved slightly among those in 
TAU group at both time-points due to probably the same reasons that affected the 
other measurements such as Hawthorne effect or measurement reactivity. 
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6.3.1.3 Improvement in self-efficacy: 
As was mentioned earlier, behavioural skills’ self-efficacy scores improved 
statistically significant for those in IMBDSME group in comparison to those in TAU 
group at three-month and six-month from baseline. The improve among those in 
IMBDSME was strongly believed as a spontaneous consequence due to receive 
IMBDSME intervention; mainly, as an extent from the statistically significant 
improvement in knowledge and motivation levels. As was described through 
intervention mapping steps in (2.2.2), those who received IMBDSME intervention 
had the chance to choose to practice a specific self-care behaviour to start learning 
and discussing the related knowledge of that behaviour through MI approach prior 
establishing goals. Once they sat up individualised short-term goals, they directed 
their attention and focus to take on board new tactics they gained from the 
education to succeed in exercising this behaviour in real life, in which motivation level 
moved upward. Their motivation strived themselves to change a DSCB positively and 
enhanced their self-efficacy toward that DSCB (Lenz and Shortridge-Baggett, 2002). 
Several studies in literature similar to our trial reported higher level of self-efficacy 
for those who receive DSME intervention. Peña-Purcell et al. (2015) delivered an 
empowerment based DSME through educational sessions to 103 participants who 
were allocated in the intervention group. They reported that those who received the 
intervention had statistically significant higher scores at three-month from baseline 
in both self-efficacy and the performance of DSCBs than those who were in the 
control group. Another study that was conducted by Dogru et al. (2019) delivered 
DSME that included MI approach and assessed self-efficacy level for participants in 
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both control group and intervention group before and after the intervention but did 
not follow them up. They used the same instrument that was used in this trial to 
measure self-efficacy level; the Perceived Diabetes Self-Efficacy Scale (PDSMS), 
which was described in (3.13.3.3). Those who received the intervention had 
statistically significant higher scores in PDSMS from baseline than those who were in 
the control group. Similar results were reported in other studies where self-efficacy 
improved statistically significant among those who received psychological DSME 
interventions (Guo et al., Liu et al., 2012 , Moriyama et al., 2009 , Shi et al., 2010). All 
in all, we can understand that other DSME interventions that included psychological 
factor such as empowerment or motivation style alongside providing information on 
DSCBs can improve participants’ self-efficacy parallel to this trials’ results.  
The perceived diabetes self-efficacy is strongly correlated with practicing DSCBs as 
was reported above. Al-Khawaldeh et al. (2012) conducted a cross sectional study in 
Jordan among 223 participants to investigate the association between the perceived 
diabetes self-efficacy and DSCBs as well as the glycaemic control. Their results shown 
a statistically significant association between participants’ self-efficacy and their 
performance in DSCBs such as diet, physical activity, and medications management. 
Those who reported higher self-efficacy level, reported better self-care behaviours. 
In addition, those who performed better self-care behaviours had better glycaemic 
control. This is consistent with the results in this trial and with the assumption of IMB 
model that was described in (2.1.2).  
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6.3.2 The effect of IMBDSME intervention: 
IMBDSME intervention was developed and mapped onto IMB model main 
determinants as was explained in (2.2.2). It is less likely that a separate determinant 
whether knowledge, motivation or behavioural skills was solely responsible in 
changing participants’ level of practicing DSCBs. All those determinants interacted to 
change the primary DSCBs. Information about DSCBs were given in an educational 
booklet and those information were discussed during the delivery process 
throughout MI and BAP approach alongside with individualised goal setting in a 
collaborative way as was explained in chapter (2). Comparably, didactic DSME 
intervention produced less favourable results in literature than collaborative DSME 
interventions as stated by Norris et al. (2001) because the effect on the outcomes 
were short-lived. Empowering participants through DSME intervention by using 
motivational approach such as MI, supports the opportunity for interpreting their 
newly received knowledge into changing DSCBs practice as a result of improving self-
efficacy state (Siminerio et al., 2005). It would have been useful to statistically 
estimate and evaluate the extent to which of the three main determinants of IMB 
model explained the variability in each DSMB such as diet. These estimations were 
not computed as they were out of the scope of the trial’s research question as 
mentioned earlier. Therefore, exploring those associations statistically in the 
literature is pointless in this section. However, the fact that each determinant of 
IMBDSME intervention contributed differently in changing each DSCB cannot be 
denied because they certainly did not equally contribute in changing the level of each 
DSCBs for those in IMBDSME group. This claim can be supported from the results 
289 
PhD Thesis September 2020 Student ID 4220143 
 
reported by Osborn and Egede (2010) who conducted an RCT to validate the 
utilisation of IMB model in DSME to improve diet and exercise self-care behaviours 
among a sample of T2DM. They examined the fundamental assumed relationships 
between IMB model constructs to help inform any potential modifications to the IMB 
model based DSME intervention using structural equation modelling. They showed 
how each determinant of IMB model impacted their trial outcomes and this will be 
cited in the next sections below additionally with the effect of IMB determinants on 
each of this trial outcomes. It is explained narratively and supported with evidence 
from the literature whenever is applicable.  
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6.3.2.1 Effect on diet self-care behaviour: 
According to trial results, those who were in IMBDSME intervention reported a 
statistically significant positive change in diet self-care behaviour at three-month and 
six-month points. In fact, after receiving the IMBDSME intervention, they reported 
that they have improved in planning for healthful eating diets, consuming five or 
more servings of fruits and vegetables and eating less high fat foods such as red meat 
and full-fat dairy products over the last seven days from reporting. These outcomes 
could not be met unless they were informed about how to control portion sizes using 
“Dividing the plate approach” to balance all types of food across daily meals and how 
food types affect their diabetes condition. For example, how eating food with 
carbohydrate increases the blood glucose level and how different food with 
carbohydrates increases the glucose level differently where glycaemic index varies. 
With regard to eating out and snacks, a detailed guidance was included on what type 
of snack to eat between meals (three main meals) and what to choose when eating 
out and how many calories are in many of the well-known fast-food items. All this 
knowledge was vital and fundamental for participants in IMBDSME group to be able 
to make an informed decision on their healthy dietary plans, that is, if they were 
motivated enough to exercise diet self-care behaviour. However, if they had the 
required motivation to change their dietary habits without any evidence-based 
knowledge on healthy diet, they could have exercised diet self-care behaviour based 
on their previous eating behaviours. Generally, eating behaviour includes food 
selection and eating pattern and is usually influenced by behavioural, cultural and 
social elements (Oltersdorf et al., 1999 , Nestle et al., 1998). Participants’ previous 
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eating behaviours contributed to the development of T2DM and is a lifelong history 
that cannot be altered rapidly as a result of the diagnosis (Savoca and Miller, 2001). 
Their past eating pattern and knowledge on diet could be a mixture of facts and 
myths that were developed and collected from different resources and were 
interpreted incorrectly or derived from the culture. An example on food selection, 
vegetables are recommended for those with T2DM as healthy type of food, but 
potatoes cannot be treated same as carrots due to high level of carbs, which is in fact 
need to be controlled. Another example on eating pattern where some participants 
thought that by replacing all-day meals with one big meal is an efficient way to limit 
food intake regardless of the types of food consumed. One of the IMBDSME 
participants was aware of the fact that fruits or vegetables are healthy choices for 
patients with T2DM and was motivated to start practicing this healthy habit. When it 
was discussed to create a SMART goal as part of BAP it was revealed that she was 
inadvertently planning to consume five portions of fruits such as banana in a form of 
juice as it facilitates consuming larger quantity of vitamins and was perceived as 
better practice while ignoring the benefits of the wasted fibers. Another factor is the 
food preparation process where there is huge difference between fried, boiled or 
grilled. The majority of participants were not aware on the fact that the quantity of 
fat is also important alongside the type of fat in managing their dietary fat intake that 
ultimately affects their weight status. To give an example, olive oil is seen as a healthy 
and recommended type of fat for Jordanians as the majority of population farm 
olives, thus, the availability. It is considered as a prestigious type of oil due to its 
cultural and religious root in Jordan. Therefore, significant number of participants in 
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IMBDSME group were underestimating the amount of olive oil used in food 
preparation. Due to its known benefits, they were ignoring the fact that olive oil 
produces high level of energy similar to other types of oil. That energy is stored as fat 
when it is not consumed in energy cycles, which in turn, increases insulin resistance 
and worsen glucose level control (Pérez-Jiménez et al., 2007).  
Away from IMB model, De Vriendt et al. (2009) investigated the role of nutrition 
knowledge and their dietary behaviour among 803 Belgian women. They concluded 
that higher level of nutrition knowledge was significantly associated with higher 
consumption of fruit and vegetables and those who had higher level of nutrition 
knowledge perform better dietary behaviours in general.  
From the discussion above, it can be concluded that knowledge determinant within 
IMB model was predominant to change diet self-care behaviour for participants in 
IMBDSME group at six month. This conclusion can be supported by Osborn and Egede 
(2010) study who examined the effectiveness of a brief IMB model-based DSME and 
reported that knowledge determinant had a significant direct impact on the diet self-
care behaviour. While for motivation determinant, they reported that motivation 
determinant had no significant direct impact on diet self-care behaviour, 
nonetheless, it had a significant impact on diet-related behavioural skills, which in 
turn, had direct significant impact on diet self-care behaviour for those who received 
the intervention. They concluded that IMB model was accounted for almost 40% of 
the change in diet self-care behaviour. 
Although it appears that knowledge determinant deemed predominant, 
underestimating the impact of motivation determinant is not true and knowledge 
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determinant as standalone intervention has down sides. Ekong and Kavookjian 
(2016) explored the evidence in literature for MI interventions and outcomes in 
adults with T2DM by conducting a systematic review. Seven out of 14 studies that 
were included in their review assessed eating behaviour changes such as increase 
fruit and vegetables or reduce saturated fat intake. Five studies reported statistically 
significant improvement in eating behaviours for those who received MI intervention 
than of those in TAU group. To elaborate how knowledge and motivation work 
together, Miller and Cassady (2012) conducted a study to understand how younger 
and older adults make decision regarding food choices by examining the association 
between diet-related knowledge and motivation. They concluded that diet-related 
knowledge mediates the relationship between self-motivation and how well they can 
decide upon healthful food. Their study results indicated that although motivation 
provides the required impetus to apply what people know about food choices, 
motivation with higher level of knowledge together increased the accuracy in making 
healthier food decisions when making comparisons between different food choices 
and improved decision quality. 
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6.3.2.2 Effect on physical activity self-care behaviour: 
Trial results showed that participants in the IMBDSME group reported higher change 
from baseline score in physical activity than those in TAU group at three-month and 
six-month visits. Although there were positive changes for IMBDSME group in 
physical activity, the change appeared to be not statistically significant after baseline 
adjustment. After receiving IMBDSME intervention, participants who were in 
IMBDSME group reported that they were practicing at least 30 minutes’ walking a 
day and participated in physical exercises more frequently over the last seven days 
from reporting. These achievements were highly likely related to the IMBDSME 
intervention as it is clear that those who were in TAU group did not achieve any 
noticeable progress in physical activity at three-month and six-month points as 
mentioned in section (4.7.2). Similar to the diet self-care behaviour, knowledge 
determinant provided the required knowledge to practice an adequate level of 
physical activity that could affect their diabetes condition positively. IMBDSME 
intervention included a chapter called “Be Active” that described variety of ways to 
exercise and practice physical activities during the day. It stressed out the importance 
of walking briskly for at least 30 minutes on a daily basis and how this can lower blood 
glucose level and increase their insulin resistance. Information on the appropriate 
pace of walking and how to manage glucose level after an exercise were also 
provided. However, for those who had trouble in practicing walking exercise, other 
activities were encouraged such as chair exercise, stretches while sitting in a chair, 
and to wheel themselves if they use wheelchair using their arms and hands. Other 
ideas for physical exercise were delivered such as using stairs instead of lifts and park 
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further away from their destination to allow for longer walk. All these instructions 
were discussed with participants in IMBDSME group at one or more interventional 
phone call using MI and BAP where large number utilized goal setting approach to 
improve their physical activity behaviour. However, two scenarios can explain the 
trial results regarding physical activity self-care behaviour. First scenario, the 
improvement among participants in IMBDSME group could be due to chance because 
the baseline score for IMBDSME group was higher than of those in TAU group, which 
means that IMBDSME participants might have been already practicing physical 
exercise more often than participants in TAU group before delivering any 
intervention. Therefore, it can be seen in the trial results that there was a statistically 
significant difference between the trial groups at three-month and six-month points 
before adding any adjustments in the analysis model as it shown in (4.7.2.1), while 
after the adjustments the differences between trial groups were statistically 
nonsignificant despite the fact that those in IMBDSME group had higher mean scores 
than those in TAU group at three-month and six-month points.  
On the other side, a second scenario can be considered as reasonable interpretation 
and claim that IMBDSME intervention was effective to improve the physical activity 
behaviour for those who received it, and a statistically significant relationship is really 
existed, but the analysis model could not detect any between trial groups due to 
several internal threats. Threats such as small sample size and the reliability of the 
subscale that measured physical activity behaviour. Both have led to be fallen in type 
II or  error in terms of measuring physical activity behaviour. First, as mentioned in 
section (6.2.3), the calculated sample size was not achieved, thus the trial was 
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underpowered, and this can be supported by two claims. First, the increment from 
baseline at three-month in physical activity behaviour was far higher for those in 
IMBDSME group than the increment for those in TAU group and that level of physical 
activity was maintained at six-month point for IMBDSME group as shown in (4.7.2). 
Second, after modelling GEE in (4.7.2.1), those in IMBDSME group had P values of 
0.21 and 0.19 at three-month and six-month visits respectively and were near the 
marginal statistically significant point. An average of P value of 0.2 defines as there 
was 80% chance to accept the fact that improvements for those in IMBDSME group 
at three-month and six-month were due to the IMBDSME intervention, a probability 
of type II or  error is 80% and a probability of type I error by 20% (Tanha et al., 2017). 
Second, only two questions were used in measuring the performance of physical 
activity self-care behaviour and were administered as a subscale within SDSCA 
instrument. More details about SDSCA are presented in section (3.13.2.1). The first 
question asked about the frequency of walking for at least 30 minutes and the second 
question asked if they generally have exercised any other activities apart from 
walking or other Homework. Both asked to self-report their activities over the last 
seven days from the point of reporting. However, the instrument did not include 
measuring other physical activities such as the frequency of using stairs, chair 
exercises or the walking pace. Those activities could have been measured and 
reflected in the analysis model leading to greater differences between trial groups, 
thus, increasing the chance to interpret the improvement in the IMBDSME group 
compared to TAU group as a statistically significant difference. Having into 
consideration the scenarios above, second scenario was highly likely the most 
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reasonable interpretation for not detecting statistically significant differences 
between trial groups at three-month and six-month points due to the justifications 
mentioned above. 
Physical activity behaviour is complex due to everyday barriers that need ongoing 
problem-solving skills and new ideas to add more physical activity into routine. As 
previously mentioned, knowledge, motivation and behavioural skills determinants 
were delivered within IMBDSME intervention and defining which determinant was 
mostly predominant in changing in physical activity behaviour statistically is not 
possible. However, from a descriptive point of view, the provided knowledge to 
improve physical activity behaviour within IMBDSME intervention was summarized 
in one chapter and was in contrast to that for diet self-care behaviour where several 
chapters were about diet and eating behaviour. This is similar to what Osborn et al. 
(2010) reported when they examined the relationship between IMB model 
constructs in terms of physical activity behaviour. They stated that knowledge 
determinant had no significant direct impact on physical activity behaviour and the 
most critical determinant was the personal motivation that represented ones’ 
attitudes toward physical activity and had significant impact on physical activity 
behaviour when mediated through behavioural skills determinant. Similarly, they 
reported statistically nonsignificant difference in physical activity behaviour between 
those who received IMB model-based intervention and those who received TAU 
group and concluded that their intervention accounted for 23% of the variability in 
physical activity behaviour and was considered as small effect size.  
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Away from IMB model, Ekong and Kavookjian (2016) stated that across all the 14 
studies that used MI interventions, no statistically significant differences were 
detected between those who received MI intervention and TAU group in the studies 
that examined physical activity behaviour. 
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6.3.2.3 Effect on medications management self-care behaviours: 
After delivering IMBDSME intervention, participants in both trial groups reported 
higher scores in medication management self-care behaviour at three-month and six-
month than baselines score. Although both groups had relatively high scores of 
around eight out of ten at baseline and improved at three-month and six-month, the 
improvement was higher for IMBDSME group. For both groups, the improvements 
were statistically significantly at three-month and only statistically significant higher 
for IMBDSME group than those in TAU group at six-month. The significant 
improvements in IMBDSME group at both visits were due to trial intervention as 
clearly they maintained higher level of medications adherence in contrast to those in 
TAU group according to the trial results in (4.7.3).  
Before delivering IMBDSME intervention, medications’ side effects were reported as 
the main reason to avoid taking medications during baseline assessment. Likewise, 
for those who use insulin, how and when to take the insulin dose and how to handle 
missed dose were the mostly discussed issues during the interventional phone calls. 
These barriers were also reported in Rubin (2005), Rezaei et al. (2019) and Mayberry 
and Osborn (2014) studies in literature. Rezaei et al. (2019) in their qualitative study 
found out that medications’ side effects had negative impact on their lived 
experience with T2DM and led to avoid or skip medications because they were 
lacking the required knowledge on how to deal with those side effects. Furthermore, 
Mayberry and Osborn (2014) study reported the same barrier regarding insulin 
administration during their empirical study among patients with T2DM. While after 
receiving IMBDSME intervention, medications adherence practice improved for 
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those in IMBDSME group as those barriers were discussed and tackled within 
knowledge and skills determinants using MI and BAP as explained in chapter 2. 
However, the slight improvement in medications adherence mean score for those in 
TAU group at both visits might have been caused mainly by two factors; their poorly 
controlled diabetes condition, and Hawthorne effect by the influence of 
measurement reactivity factor. Those factors might have interacted together 
because they were introduced at baseline, and thus, amplified their motivation 
toward medications adherence over the following three-month. To explain, all those 
who participated in the trial had an uncontrolled HbA1c as per the eligibility criteria, 
and their poor HbA1c level was announced and discussed during their consultation 
visit with the physicians at trial settings, where at the same visit, most of them were 
asked to respond to the Medications Adherence Rating Scale (MARS) as part of the 
baseline collection once they finished the visit. It is believed that those factors 
interacted and increased their passion to control their diabetes condition over the 
following three-month for those in TAU group, and yet, had no options apart from 
focusing on the practice of adhering with diabetes medications since they have not 
received any further guidance on other self-care behaviours that could improve 
glucose level such as diet and physical activity self-care behaviours. Another reason 
that could have influenced the improvement in medications management in TAU 
group is the delivered guidance during critical situation such as dealing with 
emergent hypoglycaemic episodes. During out of hours, health advice service is not 
available through phone call in Jordan, and the last resort was to call the trialist to 
receive an advice which was ethically inevitable. Participants in TAU group received 
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guidance on how to handle an ongoing hypoglycaemic episode and were encouraged 
to visit or call their medical practice next day on several occasions.  
In terms of the MARS instrument, it is highly likely that it masked a great level of 
improvement for participants in IMBDSME group due to different reasons. First, 
participants were asked to respond to ten questions by choosing either “yes” or “no” 
for each question. In other words, these questions asked whether participants 
agreed or disagreed with their statement where there was a great tendency to agree 
with the statement regardless of their content generating another type of bias called 
acquiescence bias (Hinz et al., 2007). According to Callegaro et al. (2015), this type of 
questions is called forced choice question and can generate an overestimated 
response when it is administered as self-report instrument by a factor of 1.42 
compared to choose-that-all-apply format, in this case, the medications adherence 
level for those in TAU group might have been overestimated. Second, MARS 
instrument did not include questions about insulin administration or dealing with 
insulin complications, which was discussed significantly during the interventional 
phone calls with those in IMBDSME group and use insulin. This means that the overall 
response for those in IMBDSME group might have not been completely reflected, 
and thus, underestimated. This is consistent with the trial results when it is 
interpreted ahead. To reflect on the trial results for argument purposes, mean scores 
of medications adherence behaviour above in (4.7.3) at both visits showed that 
IMBDSME group answered approximately one more question correctly from 
baseline, while those in TAU group answered approximately half a question more 
correctly from baseline. The difference between groups in mean scores at three-
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month and six-month can be considered as inaccurate representation of the true 
improvement that was caused by IMBDSME intervention. 
Although a considerable amount of information on medications management was 
provided, only case-relevant information was discussed with IMBDSME participants 
using MI and BAP during interventional phone calls to facilitate simplicity in using the 
educational toolkit. Similar to diet and physical activity self-care behaviours, 
knowledge determinants within IMBDSME intervention provided information on 
diabetes medications, in particular, antihyperglycemic tablets, while those who were 
on regular insulin doses received a separate appendix as an addition for insulin 
administration. The IMBDSME intervention explained the importance of diabetes 
medication, how they help to adverse the long-term complications, how they affect 
blood glucose level once administered and what may happen otherwise. In addition, 
expected side effects of diabetes medications were addressed such as metformin 
that can cause diarrhoea and how to manage hypoglycaemia once occurred by 
tablets or insulin. Other situations were addressed such as the importance of not 
skipping meals by maintaining food or snack nearby, check their glucose level, use 
their own needles before administering any insulin, the best place to store insulin 
and the best places to inject insulin with the importance to rotate the injection site 
each time to avoid Lipohypertrophy (insulin lumps). For behavioural skill 
determinant, all insulin-related administration instructions were demonstrated 
graphically whether using insulin pen or using insulin vials and when to administer 
insulin whether short acting, long acting and mixed insulin. All the above knowledge 
and skills aimed to increase the level of skills and understanding for those in 
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IMBDSME to properly adhere with their medications. It can be established that 
knowledge determinant highly contributed and was leading the improvement in 
medications adherence level. This can be supported by Mayberry and Osborn (2014) 
who conducted a study to validate IMB model of diabetes medications adherence 
among patient with T2DM. Although they showed that knowledge determinant and 
motivation determinants had an indirect impact on the medication’s adherence 
behaviour, they explained that knowledge showed a trend of direct impact on the 
adherence behaviour because it was near the marginal statistically significant point 
(p0.08). They rationalised the statistically nonsignificant result to the fact that their 
knowledge assessment was not complex enough to cover further details about 
medications adherence. They added that the effect for both determinants was highly 
statistically significant on medications’ adherence behaviour when mediated by the 
adherence behavioural skills as per the original assumption of IMB model. IMB model 
explained 41% of the variability in medications’ adherence behaviour in their 
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6.3.2.4 Effect on HbA1c level: 
According to trial results, although the improvement in HbA1c for those in IMBDSME 
group at three-month and six-month were higher compared to those in TAU group, 
it was not statistically significant. On the other hand, the improvement for those at 
TAU group was statistically significant at six-month but not at three-month visit. It 
was noticeable that the improvements after the adjustments for both groups had a 
trend toward statistical significance as P values were below 0.10 at three-month visit. 
The statistically nonsignificant results might be due to being underpowered trial and 
had fallen in Type II or β error as was explained in (6.2.3), similar to physical activity 
behaviour. Another explanation that is more likely possible is that the improvement 
could be due to multiple factors and not necessarily due to IMBDSME intervention 
because TAU group had the same trend in P values. These inconsistent results were 
also found in literature. A systematic review that was done by Chrvala et al. (2016) 
found that when reviewing trials that examined the effectiveness of DSME on 
glycaemic control, multiple factors contributed with the outcomes due to 
interventions heterogeneity. Factors such as clinical and demographic 
characteristics, mode of DSME delivery, DSME provider qualification, duration and 
contact hours. Per se, they showed that 73 trials (61.9%) demonstrated statistically 
significant difference between intervention and control groups compared with 45 
trials (38.1%) that resulted in no statistically significant difference between groups. 
Parallel to our trial results in regard to HbA1c, their review reported that almost 47% 
of those individually delivered DSME interventions had no statistically significant 
difference between trial groups while 53% had statistically significant difference. 
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Moreover, 43.7% of those DSME interventions that were delivered by single provider 
were associated with no statistically significant difference between trial groups. From 
the above, it can be concluded that this is not the only trial that found no statistically 
significant difference between trials groups, but there was a trend toward statistical 
significance point in both groups. It is clinically known that Hba1c greatly explain the 
change in HbA1c and that trend might be caused by other confounders, and highly 
likely in this case, different treatment regimens in each trial site. It was explained in 
(3.9.2) how each trial site manage diabetes conditions, what are the facilities and 
services available for those patients and the qualifications for those Health Care 
Professionals (HCPs) in each trial site. Those differences are believed due to have 
different sponsor for each. As such, it was noticeable that each trial site used 
different treatment regimens with respect to prescribing diabetes medications 
especially insulin as presented in (4.4.2.1) in Table 11. Therefore, it was worth 
investigating Hba1c levels across trial sites at three-month and six-month since there 
was a statistically significant difference in HbA1c at baseline between participants 
who attended PHH who had higher mean of HbA1c 10.2 ± (1.8) than participants who 
attended JUH who had mean of HbA1c of 9.5 ± (1.5). By observing the prescribed 
insulin in each site in Table 11, the trend in PHH was prescribing pre-mixed insulin 
(Mixtard) additionally with Anti Hyperglycaemic Tablets (AHTs) for the majority, 
while in JUH they used to prescribe basal insulin (Lantus) additionally with other 
AHTs, and often, escalated to prescribe two types of insulins basal-bolus if it was not 
controlled by the basal insulin alone. In numbers, none of those who attended PHH 
were using the basal and bolus insulin regimen and only one participant was 
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prescribed basal insulin compared to the rest who were using pre-mixed insulin in 
addition to the AHTs. While in JUH, almost half of participants were using either basal 
insulin or basal-bolus insulin in addition to the AHTs compared to twenty participants 
(19.1%) who were using pre-mixed insulin. 
Regardless of the group allocation, it can be claimed that Hba1c was managed 
greater by those who used basal and bolus insulins and attended JUH compared to 
those who used pre-mixed insulin and attended PHH according to the results from 
each trial sites at three-month and six-month visits. In PHH, although the differences 
between trial groups were not statistically significant after the adjustments at both 
visits, the improvements in HbA1c for those in IMBDSME group were far greater than 
those in TAU group at both visit and P values were near the significant margin (0.08) 
and (0.14) at three-month and six-month respectively as shown in (4.8.4.4) and 
Figure 19. Similarly in JUH, the improvements in HbA1c were greater for those in 
IMBDSME group than those in TAU group at both visits and was only statistically 
significant at three-month visit as shown in (4.8.4.6) and Figure 20. The latter claim 
above can also be supported by recognising the greater improvement in HbA1c for 
those in TAU group and attended JUH than those who attended PHH in the same 
group despite the fact that they did not receive any external educational 
intervention. Therefore, IMBDSME intervention as well as the treatment regimens in 
each trial sites have already contributed to the improvement in HbA1c results in 
IMBDSME group at three-month and six-month visits.  
Bellido et al. (2015) and Shanmugasundar et al. (2012) both compared the basal-
bolus and premixed insulin regimens in separate studies and concluded that both can 
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improve HbA1c and found no statistically significant difference between the 
regimens. None of them was found to be superior on the other. However, both 
reported that those who used the pre-mixed insulin reported statistically significant 
higher incidences of hypoglycaemic episodes that could have affected their 
adherence to the insulin regimen. Garcia-Perez et al. (2013) reported in their article 
about the adherence to therapies in patients with T2DM that hypoglycaemic 
episodes hugely impact the adherence to insulin treatment and lead to low 
adherence to the treatment regimen and uncontrolled HbA1c as it is highly likely the 
case among those who attended PHH and used pre-mixed insulin in this trial. This 
was also backed by Skyler et al. (2009) who reviewed the relationship between the 
intensive glycaemic control treatment and cardiovascular events. This low adherence 
to insulin might have not been detected in this trial because the Medications 
Adherence Rating Scale (MARS) that was used in this trial did not include questions 
about the adherence to insulin as mentioned before in (6.3.2.3). Nevertheless, those 
who attended JUH and were using pre-mixed insulin were in better position 
compared to those who attended PHH because they usually were referred to a 
diabetes educator to be educated on administering insulin and may know how to 
deal with hypoglycaemic episodes. While in PHH, this service was not available. 
Another factor was the demographic characteristics for those who attended trial 
sites. As mentioned before, JUH in a university hospital and serves mainly academic 
staff and their families that could have added more privilege regarding the 
educational level, and thus, better diabetes management, while PHH serves ordinary 
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6.3.2.5 Effects on quality of life: 
According to trial results in (4.8.5), participants in IMBDSME group reported higher 
quality of life scores compared to TAU group and these improvements were 
statistically significant at three-month and six-month visits. Before delivering 
IMBDSME intervention, it was assumed that IMBDSME intervention improves the 
levels of knowledge, motivation and behavioural skills, and subsequently, improves 
the level of practicing self-care behaviours which will reflect on their quality of life. 
According to the ADDQOL instrument, the improvements were reported among 
IMBDSME group in the first two general questions and in the additional 18 items that 
asked how their T2DM impacted certain aspects in their life such as the enjoyment 
of food, holidays or leisure activities. While for TAU group, although participants 
reported a statistically significant higher level of general quality of life in the first 
question only when they were asked at three-month visit, the improvement was 
relatively smaller than of those in IMBDSME group. What is more, their mean scores 
decreased significantly when they were asked how their life would be without 
diabetes in the second question and when they responded to the 18 additional items. 
The improvement was expected in IMBDSME group after delivering the intervention 
as a result of practicing self-care behaviours more frequent than before the 
intervention. They reported that the impact of T2DM on their general quality of life 
was shrinking and was changing positively almost similar to the life they used to live 
before the onset of T2DM, or interestingly, better than before in some cases. For 
example, some participants reported they were more confident, knowledgeable and 
motivated after IMBDSME intervention with regards changing their physical 
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appearance, enjoyment of chosen food, freedom to eat and drink in the ADDQOL 
instrument and became more in control on their lifestyle. Similar finding was found 
by Chong et al. (2017) study that compared behavioural changes between those who 
changed their lifestyle after being diagnosed with T2DM and those who were without 
T2DM. During follow up period, they found that those who changed their lifestyle 
had statistically significantly lost more weight, increased their vegetables’ 
consumption and decreased the number of smoked cigarettes compared to those 
who were not diagnosed with T2DM. They concluded that being diagnosed with 
T2DM may act as a wakeup call and led to minimally change unhealthy lifestyle habits 
by practicing healthy self-care behaviours. 
Deakin et al. (2006) conducted a trial where they used ADDQOL to measure the 
effectiveness of a group-based self-management educational program (X-PERT) on 
quality of life as one of the secondary outcomes. Apart from being delivered in a 
group setting, their intervention was parallel to IMBDSME intervention as they 
developed their program on theories of empowerment. They reported that those 
who received X-PERT intervention experienced more freedom to eat and drink and 
reported higher level of quality of life on the 18-items of ADDQOL compared to those 
who did not receive the intervention, but the differences between trial groups were 
not statistically significant and was near the statistically significant margin (P < 0.1) 
during follow up period. It can be justified that X-PERT intervention could not change 
quality of life as an outcome significantly because it was not a tailored and 
individualized message as IMBDSME intervention that produced statistically 
significant change as mentioned earlier. To add on this point, individually tailored 
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DSME programs, such as IMBDSME intervention, proved to be more effective than 
those delivered at a group level and developed as “one size fits all” as mentioned 
before in literature review in (1.7.1) Kreuter and Skinner (2000). 
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6.4 Conclusion 
In this chapter, principal results of this trial were described at the beginning and were 
interpreted along the entire chapter. These results were explained around the axis 
of IMB model by exploring how the IMBDSME intervention changed the level of main 
determinants of IMB model at three-month and six-month, and subsequently, how 
this affected the trial outcomes whether primary or secondary. In terms of the 
strengths and limitations in this trial, a considerable section shed the light on the 
conducted stages of trial design such as the recruitment process, randomization, 
sample size and retention rate across the trial visits.  
As was explained earlier in this chapter, high level of control was exerted to minimize 
all forms of bias whether response bias or selection bias. However, the explanation 
of cause-and-effect relationship under the controlled conditions might not be the 
same explanation occurs in real situations (Privitera, 2017). Although internal and 
external threats existed here and could have affected the quality of the trial, this can 
be considered as high valued RCT and those improvements at three-month and six-
month visits in primary and secondary outcomes for those in IMBDSME group were 
due to the trial intervention and not due to chance except for physical activity 
behaviour.  
Trial results were interpreted and compared with other studies in literature, in 
particular, those that used IMB model among patients with T2DM. In consistent with 
Mayberry and Osborn (2014) and Osborn et al. (2010) studies, this trial revealed that 
knowledge and behavioural skills determinants contributed greatly in the 
improvements of practicing diet and medications management self-care behaviours. 
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In contrast, motivation determinant was found to hugely affecting the level of 
practicing physical activity more than knowledge and behavioural skills 
determinants. Moreover, in comparison to those two aforementioned studies that 
used IMB model, this trial examined the change in the level of determinants before 
and after delivering the IMBDSME, while other studies did not and focused on the 
changes in the outcomes. However, the comparison with other studies that did not 
use behavioural change model and appeared to measure the same outcomes were 
often confronted by the heterogeneity factor whether methodological or clinical and 
the fact that each trial used different outcomes measures (Coster, 2013 , Fletcher, 
2007). 
From the above, this trial can lead to multiple implications on clinical practice and 
research. In terms of clinical setting, IMBDSME intervention was found to be effective 
within DSME interventions and was delivered in busy clinics and over phone calls. 
The impact on those behaviours were mediated by motivation determinant. 
Motivation determinant was directly linked to the improvement in physical activity 
behaviour, nonetheless, many barriers were not addressed within the IMBDSME 
intervention that need ongoing support. These barriers need to be investigated and 
addressed in the future. These features within IMBDSME intervention are important 
nowadays during these unprecedented circumstances due to COVID-19 virus where 
many health care services are turning to provide remote advice because many 
patients with chronic diseases are not followed up properly due to missing and 
cancelling appointment as a result of self-isolation. Therefore, IMBDSME 
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intervention is substantial and necessary to be implemented at the organisational 
level and training on how to use MI and BAP style are crucial than ever.  
According to the implication on research, this trial showed the importance of 
investigating the cultural and physical barriers that preventing patients from 
practicing physical activity self-care behaviour among Jordanian patient with T2DM. 
Practicing physical activity behaviour is vital to avoid macrovascular complications 
such as MI and strokes. What is more, in order to detect any improvement or down 
sides of any future intervention, well-fitted instruments should be implemented to 
detect any facilitators or barriers toward any targeted self-care behaviour. Another 
factor that may help to achieve robust and valid conclusion is planning carefully for 
recruitment process to be able to approach the required sample size. Involving 
independent recruiters in randomised controlled trials was found to be worthy 
because considerable proportion of those who were eligible could not be 
approachable. Future trials need to consider the differences in the existed practice 
within trial sites especially if they are sponsored from different governmental bodies. 
This was shown to generate a valid difference in clinical and treatment regimens 
between participants who attend different sites at baseline that may interfere with 
how new intervention act. This trial results can be included in future systematic 
reviews or meta-analysis to influence any future clinical guidelines. 
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Appendix 14 The trial questionnaire in Arabic language  
 استبيان 
 
: األمير حمزة / المستشفى    . : ....................... رمز المريض
 الجامعة األردنية 
: متزوج / أعزب الحالة االجتماعية : ذكر / أنثى الجنس  : ................... العمر
 أرملة / مطلقة.  /
 سنة.  12سنة / أكثر  12سنة /  12متعلم / أقل من غير : المستوى التعليمي
 : مدخن سابق / غير مدخن / مدخن ...........سيجارة في اليوم. التدخين
 ……: عامل مياومة/ عامل محترف / مدير أو مسؤول / ربة منزل / أخرى الوظيفة
 : مؤمن / غير مؤمن.التأمين الصحي
شرب       : ....................شهري. الدخل المادي
 : نعم / ال. الكحول
  ............ : ........عمر مرض السكري
 األمراض المزمنة: 
أمراض    نعم/ ال. الدهنيات:    . نعم / ال ضغط الدم: 
 نعم / ال. القلب: 
اعتالل    : نعم /ال. اعتالل الشبكية   : نعم / ال. اعتالل الكلى
  : نعم /ال.األعصاب
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Anthropometric and Laboratory measurements: 
 الزيارة الثالثة 
.. التاريخ ......
/...../.....16 
 الزيارة الثانية 
. .. . ....التاريخ 
/......./...16 
 الزيارة األولى 
... .. .التاريخ 
/ .... .. /..16 
 
 المؤشر 
 الوزن    
 الطول    
محيط    
 الخصر 
 ضغط الدم    
   HbA1c 
   F.S/ 
R.S 
   HDL 
   LDL 
   Triglyc
e 
   Cholest 
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Diabetes self-management knowledge questionnaire (SKILLD): 
ماهي عالمات وأعراض ارتفاع السكر في الدم؟ بماذا تشعر عندما يكون السكر في دمك  .1
ماهي عالمات وأعراض انخفاض السكر في الدم؟ بماذا  بالسكري؟مرتفعا أو لحظة تشخيصك 
 تشعر عندما انخفاض السكر في دمك؟ 
 
كيف تتعامل مع انخفاض السكر في دمك؟ ماذا عليك أن تفعل في حاالت انخفاض السكر؟  .2
كيف تتعامل مع ارتفاع السكر كيف من الممكن أن ترفع السكر في دمك في حالة االنخفاض؟ 
 في الدم؟ ماذا عليك أن تفعل في حاالت االرتفاع؟
 
ة يجب أن تأكل في اليوم؟ وكم كيف تتعامل مع وجباتك الغذائية في اليوم؟ كم وجبة رئيسي  .3
وجبة فرعية؟ كيف هي الطريقة الصحيحة في تعاملك مع صحنك وقت األكل؟ ماهي طريقة 
 توزيع الغذاء في صحنك؟ 
 
هل يجب أن أتوقف عن أيا منهم؟ أية نوع منهم يجب أن أكل ماهي أنواع الغذاء الرئيسية؟  .4
 أكثر؟ وأية نوع منهم يجب أن أقلل؟ 
 
ماذا تفعل عندما ال تأكل  أم عندما يكون السكر مرتفع؟ كل يوم واء السكري دهل يجب أن أخذ  .5
 وجبتك الرئيسية، هل تؤجل أخذ الدواء أم عليك أن تأخذه؟ 
 
كيف هي الطريقة الصحيحة لتأخذ دوائك سواء الحبوب أو اإلبر كل يوم؟ هل يجب أن أمتنع  .6
أن أفعل في حاالت االرتفاع؟  عن أخذ دواء السكري في حاالت االنخفاض؟ ماذا يجب علي
 هل يجب أن أزيد جرعة الدواء؟ 
 
ما هو المعدل الطبيعي للسكر في الدم وأنت صائم؟ عندما تستيقظ من النوم وتفحص السكر قبل  .7
 األكل أو قبل أخذك للدواء، كم يجب أن يكون؟ ما هما الرقمين؟
 
دم من يديك، ما هو المعدل ما هو المعدل الطبيعي للسكر التراكمي في الدم؟ عندما يسحب  .8
 الطبيعي لقراءات السكر التراكمي؟ ماذا يجب أن يكون؟ 
 
كم مرة باألسبوع يجب على مريض السكري أن يمارس الرياضة؟ وكم تحتاج من الوقت في  .9
 اليوم لتمارس الرياضة؟ 
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ماهي المضاعفات للسكري الغير منتظم على المدى البعيد؟ هل تعرف أحد يعاني من هذه .10
 مضاعفات؟ أذكر بعض هذه المضاعفات؟ ال
 
Diabetes Self-Management Motivation (Diabetes Empowerment Scale (DES) + 
Medical Outcomes Study Social Support Survey (MOS-SSS)): 















aspects of diabetes 
(9 items)  
بشكل علم أعتقد أني أعرف طرقا  5 4 3 2 1
إيجابية تساعدني ألتكيف مع القلق 
 المصاحب للسكري 
أعتقد أني أستطيع التكيف  بشكل عام, 5 4 3 2 1
 جيدا مع القلق المصاحب للسكري 
بشكل عام, أعتقد أني أعرف أين من  5 4 3 2 1
الممكن الحصول على مساعدة 
 لالعتناء بالسكري 
بشكل عام, أعتقد أني أستطيع  5 4 3 2 1
الحصول على المساعدة لالعتناء 
 عند الحاجة  بالسكري
أعتقد أني أستطيع  بشكل عام, 5 4 3 2 1
مساعدة نفسي في التعامل مع 
 السكري 
بشكل عام, أعتقد أني أعرف ما  5 4 3 2 1
يساعدني ألبقى مندفعا لالعتناء 
 بالسكري 
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بشكل عام أعتقد أني مندفعا لالعتناء  5 4 3 2 1
 بالسكري 
أعتقد أني على دراية  بشكل عام, 5 4 3 2 1
كافية بالسكري ألختار الطريقة 
 الصحيحة ألعتني بنفسي. 
بشكل عام, أعتقد أني على دراية  5 4 3 2 1
كافية عن قدرتي لوضع خيارات 















readiness to change 
(9 items)  
بشكل عام, أعتقد أني أعرف أية جزء  5 4 3 2 1
من العناية الشخصية بالسكري أنا 
 راضي عنه 
أعتقد أني أعرف أية جزء  بشكل عام, 5 4 3 2 1
من العناية الشخصية بالسكري أنا 
 غير راضي عنه 
بشكل عام, أعتقد أني أعرف أية جزء  5 4 3 2 1
من العناية بالسكري أنا مستعد 
 لتغييره. 
أعتقد أني أعرف أية جزء  بشكل عام, 5 4 3 2 1
من العناية بالسكري أنا غير مستعد 
 .لتغييره 
بشكل عام, أعتقد أني أستطيع التحدث  5 4 3 2 1
 عن شعوري كمريض سكري. 
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بشكل عام, أستطيع التحدث عن  5 4 3 2 1
 شعوري حول العناية بمرض السكري 
أعتقد أني أعرف كيف  بشكل عام, 5 4 3 2 1
 ممكن أن يقلقني السكري في حياتي 
بشكل عام, أعتقد أني أعرف طرقا  5 4 3 2 1
سلبية للتكيف مع القلق المصاحب 
 للسكري 
أعتقد أني قادر على تمييز  بشكل عام, 5 4 3 2 1
ما اذا كان يستحق العناء بأن أغير 
 الطريقة التي أعتني بها بالسكري 
بشكل عام, أعتقد أني أستطيع اختيار  5 4 3 2 1
 أهداف معقولة لتنظيم السكري 
بشكل عام أعتقد أني أعرف أية  5 4 3 2 1
 أهداف تنظيم السكري هي األهم لي 
أعتقد أني أعرف أشياء  بشكل عام, 5 4 3 2 1
عن نفسي اما تساعدني أو تمنعني 
من الوصول لألهداف التي أضعها 
 لتنظيم السكري 
بشكل عام أنا قادر على تبني أفكار  5 4 3 2 1
 جيدة تساعدني على الوصول ألهدافي 
أعتقد أني قادر على  بشكل عام, 5 4 3 2 1
تحويل أهداف تنظيم السكري الى 
 خطة فعالة على أرض الواقع 
بشكل عام, أعتقد أني قادر على  5 4 3 2 1
الوصول الى أهداف تنظيم السكري 
 عند وضع الخطط وتحديد األفكار 
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بشكل عام, أعتقد أني أعرف أية  5 4 3 2 1
تجعل من تحقيق أهداف تنظيم  عرائق
 السكري شيء أصعب من ذي قبل 
بشكل عام, أعتقد أني أستطيع التفكير  5 4 3 2 1
بطرق أخرى لتجاوز العوائق خالل 
 تحقيق أهداف تنظيم السكري 
أعتقد أني أستطيع تجربة  بشكل عام, 5 4 3 2 1
طرق مختلفة لتجاوز العوائق خالل 
 تحقيق أهداف تنظيم السكري. 
أعتقد أني قادر على  بشكل عام, 5 4 3 2 1
اختيار أية طريقة أفضل معي لتجاوز 
العوائق خالل تحقيق أهداف تنظيم 
 السكري. 

















     Emotional/informational 
support 
شخص تلجأ اليه ألخذ اقتراحات حول التعامل  5 4 3 2 1
 مع مشكلتك الشخصية 
 شخص يستطيع تفهم مشاكلك  5 4 3 2 1
     
Tangible support 
كنت طريح  لمساعدتك إذاشخص موجود  5 4 3 2 1
 الفراش 
 احتجت  إذاالطبيب  إلىشخص موجود ألخذك  5 4 3 2 1
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كنت غير  إذاشخص موجود يحضر لك وجباتك  5 4 3 2 1
 قادر على عملها بنفسك 
شخص موجود لمساعدتك في حياتك الروتينية  5 4 3 2 1
 كنت مريض إذا
     
Affectionate support 
شخص تحبه ويجعل منك شخص مرغوب به  5 4 3 2 1
 دائما 
     
Positive social interaction 
شخص تستمتع بوجودك معه وتقضي معه وقتا  5 4 3 2 1
 جيدا 
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Diabetes self-management self-efficacy questionnaire (Perceived Diabetes Self-















أعتني بنفسي جيدا باعتبار أني  5 4 3 2 1
 مريض سكري 
أنا قادر على تنظيم وترتيب كل  5 4 3 2 1
األمور المتعلقة بالسكري كما هو 
 الحال مع معظم الناس 
أنا دائما أنجح في خططي التي  5 4 3 2 1
 أتبعها لتنظيم السكري 
أنا قادر على تحقيق أهدافي التي  5 4 3 2 1













من الصعب أن أجد حلول فعالة  1 2 3 4 5
مشاكل التي تواجهني خالل لل
 تنظيم السكري 
جهد كبير لتغيير  إلىأحتاج  1 2 3 4 5
 عادات سيئة خالل تنظيم السكري 
كل خططي لتنظيم  حرفيا، 1 2 3 4 5
 السكري ال تنجح كما أريد 
تنظيم  واجتهاد،مهما حاولت بجد  1 2 3 4 5
السكري ال ينجح معي كما كنت 
 متوقعا 
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The Summary of Diabetes Self-Care Activities Scale (SDSCA) 
and Medications Adherence Rating Scale (MARS): 
Summary of Diabetes Self-Care Activities (SDSCA): 
التي مارستها خالل السبعة أيام  األسئلة التالية سوف تسألك عن أنشطة العناية الذاتية بالسكري
 الماضية. اذا كنت مريضا خاللها، فكر في األيام السبعة التي سبقت أيام مرضك: 
 
(0 ) (1 ) (2 ) (3 ) (4 ) (5 ) (6 ) (7 )  
 الحمية الغذائية: 
كم مرة خالل السبعة         
أيام الماضية اتبعت 
 حمية غذائية صحية؟ 
بالمعدل خالل الشهر         
الماضي، كم يوم 
باألسبوع اتبعت خطتك 
 الغذائية؟ 
كم مرة خالل السبعة         
أيام الماضية أكلت 
خمس حصص أو أكثر 
من الخضروات 
 والفواكه؟ 
كم مرة خالل السبعة         
غذاء أيام الماضية أكلت 
ملي بالدهنيات مثل 
اللحم أو منتجات األلبان 
 الدسمكاملة 
Reversing item 
 التمارين الرياضية  ( 7) ( 6) ( 5) ( 4) ( 3) ( 2) ( 1) ( 0)
كم مرة خالل السبعة         
أيام الماضية اشتركت 
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على األقل لمدة نصف 
ساعة في نشاط بدني 
 مثل المشي؟ 
كم مرة خالل السبعة         
أيام الماضية اشتركت 
على األقل في نشاط 
رياضي معين مثل 
السباحة أو ركوب 
الدراجة )عدا عن 
المشي أو األفعال 
 المنزلية(؟ 
 فحص السكر في الدم ( 7) ( 6) ( 5) ( 4) ( 3) ( 2) ( 1) ( 0)
كم مرة خالل السبعة         
أيام الماضية فحصت 
 السكر في دمك؟ 
كم مرة خالل السبعة         
أيام الماضية فحصت 
 السكر في دمك؟ 
 
Medication Adherence Rating Scale: 
التي تمثل تصرفاتك وطريقتك في التعامل مع أدوية اإلجابة  وضع دائرة حول الرجاء منك
 السكري خالل السبعة أيام الماضية: 
 
 :Questions ال  نعم
 أدوية السكري الخاصة فيك؟ هل نسيت أن تأخذ  ( 1ال ) ( 0نعم ) 
 هل أنت غير مهتم بالمواعيد المطلوبة منك ألخذ أدوية السكري؟ ( 1ال ) ( 0نعم ) 
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 عندما تشعر بتحسن، هل تتوقف عن أخذ أدوية السكري؟  ( 1ال ) ( 0نعم ) 
 أحيانا عندما تشعر بأعراض الدواء الجانبية، هل تتوقف عن أخذ الدواء؟  ( 1ال ) ( 0نعم ) 
 أنا أخذ أدويتي فقط عندما أشعر بسوء أو في حالة سيئة؟  ( 1ال ) ( 0نعم ) 
 من غير الطبيعي لجمسي وعقلي أن يتحكم به عن طريق األدوية؟ ( 1ال ) ( 0نعم ) 
 أفكاري تكون أوضح عندما أخذ الدواء  ( 0ال ) ( 1نعم ) 
مضاعفات طالما أنا أخذ الدواء باستمرار، إذا أنا أستطيع أن أمنع  ( 0ال ) ( 1نعم ) 
 السكري 
 أشعر بأني غريب عندما أخذ دواء السكري ( 1ال ) ( 0نعم ) 
 الدواء يجعلني أشعر بأني مرهق ومنطوي على نفسي  ( 1ال ) ( 0نعم ) 
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Acceptability questionnaire: 
األسئلة التالية سوف تسألك عن رأيك في البرنامج التثقيف الصحي للسكري الذي تلقيته عن 












 لطيف ويساعد كثيرا  5 4 2 1
 اتصال مناسبة لي  أوقات 5 4 2 1
 المتصل يعرف جيدا بالسكري  5 4 2 1
 المتصل يزودني دائما بنصائح عملية  5 4 2 1
 سعيد بأني أتحدث مع نفس المتصل دائما  5 4 2 1
 حبيت فكرة التواصل الهاتفي  5 4 2 1
 فترة االتصال على الهاتف مقبوال  5 4 2 1
عملي  ءكان شي  األسبوعيتعبئة السجل  5 4 2 1
 بالنسبة لي 
سعيد بالعناية الصحية التي تلقيتها  5 4 2 1
 بالهاتف 
 من السهل فهم النصائح المعطاة لي  5 4 2 1
أفضل زيادة عدد المكالمات الهاتفية  5 4 2 1
 المستقبلة 
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 التثقيف الصحي كان مناسب لحالتي الصحية  5 4 2 1
 وقت المكالمة كان كافيا لإلجابة على أسئلتي  5 4 2 1
 تحدثنا عن أشياء مناسبة لحالتي الصحية  5 4 2 1
من دافعي وثقتي  دالمتصل كان دائما ما يزي 5 4 2 1
 بنفسي 
أحسست بتحسن بعد تلقي النصائح خالل  5 4 2 1
 الهاتف 
أنصح بالبرنامج التثقيفي لباقي مرضى  5 4 2 1
 السكري 
أشعر بأني أعرف عن السكري أكثر من ذي  5 4 2 1
 قبل 
أعمل بالنصائح الطبية التي تلقيتها على  5 4 2 1
 الهاتف يوميا 
أسيطر على السكري أكثر من ذي أشعر بأني  5 4 2 1
 قبل 
 أفضل رؤية الطبيب  5 4 2 1
 زاد من مستوى الوعي لدي  5 4 2 1
أشهر كانت كافية لتغير من عاداتي  3 5 4 2 1
 الصحية تجاه السكري 
 يجب أن يتم تفعيل البرنامج في المستشفى  5 4 2 1
 عدد المكالمات المستقبلة كان كافيا  5 4 2 1
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